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HIV-associated neurocognitive disorders (HAND) are comprised of a host of behavioral, cognitive, and
motor disabilities and can range from more minor disorders that largely allow basic daily functioning to
severe disorders, such as HIV-associated dementia. The mechanisms that ultimately result in neuronal
death in HAND are not known. Presented here are data demonstrating activation of the Integrated Stress
Response (ISR) in cortical autopsy tissue from HAND patients, as well as data characterizing the nature
of the activation of this cellular stress response in this disease. Specifically, we have shown that there are
increased levels of the molecular chaperone protein, BiP, which serves as an indicator of general ISR
activation. We then present data to suggest that, of the three prongs of the ISR, the prong initiated by
ATF6 appears to be active, while PERK does not appear to initiate the prong it regulates. However,
intriguingly, proteins downstream of PERK, namely global pEIF2α and astrocytic ATF4 do appear to be
activated, suggesting that other initiators outside of the PERK pathway may be acting on these classic
components of the ISR. Finally, we show data suggesting that Nrf2, the master regulator of the
endogenous antioxidant component of the ISR, may be active in the cortex of HAND patients. While the
ISR is clearly a protective response, able to help individual cells protect themselves from toxic insults, it is
also able to initiate cellular apoptosis, which in principle protects healthy cells from a dangerous necrotic
death of neighboring cells. However, under conditions of chronic stress in the CNS, such as that seen in
HAND, too many neurons may die as a result of ISR-initiated apoptosis, thereby resulting in the
neurocognitive decline with which these patients are afflicted. Thus, the findings presented here provide
starting points of investigation for research aimed at developing potential therapeutic targets for HAND,
with some targets for which their response must be increased by therapies and other targets for which
their response must be dampened by therapies.
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ABSTRACT

ACTIVATION OF THE INTEGRATED STRESS RESPONSE IN HIVASSOCIATED NEUROCOGNITIVE DISORDER
Kathryn A. Lindl

Kelly L. Jordan-Sciutto

HIV-associated neurocognitive disorders (HAND) are comprised of a host of behavioral,
cognitive, and motor disabilities and can range from more minor disorders that largely
allow basic daily functioning to severe disorders, such as HIV-associated dementia. The
mechanisms that ultimately result in neuronal death in HAND are not known. Presented
here are data demonstrating activation of the Integrated Stress Response (ISR) in
cortical autopsy tissue from HAND patients, as well as data characterizing the nature of
the activation of this cellular stress response in this disease. Specifically, we have shown
that there are increased levels of the molecular chaperone protein, BiP, which serves as
an indicator of general ISR activation. We then present data to suggest that, of the three
prongs of the ISR, the prong initiated by ATF6 appears to be active, while PERK does not
appear to initiate the prong it regulates. However, intriguingly, proteins downstream of
PERK, namely global pEIF2α and astrocytic ATF4 do appear to be activated, suggesting
that other initiators outside of the PERK pathway may be acting on these classic
components of the ISR. Finally, we show data suggesting that Nrf2, the master regulator
of the endogenous antioxidant component of the ISR, may be active in the cortex of
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HAND patients. While the ISR is clearly a protective response, able to help individual
cells protect themselves from toxic insults, it is also able to initiate cellular apoptosis,
which in principle protects healthy cells from a dangerous necrotic death of neighboring
cells. However, under conditions of chronic stress in the CNS, such as that seen in
HAND, too many neurons may die as a result of ISR-initiated apoptosis, thereby
resulting in the neurocognitive decline with which these patients are afflicted. Thus, the
findings presented here provide starting points of investigation for research aimed at
developing potential therapeutic targets for HAND, with some targets for which their
response must be increased by therapies and other targets for which their response must
be dampened by therapies.
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OVERVIEW

The long-term goals of this project are to understand the neuropathogenesis of HIVassociated neurocognitive disorder (HAND), a syndrome in which patients show motor,
cognitive, and behavioral impairments. Characteristics of HAND can include pervasive
reactive astrocytosis, myelin pallor, activated resident microglia, infiltration by
circulating

monocytic

cells,

perivascular

inflammation,

microglial

nodules,

multinucleated giant cells, dendritic simplification, and increased cell death, both
astrocytic and neuronal (1-3). Interestingly, rather than correlating with viral load in the
central nervous system (CNS), clinical signs of HAND more closely associate with
increased numbers of microglia, evidence of excitotoxins, and selective neuronal loss (2).
These findings suggest that, although HIV invasion into the brain may be a necessary
initial step in HAND progression, other mechanisms more directly lead to the functional
losses associated with this disease. While neuronal cell death is clearly associated with
the development of HAND symptoms, HIV rarely, if ever, infects neurons themselves (2,
4, 5). Rather, productive HIV infection in the brain occurs in cells of the macrophage
lineage, including monocyte-derived perivascular macrophages and microglia (1-3).
When activated through direct HIV infection or through exposure to viral particles,
macrophages and microglia release numerous soluble molecules, including viral proteins
(only released by directly infected cells), glutamate receptor agonists, nitric oxide (NO),
platelet

activating

factor

(PAF),

superoxide

anions,

matrix

metalloproteases,

chemokines, growth factors, and proinflammatory cytokines, including tumor-necrosis
factor (TNF) (5, 6). While some of these molecules, such as growth factors (i.e. brainderived neurotrophic factor (BDNF)) and β-chemokines (i.e. regulated upon activation-
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normal T-cell expressed and secreted (RANTES)), are believed to play a neuroprotective
role, a number of the other non-viral factors have proven to be neurotoxic (2, 5, 7, 8).
Additionally, although NO and TNF appear capable of neuroprotective function under
some conditions, they also can both act to impair the neuroprotective functions of
astrocytes, including maintenance of the blood-brain barrier and glutamate reuptake,
and can also increase rates of astrocytic apoptosis (1, 5). The concomitant release of
excessive excitatory amino acids and reduction in glutamate reuptake creates an
excitotoxic environment. Due to excessive activation of N-methyl-D-aspartate glutamate
receptors (NMDARs), intraneuronal Ca2+ concentrations reach toxic levels, resulting in
production of free radicals (including reactive oxygen species (ROS) and NO) and in
neuronal apoptosis (2, 5). In fact, changes in cellular lipid metabolism that occur as a
result of oxidative stress produce characteristic molecules, such as ceramide,
sphingomyelin, and hydroxynoneal, all of which are found in individuals displaying HAD
(2, 9). Oxidative processes and the resulting stresses are capable of inducing cell death,
even in the absence of viral infection, as suggested by the role of oxidative stress in a
number of other neurodegenerative diseases (10).
A major consequence of increased oxidative stress and excitotoxicity is activation
of the integrated stress response (ISR), which, as the name implies, is a response that
encompasses two key stress responses: the unfolded protein response (UPR) and the
endogenous antioxidant response, mediated by the transcription factor, nuclear factor
(erythroid-derived 2) (NF-E2)-related factor 2 (Nrf2) (11). Thus, the ISR regulates a host
of cellular processes, including intracellular Ca+2 levels, global and targeted protein
translation, protein folding and degradation, via increased transcription of ER chaperone
genes, and initiation of the endogenous antioxidant response, via activation of Nrf2 (1220). The ISR is comprised of three prongs, each headed by an initiator protein that is
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held inactive via complex with the ER resident chaperone, Binding-protein (BiP) (also
known as glucose-regulated protein 78 (GRP78)), when stress is absent (21). These three
initator proteins are: activating transcription factor 6 (ATF6), PKR-like ER kinase
(PERK), and inositol-requiring enzyme 1α (IRE1α). In the presence of a variety of
cellular stressors, BiP releases the initiator proteins, thereby allowing activation of ISR
pathways, all of which ultimately result in transactivation of genes containing the ER
stress response element (ERSE) in their promoter region, including BiP itself. Thus, BiP
is not only the master regulator of the ISR, but is also a key indicator of ISR activation,
regardless of which of the three pathways are active.
Nrf2 is the key regulator of antioxidant response genes (22-25) and acts through
its interaction with the antioxidant-responsive element (ARE) found in the promoter
region of genes encoding antioxidant proteins (23, 24). Kelch-like ECH-associated
protein 1 (Keap1) is a major regulator of Nrf2 activation, acting by controlling Nrf2
subcellular localization and by targeting Nrf2 for degradation via the ubiquitinproteasome pathway (23, 24, 26-28). Additionally, Nrf2 is a target for activating
phosphorylation by the ISR initiator protein, PERK (29), as well as other kinases,
including protein kinase C (PKC) and phosphoinositide-3 kinase (PI3K) (30-34).
Interestingly, Nrf2 mediates neuroprotection in cultures treated with toxins implicated
in HAND (35-39). However, these studies have focused on the Nrf2 response in
astrocytes and many of them have examined the role of Nrf2 using a Nrf2 knockout
mouse or an ARE reporter mouse and, thus, did not discriminate between the Nrf2
response in different neural cell types. Therefore, Nrf2 remains poorly characterized in
neurons, and any study of the antioxidant response in CNS diseases must include
examination of the function and regulatory mechanisms of Nrf2 in neurons.

3

Through the work presented in this thesis, we demonstrate evidence for ISR
activation in HAND. In the first chapter, using immunofluorescent analysis (IFA) and
immunoblotting, we show that there is increased expression of BiP in midfrontal cortical
tissue of autopsy cases from HAND patients, indicating that there is ISR activation in the
CNS of these patients (40). In the second chapter, we further characterized the nature of
ISR activation in HAND, by utilizing IFA to examine key proteins in the ISR and
determine which prongs of this major stress response are active in this disease. The third
chapter provides a detailed methodology for conducting IFA in a manner that allows for
accurate detection of differences between disease and control conditions (41). While this
chapter is focused on IFA for Nrf2, it is applicable for examination of other proteins and
was used extensively for the studies conducted in chapters 1 and 2. Chapter four narrows
examination of ISR activation to the antioxidant response component and branches out
into other neurodegenerative diseases that exhibit evidence of oxidative stress.
Specifically, studies presented in this chapter demonstrate alternative expression of Nrf2
in autopsy tissue from both Alzheimer disease cases and Parkinson disease cases when
compared with control tissue (42). Finally, chapter five begins the examination of Nrf2 in
HAND and includes the start of a study of Nrf2 in vitro, to begin characterization of Nrf2
in different neural cells, with an initial emphasis on neurons.
ISR activation is a double-edged sword where cell survival is concerned. While it
often acts to promote cell survival and recovery from a vast array of insults, it also acts to
initiate cell death via apoptosis under some circumstances, presumably including
extreme or chronic stress, such as that often seen in neurodegenerative diseases. Thus,
the work presented in this thesis provides important information, not only about a the
activation of a cellular survival mechanism activated in HAND, but also about a possible
mechanism of cell death in this, and potentially other, neurodegenerative diseases. A

4

review of the pathogenesis and potential therapeutic opportunies is given in the
introduction of this thesis, immediately following this overview (43).
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Abstract

Human immunodeficiency virus type 1 (HIV) infection presently affects more that 40
million people worldwide, and is associated with central nervous system (CNS)
disruption in at least 30% of infected individuals. The use of highly active antiretroviral
therapy (HAART) has lessened the incidence, but not the prevalence of mild impairment
of higher cognitive and cortical functions (HIV-associated neurocognitive disorders
(HAND)) as well as substantially reduced a more severe form dementia (HIV associated
dementia, HAD).
adjunctive

Further, improving neurological outcomes will require novel,

therapies

that

are

targeted

towards

mechanisms

of

HIV-induced

neurodegeneration. Identifying such molecular and pharmacological targets requires an
understanding of the events preceding irreversible neuronal damage in the CNS, such as
actions of neurotoxins (HIV proteins and cellular factors), disruption of ion channel
properties, synaptic damage, and loss of adult neurogenesis. By considering the specific
mechansms and consequences of HIV neuropathogenesis, unified approaches for
neuroprotection will likely emerge using a tailored, combined, and non-invasive
approach.
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Introduction
Over 40 million people worldwide are infected by human immunodeficiency
virus-1 (HIV) (UNAIDS/WHO), and, while HIV is most well known for its devastating
effects on the immune system and the resulting acquired immunodeficiency syndrome
(AIDS), it can also cause several neurological disorders, collectively known as HIVassociated neurocognitive disorders (HAND). HAND syndromes (minor cognitive motor
disorder

(MCMD),

HIV-associated

mild

neurocognitive

disorder

(MND),

and

asymptomatic neurocognitive impairment (ANI)) are characterized by cognitive, motor,
and behavioral abnormalities (Kaul et al. 2005) and are classified according to patient
performance in areas of neurological and behavioral functioning and neuropsychological
testing (Sacktor et al. 2001; Sacktor 2002; McArthur 2004; Antinori et al. 2007). Prior to
the widespread use of highly active antiretroviral therapy (HAART), 20-30% of
individuals with advanced HIV infection displayed symptoms of the most severe HAND
disorder, HIV-associated dementia (HAD) (Gonzalez-Scarano and Martin-Garcia 2005;
Kaul et al. 2005). Since the widespread use of HAART, the incidence of HAD has
dramatically decreased; however, as many as 40% of HIV-positive patients continue to
suffer from HAND. (Sacktor et al. 2001; Sacktor 2002; McArthur, 2004; Antinori et al.
2007). Further, although the incidence of HAD has decreased, its prevalence is actually
increasing, due in part to the longer life expectancy for individuals with HIV and to
patient resistance to HAART drugs (Gonzalez-Scarano and Martin-Garcia 2005). The
persistently high prevalence of milder forms of HAND (Sacktor 2004) suggests a shift in
the relative distribution of HAND subtypes in the post-HAART era. In patients
presenting with even the milder forms of HAND, quality of life is greatly affected, with
these individuals suffering from disruptions in ability to perform activities of daily living,
perhaps most importantly, that of adherence to the HAART regiment (MacArthur 2004).
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HAD manifests as a subcortical dementia characterized by psychomotor slowing,
changes in mood and anxiety levels, and deficits in memory, abstraction, information
processing, verbal fluency, decision-making, and attention (Navia et al. 1986; Grant et al.
1987; Price et al. 1988; Portegies et al. 1993). Surprisingly, deficits in olfaction are
common in HAD, and the severity, onset, and progression of the disease can reliably be
characterized using well-established olfactory tests (Grahm et al. 1994; Razani et al.
1995; Westervelt et al. 1997; Hornung et al. 1998; Mueller et al. 2002; Zucco and
Ingegneri 2004; Vance 2007). As this collection of symptoms would suggest, the brain
regions most commonly damaged in HAD are the basal ganglia, deep white matter,
hippocampus, and cerebral cortex (Gorry et al. 2003). Pathological features of HAD
include pervasive reactive astrocytosis, myelin pallor, activated resident microglia,
infiltration by circulating monocytic cells, perivascular inflammation, microglial nodules,
multinucleated giant cells, dendritic simplification, and cell death, both astrocytic and
neuronal (Gorry et al. 2003; Kaul et al. 2005). Interestingly, rather than closely
correlating with viral load in the central nervous system (CNS), clinical signs of HAD
more closely associate with increased numbers of microglia, evidence of excitotoxins,
and selective neuronal damage and loss (Kaul et al. 2005). These findings suggest that,
although HIV invasion into the brain may be a necessary initial step in HAD progression,
other mechanisms more directly lead to the functional losses associated with this
disease.
HIV infection in the central nervous system (CNS)
HIV primarily infects cells of the immune system, and untreated infection
ultimately results in AIDS and eventually death in the vast majority of cases.
Approximately 2-3 weeks after the primary infection, a patient with HIV infection enters
the acute stage of infection, which presents most commonly as fever, skin rash, oral
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ulcers, and lymphadenopathy (Pope and Haase 2003). HIV specifically infects and kills
CD4+ T cells, monocytes, and macrophages, and at this early stage of infection, the virus
establishes a reservoir within the lymphoid tissue and enters into the CNS. In lymphoid
tissue, productively infected, activated CD4+ T cells produce and release billions of
virions daily, accounting for the systemic viral load (VL) detected by patient plasma
sampling. Within the CNS the virus establishes its reservoir within the perivascular and
perhaps the parenchymal macrophage populations (Morris et al. 1999). Virus detected
through sampling cerebrospinal fluid (CSF) likely reflects contributions from both the
systemic and CNS reservoirs, with the CNS reservoir contributing more to CSF VL in
advanced infection (Ellis et al. 2000; Ritola 2005).
Neuropathogenesis of HAND: overview
While neuronal cell damage and death are clearly associated with the
development of HAD/HAND symptoms, HIV rarely, if ever, infects neurons themselves
(McArthur et al. 2003; Gonzalez-Scarano and Martin-Garcia 2005; Kaul et al. 2005).
Rather, productive HIV infection in the brain occurs in cells of the macrophage lineage,
including monocyte-derived perivascular macrophages and microglia (Gorry et al. 2003;
Kaul et al. 2005). According to the most widely accepted model, HIV invades the brain
through a “Trojan Horse” method (Liu at el. 2002), crossing the blood-brain barrier
(BBB) through infected monocytes that later differentiate into macrophages (Albright et
al. 2003). This can occur within 1-2 weeks after virus enters into the systemic circulation
(Davis et al. 1992; Gray et al. 1993). Subsequent infection and activation of neighboring
cells occurs via direct contact with infected cells (Gonzalez-Scarano and Martin-Garcia
2005). Cells directly contacted by infected ‘Trojan horse’ cells include perivascular
macrophages, astrocytes, and microglia (Williams and Hickey 2002; Gonzalez-Scarano
and Martin-Garcia 2005). Importantly, while astrocytes do appear susceptible to HIV
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infection, they do not develop productive infection, and thus, perivascular macrophages
and microglia are the only resident CNS cells capable of increasing HIV infection in the
brain (Gorry et al. 2003; Gonzalez-Scarano and Martin-Garcia 2005).

Considering that HAND symptoms are closely associated with neuronal damage
and loss, and the observation that HIV is unable to infect neurons, mechanisms other
than direct infection must mediate the neuropathogenesis of HIV infection. Currently,
two major models account for neurodegeneration and development of neurological
symptoms in HAND: the direct model and the indirect model. Each of these models
requires the initial productive infection of perivascular macrophages and microglia. The
direct model proposes that viral proteins released from infected monocyte-derived cells
cause neuronal death through direct interaction of viral proteins with neurons
(Gonzalez-Scarano and Martin-Garcia 2005; Kaul et al. 2005). The indirect, or
‘bystander,’ model proposes that neuronal death is mediated by the inflammatory
response mounted by infected and uninfected non-neuronal cells against HIV infection
and against HIV proteins released by directly infected cells (Gonzalez-Scarano and
Martin-Garcia 2005; Kaul et al. 2005). Clearly, these two models are not mutually
exclusive.
The indirect model of neurodegeneration in HAND centers upon soluble factors
released by non-neuronal cells as part of an inflammatory response to viral particles.
When activated through direct HIV infection or through exposure to viral particles,
macrophages and microglia release numerous soluble molecules, including the viral
proteins, gp120, Tat, and Vpr (only released from infected cells), quinolinic and
arachidonic acids, nitric oxide (NO), platelet activating factor (PAF), superoxide anions,
matrix metalloproteases, chemokines, growth factors, and proinflammatory cytokines,
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including tumor-necrosis factor (TNF) (Albright et al. 2003; Gonzalez-Scarano and
Martin-Garcia 2005). While some of these molecules, such as growth factors (i.e. brainderived neurotrophic factor (BDNF)) and some β-chemokines (i.e. regulated upon
activation-normal T-cell expressed and secreted (RANTES)), are believed to play a
neuroprotective role, a number of the other non-viral factors have proven to be
neurotoxic (Kaul and Lipton 1999; Klein et al. 1999; Gonzalez-Scarano and MartinGarcia 2005; Kaul et al. 2005). Additionally, NO and TNF impair the neuroprotective
functions of astrocytes, including maintenance of the BBB and glutamate reuptake, while
also increasing rates of astrocytic apoptosis (Gorry et al. 2003; Gonzalez-Scarano and
Martin-Garcia 2005). The concomitant release of excessive excitatory amino acids and
other N-methyl-D-aspartate glutamate receptor (NMDAR) agonists, and a reduction in
glutamate reuptake can create an excitotoxic environment that results in excessive
activation of NMDAR.

Consequently, intraneuronal Ca2+ concentrations reach toxic

levels, which results in production of free radicals (including reactive oxygen species
(ROS) and NO) and in neuronal death (Gonzalez-Scarano and Martin-Garcia 2005; Kaul
et al. 2005). Oxidative processes and the resulting stresses are capable of inducing cell
death, even in the absence of viral infection, as suggested by the role of oxidative stress
in a number of other neurodegenerative diseases (Mariani et al. 2005).
Neuropathogenesis of HAND: mechanisms of inflammation-induced neuronal insults
Both past and recent studies have provided a compelling argument for a role for
inflammation in triggering events leading to neurodegeneration in HIV infection.
Pulliam et al. (1997) first demonstrated that individuals with HAD express higher levels
of circulating activated CD14+ monocytes that co-expressed CD69 than non-HAD
individuals, and hypothesized that these activated monocytes enter the brain and
subsequently initiate neurotoxin production. Ryan et al. (2001) subsequently confirmed
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an association between plasma soluble CD14 (sCD14) and cognitive dysfunction in HIV
infection.

More recently, Ancuta et al. (2008) showed that elevated sCD14 and

lipopolysachharide (LPS) levels are associated with HAD. These observations support an
independent study which demonstrated that elevated systemic LPS levels and immune
activation in chronic HIV infection resulting from microbial translocation are associated
with HIV-induced depletion of gut associated lymphoid tissue (GALT) (Brenchley et al.
2006).

These studies clearly support the hypothesis that systemic immune

activation/inflammation triggered by HIV-induced transmicrobial translocation and
monocyte activation increases the risk for development of HAND through trafficking of
activated monocytes into the CNS.
The association between the abundance of activated macrophages/microglia in
the CNS, neuronal damage and cognitive dysfunction suggests that neuroinflammation
resulting from systemic immune activation and/or inflammation triggers the
neurodegeneration observed in HAND (Glass et al. 1995). Numerous in vitro and in vivo
studies link HIV-induced inflammation-associated neurodegeneration with macrophage
proinflammatory cytokine/chemokine production, excitotoxic neuronal injury, and
oxidative stress (Kaul et al. 2001;

Gonzalez-Scarano and Martin-Garcia).

We will

discuss each below.
a)

chemokine/cytokine effects. In response to HIV invasion of the CNS,

microglia and macrophages within the brain mount an immune response that includes
the release of both α- and β-chemokines. Since neurons express chemokine receptors
(Horuk et al. 1997; Lavi et al. 1997; Rottman et al. 1997; Miller and Meucci 1999;
Coughlan et al. 2000; Meucci et al. 2000), this HIV-induced inflammatory response may
play a critical role in the effects of HIV infection on the CNS. Studies have found elevated
levels of the α-chemokines, CXCL10/P-1o and CXCL12/SDF-1α, in the brains and CSF of
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HAD patients (Rostasy et al. 2003; Cinque et al. 2005). α-chemokines, which are
expressed in many types of CNS cells even under normal conditions, bind CXCR
chemokine receptors, thereby signaling a Gi protein-dependent increase in intracellular
calcium. α-chemokines can have both neuroprotective and neurotoxic effects (Kaul and
Lipton, 1999; Zheng et al. 1999; Khan et al. 2008). Specifically, depending on conditions,
CXCL12 can act to either enhance synaptic transmission or to activate caspase-3. When
cleaved by matrix metallic proteinases, CXCL12 changes its receptor specificity from
CXCR4 to CXCR3, which enhances the neurotoxic functions of this chemokine (Kaul and
Lipton 1999; Zheng et al. 1999; Zhang et al. 2003; Vergote et al. 2006). Similarly,
CXCL10, which acts through CXCR3 without prior proteolytic cleavage, induces
increases in intracellular calcium and activation of caspase-3 upon binding to its
receptor (Sui et al. 2004, 2006).
In contrast to α-chemokines, β-chemokines are only expressed at relatively low
levels in the brain under normal conditions. However, several β-chemokines are found at
increased concentrations in the CNS following HIV infection: CCL2, MIP-1α, MIP-1β,
and RANTES/CCL5 (Kelder et al. 1998). β-chemokines act through CCR receptors, and,
as with α-chemokines, they are capable of both neuroprotective and neurotoxic functions
in the brain (Schmidtmayerova et al. 1996). CCL5, MIP-1α, and MIP-1β all provide
protection against gp120-induced neurotoxicity in vitro (Meucci et al. 1998; Kaul and
Lipton 1999). Contrarily, CCL2 is associated with an increased risk of HAND, which may
be due to the role of this chemokine in the brain as a monocyte chemoattractant.
Further, microglia activated by interferons and astrocytes activated by IL-1β and TNF-α
express CCL2, which could also contribute to the positive correlation between CCL2
levels and increased risk of HAND (Kelder et al. 1998; Sevigny et al. 2004, 2007; Ragin
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et al. 2006). Thus, β-chemokines may contribute to neuronal toxicity via existing
pathways that are overstimulated by higher than normal concentrations of these factors.
In addition to α- and β-chemokines, elevated levels of the unique chemokine,
fractalkine/CX3CL1, have also been observed in the CSF of HAND patients (Pereira et al.
2001). CX3CL1, a member of the CX3C family of chemokines, binds to endothelial cells
and mediates monocyte attachment, potentially increasing monocyte migration across
the blood-brain barrier and into the CNS, further increasing inflammation in the brains
of patients with HIV-infection (Ancuta et al. 2003; Geissmann et al. 2003; Maslin et al.
2005). However, as with α-chemokines and β-chemokines, CX3CL1 appears to have both
positive and negative effects in the brain and, specifically, has been shown to provide a
degree of protection against neurotoxicity (Mizuno et al. 2003; Deiva et al. 2004;
Limatola et al. 2005). Thus, a delicate balance of neuroprotective and neurotoxic roles of
the major players in this response likely determine the effect on neurons of an HIVinduced inflammatory response in the CNS. However, it seems that much of the
protective function of chemokines is a counteraction to the negative effects of
inflammation, such as toxicity induced by increased intracellular calcium, and that it
may, therefore, be beneficial to treat HIV patients with drugs that protect the brain from
HIV-induced inflammation.
b)

excitotoxicity

Excitotoxicity is the process by which excess levels of an

excitatory neuotransmitter or other agent evokes prolonged periods of neuronal
membrane depolarization, thereby increasing calcium (Ca2+) levels, and consequently
activating proteases, endonucleases, and other enzymes which damage cellular
components.

The most common form of excitotoxicity in the CNS is glutamate

excitotoxicity, which is mediated by the NMDAR, a voltage and ligand-gated calcium ion
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channel that generates excitatory postsynaptic currents through calcium influx into the
neuron. The subunit composition of NMDAR varies throughout neuronal development,
and, to some degree, within different brain regions (Lynch and Guttmann 2001, 2002).
Thus, different brain regions can respond differently to excess glutamate and other
NMDAR agonists, possibly accounting for region specific damage in diseases in which
excitotoxicity plays a role, such as HAND.
Glutamate, the major excitatory neurotransmitter in the CNS, must be
maintained at physiological levels within the synapse to prevent sustained, toxic calcium
influx, (Rothman 1984; Hyrc et al. 1997). In the HIV-infected brain, activated and
infected macrophages release excitotoxic molecules that act upon the NMDAR, including
released glutamate, QUIN and the neurotoxic amine, N-Tox, and therefore, may evoke
damaging periods of NMDAR activation (Giulian et al. 1990; Jiang et al. 2001; O'Donnell
et al. 2006). Further, activated macrophages release factors that act in a paracrine
fashion to stimulate reactive CNS cells, most importantly the astrocytes and microglia.
Astrocytes, in particular, play a critical role in the regulation of extracellular glutamate
concentrations within the brain (Gegelashvili and Schousboe 1997; Kanai 1997;
Vandenberg 1998), and when activated this normal maintenance function is altered.
Therefore, altered glutamate release and uptake is thought to be a major pathway of
neurodegneration in inflammatory brain diseases such as HIV infection (Kaul et al.
2001). Notably, Ferrarese et al. (2001) reported that glutamate is elevated in the CSF of
HIV-infected individuals, further supporting a role for glutamate-mediated excitotoxicity
in the pathogenesis of HAND.

Although inward NMDAR-dependent currents evoked by glutamate derived from
astrocytes and infected macrophages/microglia are the most commonly cited contributor
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to excitotoxic death in neurons of patients with HAND, other ionic currents may also
play a role in excitotoxicity and neuronal dysfunction. Outwardly-rectifying currents
shape the action potential, interspike interval, and after hyperpolarization, and act to
determine overall membrane excitability.

Prolonged exposure to glutamate evokes

NMDAR-mediated excitotoxicity, but it is not fully understood how outwardly-rectifying
channels are modulated in response to such stimuli. Compensatory mechanisms are
likely initiated in order to attempt to restore and maintain the resting membrane
potential.

These changes in ion channel biophysics are ultimately damaging to the

neuron in the long-term because equilibrium likely favors a more depolarized voltage,
thus depleting energy stores and maintaining continual activation of ion channels and
calcium-dependent enzymes.

Any changes in ion channel properties, as well as membrane excitability,
ultimately affect the manner in which a neuron operates and processes incoming
synaptic signals. With respect to ion channels, there are several ways that HIV-related
molecules can alter biophysical properties.

Channel mean open probability, open

duration, unitary conductance, or channel inactivation and deactivation all can be
affected by various factors released by HIV-infected and/or HIV-activated immune cells
in the CNS. TNF-α evokes an increase in A-type K+ currents in cultured embryonic rat
cerebral cortex neurons (Houzen et al. 1997), and immune-activated macrophageconditioned media (MCM) also increases transient A-type (IA), as well as delayed
rectifier (IK), K+ current in cultured rat hippocampal neurons (Hu and Xiong 2009).
Glutamate produces a Ca2+-dependent dephosphorylation of Kv2.1 channels, which
disrupts channel clusters and increases mean open channel probability and conductance
(Murakoshi et al. 1997; Misonou et al. 2004). Further support for Kv channelopathy in
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HAD is observed in gene expression profiling studies demonstrating a markedly
decreased expression of two voltage-dependent K+ channels, which could likely cause
substantially decreased Kv currents (Gelman et al. 2004). Kv channels can regulate
back-propagating action potentials by influencing the postsynaptic NMDAR voltagedependent Mg2+ blockade, thereby decreasing overall membrane excitability (Paulsen
and Sejnowski 2000; Johnston et al. 2003; Birnbaum et al. 2004). Hence modulation of
Kv channels by some of these compounds could significantly affect NMDAR activation,
membrane excitability, and action potential propagation. Given the numerous
mechanisms by which HIV-infection in the brain can induce excitotoxicity, from
increases in extracellular glutamate to alterations of the channels that mediate the
electrochemical functioning of neurons, therapeutics directed against this particular
etiology of HAND are promising candidates for treatment.

c)

oxidative stress.

In addition to inflammation and excitotxocity, much

evidence supports a significant role for oxidative stress in the pathogenesis of HAND. In
fact, oxidative stress is a well-characterized down-stream effect of both inflammation
and excitotoxicity. Changes in cellular lipid metabolism that occur as a result of oxidative
stress, produce characteristic molecules, such as ceramide, sphingomyelin, and
hydroxynoneal, all of which are found in individuals displaying HAND (Kaul et al. 2005;
Sacktor et al. 2004). Additionally, oxidized proteins were detected in the CSF of patients
with HAND, further supporting a role for oxidative stress in the development of this
disease (Turchan et al. 2003). Treating rat cortical neuroglial cultures with gp120 results
in glial production of ROS and neuronal death, both of which are blocked when the
cultures are pre-treated with an antioxidant (Wakabayashi et al. 2003). HIV-proteins
may directly increase oxidative stress to neurons by inducing mitochondrial dysfunction
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and through interactions with membrane or cytosolic bound proteins. This finding
implicates oxidative stress as an important mode of neuronal death in the indirect model
of HAND neurodegeneration. Additional studies have demonstrated neuroprotective
capabilities of antioxidants in vitro (Turchan et al. 2003), and therapeutic properties of
antioxidants in vivo in HIV patients, showing both inhibition of mental deterioration
and improvement of general health (Shor-Posner et al. 2002). These findings
demonstrate a significant pathogenic role for oxidative stress in HAND, and suggest that
the endogenous cellular antioxidant response may serve as a potential therapeutic target
in this disease.

Neuropathogenesis of HAND: consequences of chronic neuroinflammation
The pathways of neuronal damage described above are often considered the "classical" or
"central" pathophysiologies of HAD. However, new and often neglected studies have
highlighted other consequences of neuroinflammation in HIV-infected and HAD
individuals, that when observed in the light of physiological mechanism, become
increasingly important in the study of disease progression.

a) Synaptic disruption. In addition to neuronal death, HAND is associated with
neuronal damage, particularly synaptic disruption. The etiologies described in this
review, specifically inflammation and excitotoxicity, provide mechanisms by which this
HIV-associated synaptic damage may occur. Activation of calcium-dependent proteases
that disrupt the postsynaptic density is a likely mechanism by which synapses may be
altered in the HIV-infected CNS. The smooth ER, which extends into the dendritic
spine, contains IP3 receptors that are tethered to mGluR and NMDARs by a complex of
adaptor proteins, including Shank, GCAP, Homer, and PSD-95 (Tu et al. 1998; Sheng
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and Kim 2000, 2002; Sheng and Hoogenraad 2007). Secondary IP3-mediated calcium
influxes are thought to play a role in LTP, however, prolonged synaptic depolarization
and IP3-mediated signaling can also activate calpain proteases that can cleave PSD-95
which releases it from NMDAR (Lu et al. 2000).

This could cause a large-scale

decoupling of the postsynaptic complex from IP3 receptors. Interestingly, PSD-95 loss is
also a hallmark sign of neurodegeneration (Gardoni 2008; Gardoni et al. 2009); hence
uncoupling or disruption of the PSD may be an important step in synaptic dysfunction
and damage. Thus, inhibition of IP3-mediated calcium currents may prevent calpain or
other protease activation, as well as block kinase enzymes from phosphorylating and
modulating Kv channels.

A summary of synaptic/cellular neurotoxic pathways and

synaptic damage is presented in Figures 1 and 2 to recapitulate the major findings
discussed in this section and to illustrate the complexity of the pathological mechanisms
evoked by CNS HIV infection.

b) Impairment of neurogenesis. The dogma of a fixed and static CNS has been
replaced by an understanding of the brain as a plastic, complex, and highly dynamic
environment where new neurons are continually generated in adult animals through the
process of adult neurogenesis (ANG). ANG is not confined to rodents, as recent work has
demonstrated the occurrence of ANG in humans and other primates (Eriksson et al.
1998; Gage 2000; Pancea et al. 2001; Kam et al. 2009). In fact, recent studies have
demonstrated that disruption of ANG is significantly involved in HAND and other
neurodegenerative diseases (ND) (Haughey et al. 2002; Donavan et al. 2006; KelleherAndersson 2006; Chen et al. 2007; Galvan and Bredesen 2007; Zhang et al. 2007;
Rodriguez et al. 2008; Taupin 2009). Further, substantial evidence demonstrates that
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ANG is involved in learning and memory, olfaction, and anxiety-related behaviors, all of
which are functions that are disrupted in HAD and ND.
The two regions of the brain that contain the highest amount of newborn neurons
are the hippocampus and the OB (Altman 1969; Lois and Alvarez-Buylla 1994a,b;
Eriksson 1998; Gage 2000). Neural progenitor cells (NPCs) arise in the subventricular
zone (SVZ) or the dentate subgranular zone (SGZ). SVZ NPCs migrate laterally and
superiorly eventually terminating in the subependymal zone of the OB and SGZ NPCs
migrate superiorly into the dentate gyrus of the hippocampus. After reaching their target
destination, NPCs then begin to integrate into existing circuits, often forming inhibitory
interneurons (Xiong et al. 2008). NPCs migrate from the SVZ to the ofactory bulb via the
rostral migratory stream, which is lined with glial cells which provide trophic support to
the migrating NPCs. As NPCs get closer to their destination, they begin to differentiate,
and form immature neurons. Immature neurons then begin to synaptically integrate
with already existing mature neurons.

HIV infection induces several processes by which ANG could be interrupted.
HIV-induced alteration of general astrocyte function, including the trophic support these
cells provide for both mature and immature neurons, may impair the proliferation and
migration of NPCs and immature neurons along their migratory route (Figure 3). Under
this hypothesis, the OB, which is the most distant structure along the RMS, would be
affected first in the earliest stages of the disease, which in fact is the case in most ND
where olfaction is perturbed, such as HAND (Grahm et al. 1994; Razani et al. 1995;
Westervelt et al. 1997; Hornung et al. 1998; Mueller et al. 2002; Zucco and Ingegneri
2004; Vance 2007). Not surprisingly, cell cycle machinery play a role in regulating the
fate of NPC (Herrup and Yang 2007). Interestingly, cell cycle proteins, such as the
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transcription factor, E2F1, and its regulator, the retinoblastoma gene product (pRb),
exhibit increased levels and altered expression patterns in AD, PD, and HAND
postmortem tissue (Jordan-Sciutto et al. 2002a,b; Hoglinger et al. 2007). Consistent
with a role for these proteins in altered neurogenesis, mice carrying a gene-targeted
deletion of E2F1 display substantially reduced ANG in the OB and hippocampus
(Cooper-Kuhn et al. 2002).

Further, doublecortin (DCX), a microtubule protein

expressed in immature neurons (Takacs et al. 2007), has several promoter sites that are
regulated by cell cycle proteins, including the E2F consensus site (Karl et al. 2005).
Thus, altered E2F1 function and a consequent disruption of DCX in HAND may cause an
interruption in ANG, thereby contributing to the pathogenesis of these HIV-associated
disorders. The CNS relies heavily on plasticity, hence, the disruption of ANG and its
molecular regulation could yield devastating consequences for circuits and brain regions
assaulted by HIV-induced toxicity.

Another mechanism by which HIV could impair ANG is the perturbation of
metabolism and associated insulin signaling pathways.

Insulin in the brain enhances

working memory, promotes neuronal survival, and regulates reproduction via the
hypothalamic-pituitary axis (Brüning et al. 2000) This hormone acts as a
neuromodulator by affecting synaptic plasticity and neurotransmitter release (Plum et al.
2005). Importantly, several lines of evidence suggest that insulin and insulin-like growth
factor (IGF) are very important in ANG. Hippocampal neural progenitor cells express the
insulin receptor (IR) and IGF-1 receptors, and insulin and IGF-1 are known to stimulate
ANG in the dentate gyrus.

ANG, synaptic plasticity and learning potential are

significantly compromised in the rodent model of type 1 diabetes (Stranahan et al. 2008;
Zhang et al. 2008), suggesting that both endocrine and brain insulin play a substantial
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role in the generation of new neurons (Kamal et al. 2000). Lang et al. (2009) also show
that ANG is severely impaired in the adult type-2 diabetic GK rats, demonstrating that
aberrant insulin signaling or insulin resistance can disrupt ANG. IGF-1 also has received
considerable attention in recent years as a potential modulator of ANG (Aberg et al.
2000, 2003; Lichtenwalner et al. 2001; Trejo et al. 2001; Anderson et al. 2002; PerezMartin et al. 2003a,b). In adults, peripheral IGF-1 mediates an exercise-induced
enhancement of neurogenesis in the hippocampus (Trejo et al. 2001) and also has a
direct proliferative effect on adult hippocampal progenitor cells in culture (Aberg et al.
2003). Intracerebroventricular infusion of IGF-1also eliminates the modest decrease in
ANG that occurs in advanced geriatric animals (Lichtenwalner et al. 2001).
HIV infection alters insulin signaling, glucose homeostasis, lipid distribution, and
metabolism in patients with or without HAART therapy (Grinspoon and Bilezikian 1992;
Sellemeyer and Grunfield 1996; Kotler et al. 1999). Mechanisms of metabolic disruption
in HIV-infected patients remain unclear, but it is hypothesized that peripheral
chemokine signaling is at least partially involved in the alteration of insulin and glucose
homeostasis (Hardly et al. 2001; Carper et al. 2007). In addition, patients on HAART
therapy experience more pronounced metabolic disturbance, leading to aberrant lipid
distribution (Safrin and Grunfield 1999). HAART and some medications used to treat
behavioral perturbations in HAD are known to cause a prolonged form of insulin
resistance (Grinspoon and Bilezikian 1992; Hardly et al. 2001; Hughes et al. 2005;
Carper et al. 2007). Some of these medications can bind the insulin receptor (IR) kinase
domain and inhibit downstream phosphorylation of targets, or reduce voltage-gated K+
channels and other anion currents (Neye et al. 2006), which are known to affect glucose
sensitivity and insulin response signaling (Xu et al. 2004; Desir 2005; Li et al. 2006;
Tschritter et al. 2006). Thus, altered signaling from the IR could potentially cause a
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form of insulin resistance, and may be one of the factors by which HAND continues to
progress in patients on HAART.

Therapeutics for HAND; current trials and considerations

Recent and past clinical therapeutic trials for the treatment of HAND have
focused on drugs as adjuncts to current HAART, and although only modest success with
adjunctive therapies has been achieved the need for more effective protection against
HAND has clearly been recognized (Clifford et al. 2009). In addition more effective
utilization of HAART drugs, based upon individual drug CNS penetration and efficacy
represents an immediate approach, and more effective delivery of HAART drugs through
nanoparticle delivery offers exciting possibilities for future consideration (Dou et al.
2009).

Some adjunctive therapies to HAART studied thus far include NMDAR

antagonists, calcium channel blockers, antioxidants, and anti-inflammatory drugs that
either specifically or non-specifically target suspected key pathways in HIV-induced
neuronal injury. Several recent, large scale trials conducted through the AIDS Clinical
Trials Group (ACTG) focus on three of these drugs:

minocycline, Memantine, and

Selegiline.

Minocycline: anti-inflammatory
Minocycline is a second-generation tetracycline antibiotic derivative developed in
the 1960s, and has become an attractive drug candidate to treat HAND and other
neurodegenerative diseases (ND). In addition to the antibiotic properties of this
molecule, it also potentially has protective and anti-inflammatory effects in the CNS.
Minocycline is able to cross the blood-brain barrier at a substantial rate (Colovic et al.
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2003), thus allowing delivery at much lower concentrations than other medications.
Minocycline has neuroprotective effects in quite a few models of neurodegenerative
diseases, as well as in traumatic and ischemic brain injury (Chen et al. 2000; Du et al.
2001; Sanchez Mejia et al. 2001; Arvin et al. 2002; Van Den Bosch 2002; Wu et al. 2002;
Metz et al. 2004). Minocycline has the advantages of being inexpensive to produce,
readily available in the pharmaceutical market, and safe to administer over a long
treatment time course.

The mechanisms by which minocycline could potentially provide protection
against HAND are numerous. Minocycline suppresses JNK activation and lowers nitric
oxide (NO) levels in the brain in SIV models of infection (Follstaedt et al. 2008), and, in
parallel with this finding, minocycline suppresses NO-induced activation of p38 and JNK
in vitro. Moreover, minocycline can inhibit ASK1 activation and disrupts the cyclical
inflammation/virus replication that is often the precursor to the encephalitic state (Zink
et al. 2005). Neuroprotective properties of minocycline are also linked to suppressed
activation of p38 mitogen-activated protein kinase, a key physiopathology of SIV
encephalitis (Barber et al. 2004). In addition, minocycline can also protect the brain by
inhibiting the immune cell infiltration and activation of microglia that lead to
encephalitis (Tikka et al. 2001a,b; Zink et al. 2005). Finally, minocycline significantly
inhibits HIV and SIV replication in vitro (Zink et al. 2005), making this drug an
excellent candidate for limiting HIV replication within the brain, which has remained a
difficult anatomical compartment for therapeutic interventions for HIV due to the lack of
BBB permeability of many such drugs.
treatment

of

HAND

A multicenter study of minocycline for the

(ACTG5235)

is

(http://clinicaltrials.gov/ct2/results?term=HIV+dementia).
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currently

underway

Memantine: anti-excitotoxicity
Memantine is a voltage-dependent, open channel NMDAR blocker that decreases
prolonged conductance of calcium via a simple uncompetitive bimolecular reaction with
the receptor that does not appear to interfere with physiological function (Chen and
Lipton 1997; Rammes et al. 2008). Memantine is effective in gp120 transgenic mice and
HIVE SCID mice. Further, it appears to have some efficacy in clinical trials in patients
with Alzheimer’s Disease (AD), another neurodegenerative disease associated with
excitotoxicity (Raber et al. 1996; Anderson et al. 2004; Lipton and Chen 2004; Tariot et
al. 2004), and is, in fact, currently FDA-approved for AD treatment.

The neuroprotective potential for NMDAR antagonists such as Memantine, in
cases of HAND has recently been investigated in a therapeutic multicenter trial of
Namenda (Memantine) (Schifitto et al. 2007b).

However, no clinically significant

benefit in neuropsychological and behavioral testing performance was observed during
the 16-week treatment phase of the trials, though there were potential neuroprotective
effects demonstrated by Magnetic Resonance Spectroscopy (MRS) in the frontal white
matter and parietal cortex in treated individuals. Further trials of pharmaceuticals that
block excitotoxic pathways, in particular glutamate and QUIN production, and trial
designs of longer duration are clearly needed and are likely to follow in the future
(Bandaru et al. 2007; Brew et al. 2007; Clifford 2008; Evans et al. 2007).

Selegiline: anti-oxidant
Selegiline is a monoamine oxidase type B inhibitor (MAOIB) that has recently
been used in clinical trials for the treatment of HAD (Sacktor et al. 2000; Schifitto et al.
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2007a, 2009). There is evidence that Selegiline has a low-dose trophic effect on neurons,
and also can reduce oxygenated free radicals. Transdermal administration of Selegiline
results in less monoamine peripheral metabolites than the oral route, suggesting that
certain toxicities may be avoided with higher transdermal doses of this pharmaceutical
(Schifitto et al. 2007a, 2009). However, the most recent study with the transdermal
application system did not yield expected results (Schifitto et al. 2009). This system
demonstrated no effect on either magnetic resonance spectroscopy metabolites or
protein carbonyl concentration from CSF, which can be a measure of oxidative stress.
The authors hypothesize that changes in oxidative stress may occur before neural
imaging performed in this study, hence Selegiline may yet prove to be an effective
treatment as more advanced clinical analyses become available.

Therapeutics for HAND; future considerations for adjunctive therapies

In addition to current treatment approaches (HAART drug delivery, NMDAR
antagonists, antioxidants, anti-inflammatory drugs), novel agents and routes of delivery
are also under consideration. Recent successes in the CNS delivery of trophic factors
(insulin,

IGF-1,

neurotrophin)

neuroprotectants against HIV.

have

provoked

interest

in

these

agents

as

The development of intranasal delivery (IND) of

neurotrophin, insulin, and IGF-1 has emerged as a potential therapeutic technique to
reduce damage associated with stroke and memory degeneration associated with HAND,
AD, or diabetes (Kern et al. 1999; Thorne and Frey 2001; Benedict et al. 2004; Thorne et
al. 2004, 2008; González 2006; Reger et al. 2006, 2008; Hanson and Frey 2007; Reagan
2007).

IND allows rapid delivery from the nose to the CNS via an extracellular route,

which does not require selective hormone binding or axonal transport mechanisms
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(Dhanda et al. 2005; Hanson and Frey 2007). One of the most interesting aspects of
IND is that after molecule administration, there is virtually no rise in blood
concentration of that particular molecule. Insulin, IGF-1, FGF-2 and HB-EGF have all
been tested intranasally and were not elevated in the serum of the test subjects/animals
nor were peripheral glucose levels affected (Jin et al. 2003; Thorne et al. 2004; Reger et
al. 2005; Hanson and Frey 2007, 2008; Reger et al. 2008a,b; Marks et al. 2009).
Delivery time and clearance rates are also quite remarkable for IND, where some studies
show anywhere from 6-20 min of peak concentration (Thorne et al. 1995, 2004), and 49h of clearance from the CSF (Thorne et al. 2004; Hanson and Frey 2007). Delivery
systems for IND are fairly simple, mimicking commercially available nasal spray
mechanical design, or for murine models, a standard P10-20 pipetteman and associated
sized plastic tip (Thorne et al. 2004; Benedict et al. 2007; Hanson and Frey 2007;
Francis et al. 2008; Marks et al. 2009). There is also no associated damage to the
olfactory epithelium, olfactory bulb, or disruption of olfactory receptor neuron axonal
targeting (Marks et al. 2009). Thus, for drug delivery to the CNS, IND appears to be a
non-invasive, fast, safe, and cost-effective solution with little, if any, of the peripheral
side effects that are often associated with oral and site-injection medications.

IND of insulin and other molecules has been demonstrated to mitigate many of
the behavioral and pathological deficits associated with HAND and other ND.
Specifically, Marks et al. (2009) demonstrated that chronic intranasal insulin delivery
enhances odor discrimination and short- and long-term memory, as well as reduces
anxiety. Reger et al. (2005; 2008a,b) also demonstrated that acute intranasal insulin
delivery enhances memory in AD patients. IND also has rapid and continual effects
where subjects receiving acute and/or chronic IND insulin have reported extended
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periods of enhanced mood, reduced anger, and enhanced self-confidence in clinical trials
(Benedict et al. 2004). In a recent comprehensive review of HAND pathophysiology, the
authors state "Now more than ever, patients are in need of therapy in combination with
ART in order to alleviate the potentially greater neuropsychological decline over a longer
lifespan" (Ferris et al. 2008). Thus, a combined HAART and intranasal therapy intended
to address multiple etiologies of HIV-induced damage in the CNS could be a promising
regimen for persons at high risk for HAND.

CONCLUSION
The therapeutic targets for HAND neuroprotection discussed in this review, as
well as others, clearly need further consideration if effective treatment regimens for
HAND are to be identified and developed. We believe that effective control of CNS viral
replication through HAART is the essential primary approach, but that it should be
complemented with adjunctive CNS-directed therapeutics. HIV-induced inflammation
and its consequences, expressed both systemically and within the CNS, are attractive
targets that could be approached through multiple pharmacologic agents. Minocycline is
a promising candidate for treating the negative effects of this inflammatory response.
Excitotoxicity is another mechanism of neural damage evoked by HIV and HIV-related
molecules in the brain. The open-channel NMDAR blocker, Memantine, has proven
beneficial in animal models of HAND, but the recently published short-term clinical trial
results are disappointing, and it is thus unclear how successful this agent will be in the
long-term. The possibilities for antioxidant therapies to reduce oxidative stress are quite
numerous. Selegiline is one of many antioxidants, but it also yielded disappointing
results in a recent short-term clinical trial. It is clear that the possibilities for future
HAND treatments abound and that novel classes of potential neuroprotectant agents, as
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well as increased duration of clinical trial testing and novel routes of administration,
should be strongly considered in future trials.
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Figure 1:

Figure 1. Toxicity pathways induced by HIV-associated soluble factors. Inflammatory molecules
released from microglia/macrophages and astrocytes evoke NMDAR activation, as well as activation of
metabotropic glutamate receptors (mGluR), receptor tyrosine kinases (RTK), voltage-gated potassium
channels (Kv), other G-protein-coupled receptors (GPCR), and potentially major histocompatability complex
subtype 1 receptors (MHC I). Excess calcium influx, as well as release of intracellular calcium via IP3
receptors, leads to activation of calpains and other calcium-dependent proteases, which are known to cleave
post synaptic density proteins such as PSD-95 leading to synaptic dysfunction and disassembly.
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Figure 2:

Figure 2. Diagram detailing the numerous processes evoked by HIV infection in the brain
that affect neuronal function and survival. Excess glutamate from the extracellular fluid and released
from astrocytes causes excitotoxic mechanisms, such as dendritic beading, sustained NMDAR activation,
increased calcium influx, and increased intracellular release of calcium. Ultimately, these processes lead to
disruption of the postsynaptic density and loss of synapses. Viral proteins such, as gp120 and TAT, activate
chemokine receptors, CXCR4 and CCR5, and can increase voltage-gated calcium (Cav) channels and
potassium channels (Kv), leading to activation of cellular death pathways that result in mitochondrial
depolarization, cytochrome p450 (Cp450) release, and ultimately DNA fragmentation associated with
apoptosis. Viral proteins can also evoke increased Na+/H+ exchange, thereby increasing the pH inside
astrocytes which promotes increased glutamate release and decreased glutamate uptake, thereby furthering
excitotoxic damage.
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Figure 3:

Figure 3. Diagram detailing the various checkpoints of adult neurogenesis (ANG) that can be
affected by HIV infection in the brain. Neural progenitor cells (NPCs) and their supporting astrocytes
can be damaged by inflammation associated with HIV infection. Multinucleated giant cells and microglia,
especially near the rostral migratory stream, could also contribute to toxicity and damage to NPCs and
immature neurons. Differentiating NPCs, as well as their integration into existing synaptic circuits, can also
be affected.
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ABSTRACT
Despite the introduction of highly active antiretroviral therapy (HAART), the prevalence
of human immunodeficiency virus (HIV)-associated neurocognitive dysfunction, which
includes HIV-associated dementia and Minor Cognitive Motor Disorder, has been
steadily increasing. Neuronal injury and loss seen in HIV associated neurocognitive
dysfunction is initiated by HIVinfected, activated macrophages/microglia via soluble
neurotoxic mediators, including reactive oxygen species (ROS), viral proteins, and
excitotoxins. These mediators are known to injure neurons directly and to alter
astrocytic homeostatic functions such as glutamate homeostasis, which can lead to
excitotoxicity and oxidative stress-mediated neuronal injury. A major downstream
response to oxidative stress is induction of the endoplasmic reticulum (ER) stress
response. We hypothesize that the ER stress response is activated in the brains of HIVinfected patients. To begin to investigate our hypothesis, we assessed the expression
patterns of an ER stress response protein, Binding Protein (BiP) by immunofluorescent
staining and immunoblotting in autopsy tissue from HIV(+) patients. BiP is a molecular
chaperone protein whose expression is controlled by all three independent branches of
the ER stress response. We observed a significant increase in total BiP levels by both
immunoblotting and immunofluorescent staining in HIV(+) cortical tissue compared
with

that

seen

in

control

tissue.

Additionally,

by

phenotypic

analysis

of

immunofluorescent staining, we saw cell-type specific increases in BiP levels in both
neurons and astrocytes (p< 0.05). Together these results suggest that the ER stress
response is activated in HIV-infected cortex in vivo.
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Introduction
The neurocognitive dysfunction observed in HIV-infected individuals manifests
as cognitive, motor and behavioral abnormalities. Prior to the widespread use of highly
active antiretroviral therapy (HAART) [1], 20-30% of individuals with advanced HIV
displayed symptoms of a severe form of neurocognitive impairment, HIV-associated
Dementia (HAD) [2, 3]. While the incidence of HAD has decreased in the post-HAART
era, the prevalence of this disorder is actually rising due to the longer life expectancy for
individuals with HIV [3]. In fact, HAD is the most common form of dementia among
young adults. Moreover, a less severe form of HIV-induced neurocognitive dysfunction,
Minor Cognitive and Motor Disorder (MCMD), has become more common in the postHAART era [4]. While it is not clear whether MCMD can progress to HAD [4], the
prevalence of these forms of HIV-associated neurocognitive impairment (NCI) suggest
that the central nervous system continues to sustain damage despite HAART.
HIV traffics across the blood-brain barrier via infected monocytes that
differentiate into macrophages and constitute a viral reservoir in the brain [3, 5-7]. There
is little evidence supporting direct HIV infection of neurons. Rather, the infected and/or
activated macrophages release various soluble neurotoxic factors including viral
proteins, cytokines, chemokines, reactive oxygen species (ROS), and excitotoxins into the
extracellular milieu [8-14]. These factors induce astrocytes, neurons and macrophages to
secrete more of these and other neurotoxic and pro-inflammatory factors, which
contribute to the neuronal damage seen in neurologically impaired HIV patients.
Hallmarks of the disease such as astrogliosis, perivascular inflammatory macrophages,
microglial nodules and multinucleated giant cells all suggest that a

chronic

inflammatory process contributes to the neuronal damage seen in the brains of HAD and
MCMD patients [6].
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Several

of

the

soluble

neurotoxic

factors

released

in

HIV-associated

neurocognitive disorders are able to induce the recently defined endoplasmic reticulum
(ER) stress response (also known as the unfolded protein response) [15]. The ER stress
response regulates protein synthesis, folding, and degradation, intracellular Ca+2 flux,
transcription of ER chaperone genes, and activation of the endogenous antioxidant
response. Thus, induction of the ER stress response acts to promote cell survival and
recovery from a variety of cellular insults, such as oxidative stress, hypoxia, nutrient
deprivation, and viral infection [16, 17, 18, 19-23].
ER stress response has three major pathways, each with its own initiator [15]:
Pancreatic endoplasmic reticulum kinase (PERK), activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1a (IRE1a). Binding-protein (BiP) (also known as
glucose-regulated protein 78 (GRP78)) is an ER resident molecular chaperone and
belongs to the Heat Shock Protein (HSP) 70 family. BiP acts as a master regulator of the
ER stress response through its coupling with PERK, ATF6 and IRE1a [24]. Under
physiological conditions, BiP complexes with and stabilizes the three ER stress response
initiators, thus suppressing ER stress response activation. However, in response to
stress, BiP releases the initiators. When not bound to BiP, PERK oligomerizes and
autophosphorylates, inducing its kinase activity. PERK in turn phosphorylates
eukaryotic initiation factor 2α (eIF2α), which inhibits translation initiation by blocking
the formation of methionine-charged tRNA. With limited charged initiator methionine
tRNA, translation re-initiation is favored over new initiation, increasing translation of
mRNAs with multiple micro open reading frames (µORF) in their 5' coding regions.
Among the translated mRNAs is the ATF4 transcript whose gene product transactivates
expression of the ER stress response element (ERSE) [18].

Additionally, PERK

phosphorylates NF-E2 related factor 2 (Nrf2), initiating its nuclear translocation, and
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consequently triggering the antioxidant response [16, 25]. When free of BiP, ATF-6
migrates to the transgolgi where the 50 kD N-terminal cytosolic fragment, ATF-6b, is
released by proteolysis. ATF-6b then translocates to the nucleus, and activates
expression of genes containing the ERSE [26-30]. Finally, disruption of BIP:IRE1α
interaction

permits

dimerization

of

IRE1α,

a

serine/threonine

kinase

with

riboendonuclease activity [31, 32]. When dimerized, IRE1α autophosphorylates,
activating a splicing activity that in turn removes an inactivating intron from the X-box
binding protein 1 (uXBP1) mRNA [33, 34]. Removal of this intron permits efficient
translation of the sXBP1 protein which also activates the ERSE [35-37]. Thus, all three
regulators increase activity of ERSE-containing promoters, which include BiP and an
apoptotic regulator, CHOP (CCAAT enhancer binding protein homologous protein) [19].
While ER stress response activation increases the expression levels of both BiP
and CHOP (GADD153), they play opposing roles in this stress response. In addition to
acting as a master regulator of the ER stress response, BiP also has an anti-apoptotic
function through its inhibition of the pro-apoptotic CHOP. CHOP promotes apoptosis by
inducing ROS generation and downregulating Bcl-2 [38]. Further, it plays a central role
in caspase-4 induced, ER specific apoptosis [22, 24, 39, 40]. Thus, a critical balance
between BiP and CHOP is vital in determining the fate of cells responding to stress, and
when the usually acute ER stress response becomes chronic, this balance might be
disrupted.
While several reports implicate ER stress response activation in a number of
conditions, including brain trauma [41], ischemia [20, 39, 42], Alzheimer’s disease [40]
and Parkinson’s disease [43, 44], there are no reports evaluating its role in HIV-induced
neuronal damage. Several factors suggest a role for chronic ER stress response activation
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in HIV-associated neurocognitive impairment. First, both in vitro and in vivo studies
suggest that prolonged exposure of the brain to HIV-infected and/or activated cells
induces oxidative stress [45-47]. Additionally, in vitro studies suggest that certain viral
infections, including borna virus [22], Japanese encephalitis virus [48], and human
cytomegalovirus [49], induce ER stress response. Thus, oxidative stress and viral
proteins in HIV infection of the brain might initiate ER stress response activation, and
further, as this stress response becomes chronic, it may contribute to the neuronal loss
seen in HIV-associated NCI.
In this paper, we sought to determine whether ER stress response activation
occurs in HIV-induced neurodegeneration. To this end, we evaluated BiP expression in
autopsied human brain tissue. Here, we report that BiP is significantly increased in midfrontal cortical gray matter of HIV-infected and neurocognitively impaired patients.
Further, we also show that the transcriptionally active fragment of ATF-6 (ATF-6b), is
also significantly increased in mid-frontal cortical autopsy tissue from HIV-infected
patients. These findings suggest a role for the ER stress response in HIV-induced
neurodegeneration and the resulting neurocognitive impairment.
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Materials and Methods
Protein Extraction and Immunoblotting: For immunoblotting, fresh frozen tissue
samples from the cortices of control (n=4) and HIV(+) (n=15) human autopsy cases were
obtained from the tissue banks of National NeuroAIDS Tissue Consortium (NNTC). The
age, sex, neurocognitive status, and postmortem interval of each specimen was provided
by NNTC (Table 1). Tissue was homogenized in a Dounce tissue grinder (Kimble/Kontes,
Vineland, NJ) in Lysis Buffer (50 mM Tris-HCl (pH 7.5), 0.5 M NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 1% SDS, 2 mM EGTA, 2 mM EDTA, 5 mM NaF, 0.1 mM PMSF, 1
mg/ml leupeptin, 1 mM DTT, and protease inhibitor cocktail (Sigma)). Homogenized
tissue was sonicated 3 times in 6 second cycles, and centrifuged at 25,000 rpm for 30
min. The supernatants from the lysates were collected and protein concentrations were
determined by the Bradford method. 100µg protein was loaded to each lane of 10 % BisTris gels for separation, transferred onto PVDF membranes, and blocked in TBS with 1%
Tween-20 (TBS-T) and 5% nonfat milk for 1h at room temperature. Membranes were
incubated at 40C overnight with either mouse monoclonal antibody to BiP (BD
BioSciences, San Jose, CA), or goat polyclonal antibody against ATF-6b (Santa Cruz
Biotechnology, Santa Cruz, CA) in TBS-T with 5 % bovine serum albumin (BSA). The
membranes were then washed three times with TBS-T and incubated with HRPconjugated secondary antibody (Pierce Biotechnology, Rockford, IL) in TBS-T + 5% BSA
for 1h at room temperature. Following three washes with TBS-T, the membranes were
developed using SuperSignal West Dura Extended Duration Substrate (Pierce
Biotechnology, Rockford, IL) and were exposed to Amersham Hyperfilm (GE Healthcare,
Piscataway, NJ). A broad range molecular weight ladder (BioRad, Hercules, CA) was run.
For quantitative band analysis, autographs were scanned into Adobe Photoshop (Adobe
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Systems, San Jose, CA), and bands were assessed for pixel intensity by NIH ImageJ
program (V 1.36b), and normalized to the pixel intensity of the loading controls.
Coomassie Staining: Loading controls were obtained by staining the PVDF membranes
with the Coomassie Brilliant-Blue R-250 (BioRad, Hercules, CA) solution (0.1%
Coomassie (w/v) in 50% Methanol) for 5 min, followed by destaining with 25% acetic
acid in 50% methanol for 30 min. The membranes were then photographed by a Nikon
Coolpix 995 camera and further analysis was done using NIH ImageJ, as described
above.
Immunofluorescent

Histochemistry:

For

immunofluorescent

staining,

paraffin-

embedded tissue sections from the cortices of control (n=4) and HIV(+) (n=14) human
autopsy cases were obtained from National NeuroAIDS Tissue Consortium (NNTC).
Glass slides containing paraffin-embedded sections (7 mm) were deparaffinized and
rehydrated as described previously [50]. Endogenous peroxidase activity was inactivated
using 3% H2O2 in methanol. Antigen unmasking was performed by target retrieval
solution (Dako, Carpinteria, CA, USA) at 95°C for 1 h. Tissue sections were then blocked
with 10% normal goat serum in PBS. Mouse monoclonal antibodies to BiP (Clone 40,
1:500,000, BD BioSciences, San Jose, CA), macrophage/microglia marker, HAM56 (
Human alveolar macrophage, clone 56, 1:100, Dako Corporation, Carpinteria, CA), and
to MAP2 (SMI-52, 1:100, Covance Research Products, Berkeley, CA), and a rabbit
polyclonal antibody to GFAP (Z0334, 1:80, Dako, Carpinteria, CA) were used. The
tyramide amplification system (New England Biolabs, Beverly, MA) was used to detect
BiP. DNA was visualized by DAPI staining (5 mM, Molecular Probes, Carlsbad, CA).
Slides were mounted in Citifluor AF1 (Citifluor, Ltd., London, UK) and were analyzed by
laser confocal microscopy on a Biorad Radiance 2100 equipped with Argon, Green
He/Ne, Red Diode, and Blue Diode lasers (Biorad, Hercules, CA, USA), as described
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previously [51]. All images shown were captured with uniform threshold and intensity
settings.
Post-acquisition analysis for immunofluorescent staining was performed using
MetaMorph 6.0 image analysis software (Universal Imaging, Inc, Downingtown, PA).
Five 212 µm x 212 µm images were captured randomly from the areas of positive staining
in the mid-frontal cortical gray matter for each case. Total BiP was determined by the
measurement of integrated pixel intensity for BiP per image, where the integrated pixel
intensity is defined as total pixel intensity per image times the area of pixels positive for
the signal. For colocalization of BiP with neurons or astrocytes, integrated pixel intensity
for BiP overlapping the pixels positive for MAP2 or GFAP respectively, was determined
for each image. BiP colocalization was normalized to the area of pixels positive for the
specific phenotypic marker, to account for differences in phenotypic marker expression
due to effects of disease. HAM56 area was determined by the measurement of the
number of the pixels positive for HAM56 signal. For correlation of BiP with
macrophages/microglia, the area of pixels positive for HAM56 and total or astrocytic BiP
from the same image were used. Averages are expressed as mean ± SEM. All data was
analyzed by GraphPad Prism 3.02 software (GraphPad Software, San Diego, CA, USA).
The Mann-Whitney test was used for statistical analysis of immunoblotting and
immunofluorescence quantification. Pearson correlation test was used for correlation
analysis. Values of p<0.05 were considered significant for all statistical analyses
performed.
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Results
BiP protein levels are increased in the mid-frontal cortices of HIV(+) cases
To determine if the ER stress response is activated in HIV(+) patients, we
assessed protein levels of the ER stress response marker, BiP, present in cortical tissue
from HIV(+) patients. Whole cell protein extracts were prepared from fresh frozen midfrontal cortical tissue of HIV(+) (n=15) and non-infected control (n=4) autopsy cases. By
immunoblotting, BiP levels were significantly increased in the HIV(+) group compared
with the control group (Figure 1A, B; p < 0.01). When BiP levels were examined
according to the neurocognitive status of the cohort, there was a significant increase in
BiP levels in the group with neurocognitive impairment (NCI) (n=13), which includes
both HAD and MCMD cases, compared with the neurocognitively normal group (n=5)
(Figure 1C, p < 0.05). Furthermore, BiP increased significantly in the HAD group (n=6)
compared with the normal group (Figure 1D, p < 0.05). In contrast, there was no
statistical difference between BiP levels in the neurocognitively normal group and those
in the MCMD group (n=7). These findings suggest that the ER stress response marker,
BiP, is increased in vivo, in the mid-frontal cortices of HIV(+) cases and in cases with
NCI.
BiP immunostaining is increased in mid-frontal cortical gray matter of
HIV(+) cases
To confirm our findings obtained by immunoblotting and to assess subcellular
localization of BiP, we performed quadruple-label immunofluorescent confocal
microscopy for BiP, CNS (central nervous system) cell phenotypic markers, and nuclear
DNA in the mid-frontal cortices of the same cohort of cases used for immunoblotting. As
shown in Figure 2, we observed BiP (green) exclusively in the cytoplasm of both neurons
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(MAP2, red, top panel) and astrocytes (GFAP, red, middle and bottom panel), in both
gray (Figure 2) and white matter (data not shown). The level of BiP immunostaining in
HIV(+) cases did not change significantly in white matter over that seen in control cases
(data not shown). BiP positive neurons and astrocytes were present in the vicinity of
HAM56-positive macrophage/microglia in HIV(+) cases (Figure 2, second row),
however, there was no correlation between increased BiP staining and increased
HAM56-postive macrophage microglia in our cases (Table 2).

However, there was a

statistically significant increase in BiP immunostaining in gray matter of the HIV(+)
group compared with that of the control group (Figure 2, Figure 3A, p < 0.05). Further
analysis showed that BiP immunostaining was increased significantly in MCMD cases (p
< 0.01) and in HAD cases (p < 0.01) compared with cases showing no neurocognitive
impairment (Figure 3B).
Astrocytic BiP expression is increased in HIV(+) cases
To further increase our understanding of the role of BiP in HIV-associated
neurodegeneration, we determined which specific cell types expressed increased BiP in
the gray matter of HIV(+) cases. In the same images collected to measure BiP
immunostaining, we used cell-specific phenotypic markers, MAP2 (red, Figure 2, top
panel) and GFAP (red, Figure 2, middle and bottom panel), to quantify the BiP
immunofluorescent staining levels in neurons and astrocytes, respectively. We did not
observe a significant increase in neuronal BiP immunostaining in the HIV(+) group
compared to controls (Figure 3C). When analysis was done using the neurocognitive
status of the cohort, we again failed to see a significant increase of neuronal BiP in the
MCMD group and in the HAD group compared with the normal group (Figure 3D),
although there was a trend towards an increase in neuronal BiP in HIV(+) cases as
compared with control cases (p < 0.08).
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In contrast, analysis of astrocytic BiP revealed a significant increase in BiP
immunostaining in the HIV(+) group compared with that seen in the control group
(Figure 3E; p < 0.01). Further, astrocytic BiP immunostaining increased in both the
MCMD and the HAD groups compared with the neurocognitively normal group (Figure
3F; p < 0.01).
Because of the important role of macrophages/microglia in the disease process
of HIV infection and disease progression in HIV-associated neurocognitive disorders, we
utilized

quadruple-label

immunofluorescent

confocal

microscopy

for

BiP,

macrophage/microglial cell phenotypic marker, HAM56 (Figure 2, second row), GFAP,
and nuclear DNA in the mid-frontal cortices of the same cohort of cases to determine
whether

there

exists

a

spatial

association

between

the

presence

of

macrophages/microglia in the HIV- infected brain and the increase in BiP expression.
HAM56 area was significantly increased in HIV(+) cases as compared with the control
group (Figure 3G; p < 0.01). Moreover, HAM56 area was increased in both MCMD and
HAD cases, as compared with the neurocognitively normal group (Figure 3H; p < 0.01).
However, we did not observe a correlation between HAM56-positive pixel area and
either total or astrocytic BiP levels by immunofluorescence (Table 2).

ATF-6b protein levels are increased in the mid-frontal cortices of HIV(+)
cases
To further establish that the increase in BiP levels observed in the mid-frontal
cortices of HIV(+) patients is a downstream event of ER stress response pathway
activation, we examined the protein levels of ATF-6b, the N-terminal fragment of ATF-6
that is responsible for the induction of gene transcription in the ER stress response. As
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seen in Figure 4, ATF-6b protein levels were significantly increased in cases with
neurocognitive impairment, compared with the neurocognitively normal group (Figure
4; p < 0.05).
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Discussion
The ER stress response is activated in various neurodegenerative diseases [20,
39, 40, 42-44]. These diseases share several proposed mechanisms of pathogenesis with
HIV-associated neurodegeneration, including oxidative stress, inflammation and
excitotoxicity [52-54]. However, the role of the ER stress response has not been studied
in HIV-induced neuronal loss and damage. Here we demonstrate for the first time that
the marker for ER stress response activation, BiP, is increased in mid-frontal cortical
gray matter of HIV-infected autopsy brain tissue. Consistent with ER stress activation,
we show that ATF-6β, one of the three initiators of ER stress, is also increased in vivo in
HIV-infected brain. As part of our analysis, we have demonstrated an increase in HAM56
expression in vivo in the brains of HIV(+), particularly those with MCMD and HAD.
In acute stress, the ER stress response alleviates cellular stress through its
attenuation of translation, its induction of the Nrf2-mediated antioxidant response, and
its inhibition of CHOP by increased levels of BiP. With the prolonged cellular stress
observed in the brains of HIV(+) patients, chronic ER stress response activation in both
neurons and astrocytes is expected.

This chronically active response may lose the

protective capabilities of an acute ER stress response, and ultimately contribute to the
progressive neurodegeneration occurring in HIV(+) brains. Certainly, prolonged
attenuation of translation, overstimulation of antioxidant pathways, and altered
BiP:CHOP equilibrium could all disrupt neuronal function leading to HIV-induced NCI.
The effect of ER stress response activation is likely to be distinct between
astrocytes and neurons. Chronic astrocytic ER stress response activation may alter the
ability of astrocytes to provide neuronal support, such as glutamate homeostasis and
trophic support. Increased astrocytic BiP may indicate that these cells are attempting to

82

mount a neuroprotective antioxidant response. However, left unchecked, this response
itself may become detrimental to neurons [55]. Finally, astrocytic BiP expression
increased more dramatically in the HAD group as compared with the MCMD group in
our

cohort,

suggesting

that

astrocytic

homeostasis

might

contribute

to

the

neurocognitive outcome of this debilitating condition warranting further investigation.
Activation of the ER stress response in neurons might function in an entirely
protective manner with no neurotoxic effects, yet become overwhelmed by the
continuous toxic stimuli found with HIV infection of the brain. Another possibility is that
chronic neuronal ER stress response activation results in a pro-apoptotic ER stress
response function, through increased CHOP expression. Interestingly, studies have
shown that CHOP acts to downregulate B-cell CLL/lymphoma 2 (Bcl-2) [56], a protein
which has protective capabilities against HIV-induced neuronal death. In our cohort, we
failed to see a change in the levels of CHOP by immunoblotting (data not shown).
However, because cells expressing high levels of CHOP have likely initiated an apoptotic
program, the number of viable cells expressing CHOP at the end stage of this chronic
disease is likely to be so low as to render CHOP expression undetectable in cortical
autopsy tissue. Regardless of the exact mechanism of neuronal death in HIV brain tissue,
the normally protective ER stress response pathways are unable to prevent neuronal
damage and loss in this disease, and may provide a point for potential therapeutic
intervention.
Macrophages/microglia are important support cells in the brain. Further, these
cells play a central role in HIV pathogenesis in the brain. They constitute the major
reservoir for establishing HIV infection in the central nervous system (CNS), and they
initiate a cascade of events, which includes direct infection of other non-neuronal cells
and initiation of an inflammatory response, eventually leading to the neuronal loss seen
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in HIV-infected brain. Given their important role in pathogenesis of HIV infection of the
CNS, it might be expected that there exists a spatial association between the presence of
macrophages/microglia in the HIV-infected brain and the increase in BiP expression. We
observed an overall increase in HAM56 pixel area in HIV(+) cases, indicating an increase
in the number of macrophages/microglia present in the mid-frontal cortex of these
patients. Importantly, HAM56 pixel area also increased when neurocognitive status was
considered, with brains of both MCMD and HAD patients showing significantly more
HAM56 than neurocognitively normal controls. This is the first data indicating that the
number of macrophages/microglia increases in the brains of MCMD patients. However,
even given the observed increase in HAM56 pixel area, we failed to find a positive
correlation between HAM56-positive cells and either total or astrocytic BiP levels by
immunofluorescence (Table 2). These findings do not rule out the contribution of the
macrophages/microglia to the chronic activation of the ER stress response for several
reasons.

1) The infected/activated macrophages/microglia are not necessarily in the

same 7 µM plane used for immunostaining. 2) Macrophage/microglia may exert their
effects in a paracrine fashion through the release of viral proteins, chemokines, and
cytokines to the brain parenchyma. 3) Moreover, neither HAM56 nor any other
commercially available macrophage/microglial marker can distinguish between
infected/activated and quiescent macrophages/microglia. 4) Finally, we are quantifying
these markers at the end stage of disease when neurodegenerative processes are widely
disseminated throughout the brain tissue precluding correlational analysis with disease
progression as we have seen previously [57]. However, the contribution of
macrophage/microglial cells to the ER stress response in HIV infected brains should be
studied as more tools become available for proper detection of the activated members of
this cell population and in animal models.
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The findings presented in this paper clearly demonstrate activation of the ER
stress response in HIV-infected brain, and in the neurocognitive disorders that often
follow this viral invasion into the CNS. Our findings cannot answer the question of
whether the ER stress response is a cause of the neuronal loss seen in HIV-infected brain
or simply a protective cellular response mounted against separate cytotoxic processes
present in the CNS of HIV-infected individuals. However, the data presented here clearly
show activation of this pathway at the end stages of HIV-infection suggesting chronic ER
stress response activation. While an acute ER stress response is usually considered a
protective mechanism, in a chronic disease it may ultimately contribute to neuronal loss.
Future studies must be conducted to more precisely elucidate the role of the ER stress
response in the CNS of HIV patients. However, regardless of the precise function of this
pathway in HIV-associated NCI, the findings presented here demonstrate that the ER
stress response provides an access point to a better understanding of the neuronal loss in
HIV infected brain and a possible tool for intervention.
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Figure 1:

Figure 1. BiP protein levels are increased in the mid-frontal cortices of HIV(+) cases.
Whole cell protein extracts isolated from fresh frozen autopsy tissue were used for assessment of BiP levels.
As shown by immunoblotting, (A) BiP expression is increased in the mid-frontal cortices of HIV(+) cases
(n=14) compared with control cases (n=4). When neurocognitive status is considered, BiP increases in cases
with neurocognitive impairment (NCI) (n= 13) compared with those with no neurocognitive impairment
(n=5). Coomassie staining of the PVDF membrane was used as a loading control for normalization of protein
levels for quantification and statistical analysis as shown in (B), (C) and (D). Case HIV 14 was dropped
from further analysis due to advanced protein degradation. * p < 0.05,
Mann-Whitney test.
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**

p <0.01, compared with control,

Figure 2. BiP immunostaining is increased in cortical neurons and astrocytes of HIV(+)
cases.
Using triple label immunofluorescent laser confocal microscopy, brain sections from control and HIV(+)
cases were labeled by immunofluorescence for BIP (green) and for phenotypic markers for neurons (MAP2,
red, first row), macrophages (HAM56, red, second row) and for astrocytes (GFAP, red, third row). Nuclei are
shown in blue. Red and green co-localization appears yellow. An example from each group is shown. BiP
(green) is increased in neurons in mid-frontal cortical gray matter from HIV(+) cases, as shown in the upper
panel. When neurocognitive status is considered, BiP immunostaining increases in NCI cases compared with
cases showing no neurocognitive impairment. HAM56-positive macrophages are more prevalent in
HIV(+)/NCI cases (second row). Note the BiP-positive astrocytes in HIV(+) / NCI cases, while none are
seen in the control/normal case (third and fourth row). Asterisks indicate activated astrocytes that are
negative for BiP staining; arrows indicate BiP-positive activated astrocytes. Representative astrocyte bodies
from each group are shown at 1200X in the fourth row.
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Figure 3. Increased cell type specific BiP expression was more prominent in HAD cases
compared with that seen in MCMD cases.

Total BiP integrated fluorescence intensity and

colocalization from 5 confocal images captured for each case was determined with MetaMorph 6.0 software.
Statistical analysis was performed using GraphPad Prism 3.02. Quantification of total BiP integrated pixel
intensity (A and B), integrated pixel intensity of BiP co-localizing with MAP2, normalized to MAP2 area (C
and D) and integrated pixel intensity of BiP co-localizing with GFAP, normalized to GFAP area (E and F)
show increased cell type specific BiP expression. Quantification of HAM56 pixel area (G and H) show
increased expression of HAM56-positive cells in both HIV(+) and neurocognitively impaired cases. * p <
0.05, ** p < 0.01, Mann-Whitney test.
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Figure 4:

Figure 4. ATF-6b protein levels are increased in the mid-frontal cortices of HIV(+) cases.
Whole cell protein extracts isolated from fresh frozen autopsy tissue were used for assessment of ATF-6b
levels by immunoblotting. (A) ATF-6b expression is increased in the mid-frontal cortices of HIV(+) cases
(n=14) compared with control cases (n=4). ATF-6b levels increases in cases with neurocognitive impairment
(NCI) (n= 13) compared with those with no neurocognitive impairment (n=5). Coomassie staining of the
PVDF membrane was used as a loading control for normalization, quantification and statistical analysis as
shown in (B), (C) and (D). Case HIV 14 was dropped from further analysis due to advanced protein
degradation. * p < 0.05, compared with control, Mann-Whitney test.
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Table 1:
Case

HIV

Gender

Age

PMI

(years)

(hr)

NeuroCog

Neuropath
Dx

HIV 1

+

M

35

9.25

HAD

Not HIVE

HIV 2

+

F

34

5

HAD

Not HIVE

HIV 3

+

M

57

5.5

HAD

Not HIVE

HIV 4

+

M

32

14.5

HAD

HIVE

HIV 5

+

M

38

5.5

HAD

HIVE

HIV 6

+

M

32

14

HAD

HIVE

HIV 7

+

M

36

2.5

MCMD

Not HIVE

HIV 8

+

M

37

11.5

MCMD

Not HIVE

HIV 9

+

M

31

8.83

MCMD

Not HIVE

HIV 10

+

M

49

67.33

MCMD

Not HIVE

HIV 11

+

M

42

27.33

MCMD

Not HIVE

HIV 12

+

M

50

21

MCMD

HIVE

HIV 13

+

M

43

unknown

MCMD

HIVE

HIV 14

+

M

46

2.75

Normal

Not HIVE

CONTROL 1

-

M

46

27.65

ND

Control

90

CONTROL2

-

F

47

19.2

ND

Control

CONTROL3

-

M

40

14.66

ND

Control

CONTROL4

-

F

51

21.75

ND

Control

Table 1. Summary of case data for autopsy tissue obtained from the NNTC. Data on the HIV
status (HIV), Gender, Age in years, post-mortem interval (PMI) in hours, and Neurocognitive diagnosis
(NeuroCog) are summarized. Abbreviations include: F – female, HAD – HIV associated dementia, M –
Male, MCMD – minor cognitive/motor disorder, and ND – not determined.
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Table 2:
Table 2. Correlation analysis between BiP and phenotypic markers of macrophage/microglia,
astrocytes, and neurons. Pearson r values are shown for all the groups analyzed. * p < 0.05. ND – not
determined.

HAM56 area

GFAP area

MAP2 area

(macrophages)

(astrocytes)

(neurons)

-0.145

-0.06

0.085
Total BiP

0.126

-0.127
0.035

Astrocytic
BiP

Neuronal

0.279
ND

-0.110

BiP
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ABSTRACT

The use of highly active anti-retroviral therapy (HAART) to prevent progression
to AIDS in HIV-infected patients has led to a significant reduction in the incidence of
HIV-associated dementia (HAD), a severe motor/cognitive disorder afflicting HIV(+)
patients.

However, the prevalence of more subtle forms of CNS dysfunction has

continued to escalate in the post-HAART era. The microgliosis, astrogliosis, dendritic
damage, and synaptic and neuronal loss observed in autopsy cases from patients with
HIV-associated

neurocognitive

disorders

(HAND)

suggest

that

an

underlying

neuroinflammatory process, due to the neurotoxic factors released by the HIV-infected
and/or activated macrophages/microglia in the brain, might underlie the pathogenesis
of HAND. These factors are known to induce the Integrated Stress Response (ISR) in
several neurodegenerative diseases, and we have previously shown that BiP, the master
regulator of the ISR and an indicator of general ISR activation, is upregulated in cortical
autopsy tissue from HIV-infected patients. The ISR includes three different pathways,
each with its own initiator protein: PERK, IRE1α, and ATF6. To further elucidate the
specific ISR pathways activated in the CNS of HAND patients, we examined the protein
levels of several ISR proteins, including ATF6 and phosphorylated PERK (pPERK), in
mid-frontal cortical tissue from HIV-infected patients. We observed a significant
increase in neuronal and astrocytic ATF-6β expression in the HAND group compared
with the neurocognitively normal control group, as well as in the HIV(+) group
compared with the HIV(-) group. We also found that, while pPERK levels do not
increase, levels of pEIF2α, a downstream target of pPERK, do increase in HIV(+) cases.
Further, ATF4, which is downstream of multiple ISR pathways, increases in astrocytes in
HAND cases, but decreases overall and in the nuclear compartment of cells in cortical
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gray matter. These findings begin to characterize the nature of the ISR response in
HAND and provide multiple potential targets for therapeutic intervention in this disease.
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Introduction

HIV-associated neurocognitive disorders (HAND) encompass a spectrum of
clinical diagnoses ranging from minimal cognitive impairment to debilitating motor,
cognitive, and behavioral deficits. However, with the advent of combined anti-retroviral
therapy (cART), the phenotype of HAND has been shifting towards the subtler forms and
away from the more severe forms, such as HIV-associated dementia, the most severe
form and an AIDS-defining disorder. In a recent study where a cohort of 200 aviremic
patients was evaluated for neurocognitive dysfunction, the prevalence was 27% for any
degree of impairment; this number is estimated to be as high as 50% in sub-Saharan
Africa (1).
The neuropathological correlate of HAD, HIV encephalitis (HIVE), exhibits
astrocytosis,

perivascular

inflammatory

macrophages,

microglial

nodules,

and

multinucleated giant cells, all of which provide evidence that an inflammatory process
underlies the pathogenesis of HAND disorders (2-4). The neuroinflammation in HAND
can be tracked to HIV-infected monocytes that differentiate into macrophages in the
brain parenchyma after crossing the blood-brain barrier (BBB) (5). These infected
macrophages constitute the viral reservoir in the brain; moreover, these infected
macrophages are thought to lead to infection and/or activation of resident CNS
macrophages and microglia. While neurons themselves lack the necessary co-receptors
for HIV binding and entry and are therefore not directly infected by the virus, extensive
studies have linked neuronal damage and death to the clinical presentation of HAND (6).
Rather, infected and/or activated macrophages, astrocytes, and neurons release a wide
range of soluble neurotoxic factors, including viral proteins, cytokines, chemokines,
reactive oxygen species (ROS), and excitotoxins, into the extracellular milieu as part of
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the inflammatory response.
Several studies have shown that some of the soluble factors that are released as
part of the HIV-induced inflammatory response, as well as HIV viral proteins, are able to
induce the Integrated Stress Response (ISR) (also known as the ER stress response or
the unfolded protein response (UPR)), suggesting that the ISR may play a role in HAND
(7). The ISR orchestrates a multitude of cellular responses against a wide range of extraand intra-cellular stresses by regulating intracellular Ca+ levels, endoplasmic reticulum
(ER) chaperone genes, protein synthesis, folding and degradation, and the endogenous
antioxidant response (7, 8, 9, 10, 11-16). A variety of insults can trigger the ISR, such as
oxidative stress, hypoxia, toxins, nutrient deprivation, and viral infection. Further, a role
for the ISR has been implicated in a number of neurodegenerative diseases, including
Alzheimer disease and Parkinson disease, as well as in CNS injury, such as brain trauma
and ischemia (12, 17-22). Importantly, while the primary purpose of the ISR is to
promote cellular survival in the short term, chronic ISR activation in response to
sustained injury/insult or in cases of extreme insult can also lead to orchestrated cell
death. Thus, chronic ISR activation may provide a link between the inflammatory
response to HIV infection in the CNS and neuronal death in HAND.
The ISR is composed of three major pathways, each mediated by an upstream
initiator protein: activating transcription factor 6 (ATF6), PKR-like ER kinase (PERK),
and inositol-requiring enzyme 1α (IRE1α) (7). All three initiator proteins are ER
transmembrane proteins and each is maintained in its inactive state by interaction of its
luminal domain with the ER resident chaperone protein, BiP/GRP78 (immunoglobulin
heavy chain-binding protein/glucose-regulated protein 78), often considered to be the
master regulator of the ISR. However, conditions of cellular stress that activate the ISR
disrupt the BiP:Initiator protein complexes, thereby freeing each of the initiators to
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activate its specific branch of the ISR.
Each initiator protein activates its path of the ISR via a distinct mechanism,
allowing for a coordinated and well-controlled three-pronged cellular stress response (7).
ATF6 is a basic leucine zipper (bZIP) transcription factor that when freed from BiP
translocates to the golgi where it is cleaved into its active form, which then moves into
the nucleus. Once in the nucleus, it binds the ER stress response element (ERSE) found
in the upstream region of genes encoding proteins important for responding to the
offending stresses, such as ER chaperone proteins and folding catalysts (16). PERK and
IRE1α are both kinases that, when released from BiP, homodimerize and activate via
autophosphorylation. PERK then activates its branch of the ISR by phosphorylating the
α-subunit of the eukaryotic initiation factor 2 (eIF2α), causing a global inhibition of
translation initiation, while simultaneously promoting the translation of certain stress
response proteins, including activating transcription factor 4 (ATF4). Like its family
member, ATF6, ATF4 is a bZIP transcription factor that binds the ESRE, thereby
transactivating stress response genes. Interestingly, eIF2α can be activated by other
kinases, each of which senses a different form of stress: general control non-depressible2 (GCN2), which senses amino acid starvation, the protein activated by dsRNA (PKR),
which is important for the cellular response to viral infection, and heme-regulated
inhibitor (HRI), which senses heme deficiency in erythroid cells. Autophosphorylation of
the initiator protein IRE1α activates its endoribonuclease domains allowing it to cleave
the mRNA of its one known target, XBP1. Once cleaved to its mature form, XBP1 mRNA
encodes yet another bZIP transcription factor capable of binding the ERSE.
While all three ISR pathways function via distinct mechanisms, they are all
capable of activating the transcription of genes with the ERSE in their promoter regions,
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including the master regulator of the ISR, BiP. This means that BiP is not only a critical
overseer of the ISR, but is also a key indicator of activity of any of the three ISR
pathways. In a previous report, we showed that BiP is increased in the mid-frontal cortex
of patients with HIV infection and with HIV-induced neurocognitive impairment,
indicating that the ISR is indeed activated in the CNS of these individuals. However,
since BiP is upregulated by all branches of the ISR, our previous study did not determine
which of the three pathways might be responding in this disease. It is important to note
that, while BiP is important in regulating all three ISR pathways, the pathways do not
necessarily always activate together (23-25), allowing a more precise functionality of the
ISR than an all-or-nothing response. Thus, in the study presented here, we sought to
more specifically characterize the activation of the ISR in the CNS of HIV-infected
patients. Specifically, we used immunofluorescence (IFA) to examine the levels of key
players in the ATF6 and PERK prongs of the ISR in mid-frontal cortical autopsy tissue
from HAND cases. Here, we report that ATF6β is increased in neurons and astrocytes in
HIV(+) tissue and in HAND tissue over HIV(-) and neurocognitively normal control
tissue, respectively. Additionally, we found that, while pPERK does not change with
disease state, peIF2α increases in both HIV(+) cases and HAND cases over HIV(-) and
neurocognitively normal controls and ATF4 increases in astrocytes of HAND cases over
neurocognitively normal controls, although ATF4 decreases over all and in the nuclei of
cells in cortical gray matter. These findings suggest that the ISR activation that occurs in
HAND and in HIV(+) tissue, as indicated by the increased expression of BiP in these
cases, is not due to activation of the entire ISR and that uncovering the nuances of ISR
activation in this disease will be important to the development of potential therapies.
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Methods:
Paraffin-embedded tissue sections from the cortices of control and HIV (+)
human autopsy cases were obtained from the tissue banks of National NeuroAIDS Tissue
Consortium (NNTC). The age, sex, neurocognitive status and postmortem interval of
each specimen was provided by NNTC and is depicted in tables 1 and 2. The glass slides
were prepared for immunofluorescent staining as described in the previous chapter (26),
except for ATF6β staining, where 10% normal horse serum was used as the blocking
agent. Rabbit polyclonal antibodies to pPERK (Thr980, 1:1000, Cell Signalling Inc,
Beverly, MA), peIF2a (pS52, 1:1000, Invitrogen, Carlsbad, CA), ATF4 (C-20, 1:600,
Santa Cruz Biotechnology, Santa Cruz, CA), GFAP (Z0334, 1:80, Dako, Carpinteria, CA,
USA), goat polyclonal antibody raised against ATF6β (N-17, 1:100, Santa Cruz
Biotechnology), and mouse monoclonal antibody to MAP2 (SMI-52, 1:200, Covance
Research Products, Berkeley, CA), were used at empirically defined dilutions. The
tyramide amplification system (New England Biolabs, Beverly, MA, USA) was used to
detect the markers of ISR. To visualize staining, slides were incubated for 30 min with
goat secondary antibodies (Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA, USA) except for ATF6β, where a donkey anti-goat secondary antibody (Jackson
ImmunoResearch Laboratories) was utilized. The primary antibodies for ISR markers
were detected by biotin-conjugated, secondary antibodies (1:200) for use with the
tyramide amplification system, and was subsequently visualized using FITC-conjugated
Streptavidin (New England Biolabs) .The GFAP and MAP2 primary antibodies were
visualized by a Cy-5-conjugated, goat anti-rabbit antibody (1:200) and a Cy-3-conjugated
goat anti-mouse antibody (1:200), respectively and DAPI was used to visualize DNA (5
mM, Invitrogen). Slides were mounted in Citifluor AF1 (Citifluor, Ltd., London, UK) and
laser confocal microscopy on a Biorad Radiance 2100 equipped with Argon, Green
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He/Ne, Red Diode, and Blue Diode lasers (Biorad, Hercules, CA, USA) was used to
analyze the immunostaining, as described previously [26]. All images shown were
captured with uniform threshold settings for each ISR marker.
Post-acquisition analysis for immunostaining was performed using MetaMorph
6.0 image analysis software (Universal Imaging, Inc, Downingtown, PA) as described in
the previous chapters. 5-10 high-magnification (600X) images were captured randomly
from the areas of positive staining in the mid-frontal cortical gray matter for each case.
Averages are expressed at mean ± SEM. All data was analyzed by GraphPad Prism 3.02
software (GraphPad Software, San Diego, CA, USA). For statistical analysis, Student’s ttest was used with post-hoc Mann-Whitney U analysis. Values of p<0.05 were
considered significant for all statistical analyses performed.
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Results:
ATF-6β protein levels are increased in the mid-frontal cortex of HAND cases
and of HIV(+) cases
In our previous study, we had demonstrated via immunoblotting and
immunofluorescence (IFA) that BiP protein levels are increased mid-frontal cortex in
HIV(+) autopsy cases and in HAND autopsy cases (26). These findings indicated that the
ISR is activated in the CNS of these patients, but demanded further study to determine
more precisely the nature of ISR activation in this disease. Therefore, in the current
study, we set out to determine which of the three ISR pathways are activated in the midfrontal cortex of these patients. First we examined the ATF6 pathway via quadruple-label
immunofluorescent confocal microscopy (IFA) for ATF6β protein levels. We had
previously examined this branch of the ISR via immunoblotting for ATF6β (26), however
the IFA method conducted in the current study allowed us to not only confirm the
increases in total levels of ATF6β, but also to examine its subcellular localization, as well
as cell-type specific changes in levels of this protein for a given disease state. In the
current study, we found that total levels of ATF6β increase in the mid-frontal cortex of
HAND autopsy cases compared with levels in neurocognitively normal cases (Figure
1a,b). Additionally, total ATF6β protein levels increase in the mid-frontal cortex of
HIV(+) autopsy cases as compared with those seen in HIV(-) cases (Figure 1a,c). These
findings parallel our immunoblotting data presented previously (26). Next we examined
cell-type specific changes in ATF6β expression by quantifying its colocalization with celltype markers, MAP2 and GFAP, which mark the cytoplasm of neurons and astrocytes,
respectively. Importantly, protein levels of these two markers are known to change in
HAND patients. Specifically, MAP2 levels decrease as neurons degenerate and die, and
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GFAP levels increase with the astrocytosis that is a hallmark of HAND-associated
pathology. Thus, to ensure that any changes in cell-type specific ATF6β levels were not
due to an increase or decrease in the amount of the phenotypic marker present, we
normalized colocalization values to total area of the phenotypic marker. We found that
ATF6β is increased in the cytoplasm of both neurons and astrocytes in HAND cases and
in HIV(+) cases as compared with ATF6β protein levels in neurocognitively normal and
HIV(-) cases, respectively (Figure 2a-d). As a transcription factor, ATF6 must move into
the nucleus to perform its function in cellular stress mitigation. We found that ATF6β
was predominantly cytoplasmic in our staining, regardless of disease state, however we
did observe some nuclear staining, particularly in astrocytes. Unfortunately, unlike
cytoplasmically localized ATF6β, we are unable to differentiate between neuronal and
astrocytic nuclear ATF6β, since our nuclear marker, DAPI, stains all DNA and therefore
marks nuclei of all cell types. Quantification of total nuclear ATF6β revealed that protein
levels increased in HAND cases over that seen in neurocognitively normal cases (Figure
2e). However, we saw no change in nuclear ATF6β levels between HIV(+) and HIV(-)
cases (Figure 2f).

peIF2α levels increase in HIV(+) mid-frontal cortical autopsy tissue, but
pPERK levels do not change with HIV or neurocognitive status
The PERK arm of the ISR is activated by dimerization of PERK, which then
activates via autophosphorylation and subsequently phosphorylates the alpha subunit of
eIF2, thereby causing a global inhibition of protein translation (7). Thus, to examine the
activation of this branch of the ISR, we conducted IFA for pPERK and for peIF2α. We
found no change in levels of pPERK associated with either HIV status or neurocognitive
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status (Figure 3). We found that pPERK staining appeared entirely nuclear, which
unfortunately means that we were unable to examine differences between neuronal and
astrocytic pPERK.
Interestingly, while levels of pPERK did not change, levels of peIF2α increased in
HIV(+) cases over those seen in HIV(-) cases (Figure 4a,c). There was also a significant
change observed in HAND cases as compared with neurocognitively normal cases
(Figure 4a,b), however this change was so small that it is questionable as to whether it is
a meaningful change. Additionally, neuronal peIF2α colocalized with MAP2 increased in
HAND and in HIV(+) tissue over respective controls (Figure 4c,d). Interestingly, as with
total peIF2α, neuronal peIF2α increases were more striking in HIV(+) tissue than they
were in HAND tissue. These data suggest that increased peIF2α in mid-frontal cortex is
associated with HIV infection, rather than with HIV-associated neurocognitive decline.
Unfortunately, neither DAPI staining nor GFAP staining were of a quality that
quantification of colocalization could be conducted using these markers. The cohort of
tissue cases used for IFA of peIF2α was different from that used for the other ISR
proteins examined in this study and was supplied by different tissue banks. Thus, it is
probable that some aspect of tissue processing differed between these brain banks that
affected the staining of these two markers.

Total and nuclear ATF4 decreases in HAND, while cytoplasmic ATF4 in
astrocytes increases in both HAND and HIV(+) tissue
While phosphorylation of eIF2α results in a global inhibition of translation, it
also typically results in an increased rate of translation of certain ISR proteins, such as
the transcription factor, ATF4 (Reviewed in 7). Thus, given the increases we saw in
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peIF2α levels, we sought to determine whether ATF4 levels were increased in midfrontal cortex from HAND autopsy cases. Interestingly, we found that total levels of
ATF4 actually decrease in HAND cases as compared with neurocognitively normal cases
(Figure 5a,b). ATF4 staining was both nuclear and cytoplasmic and when we examined
ATF4 that colocalized with DAPI we found that, like total ATF4 levels, nuclear ATF4 also
decreases in HAND cases (Figure 6e). However, we saw no change in total ATF4 (Figure
5c) or nuclear ATF4 levels (Figure 6f) in HIV(+) cases compared with those seen in
HIV(-) cases. Interestingly, when we examined cell-type specific levels of cytoplasmic
ATF4, we found that, while neuronal cytoplasmic ATF4 levels show no changes with
either neurocognitive status or HIV status (Figure 6a,b), astrocytic cytoplasmic ATF4
actually increases in HAND cases over neurocognitively normal cases and in HIV(+)
cases over HIV(-) cases (Figure 6c,d). However, as can be seen in the representative
images (Figure 5a), ATF4 staining was predominantly neuronal with a tendency towards
strong nuclear staining, so it is not surprising that total ATF4 levels parallel nuclear
ATF4 levels, with cytoplasmic levels showing different trends.
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Discussion:
The direct cause and mechanism of neuronal degeneration and death in HAND is
not currently understood. In this paper, we explore the nature of ISR activation in this
disease, since we had previously reported an increase of BiP, an indicator of ISR
activation, in the CNS of HIV(+) patients. While the ISR is a protective response, it is
also a pro-apoptotic response under certain conditions, and thus our observations of ISR
activation in HAND need to be further characterized to determine whether the ISR
ultimately provides protection or causes neuronal death or perhaps a combination of
both in this disease. In this reposrt, we show that cytoplasmic ATF6β is increased in both
neurons and astrocytes in both HAND and HIV(+) cases when compared with
neurocognitively normal and HIV(-) cases, respectively. Total nuclear ATF6β is only
increased in HAND cases, not with HIV infection alone. We then showed that, although
pPERK does not increase with disease, peIF2α increases significantly in both HAND and
HIV(+) cases over respective controls; however the increase with HIV infection is more
striking than that in HAND cases. Cytoplasmic neuronal peIF2α follows the same trend
as total eIF2α. Unfortunately, nuclear and astrocytic peIF2α could not be determined.
Finally, we show that total and nuclear ATF4 both significantly decrease in HAND tissue
but not in HIV(+) tissue, compared with respective control cases. However, cytoplasmic
neuronal ATF4 does not change with disease, and cytoplasmic ATF4 in astrocytes
actually increases in both HAND cases and HIV(+) cases compared with respective
controls. The findings presented here demonstrate the nuanced nature of the ISR,
showing that it is not an all or nothing response and that it can vary across cell types.
In our previous paper (26), we had shown that, in addition to an increase in BiP
protein levels in HIV(+) and HAND tissue, ATF6β increased as seen by immunoblotting.
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Here, we continue the examination of the ATF6β response in HIV(+) cortical tissue using
IFA, which allows us to examine protein levels as they vary across subcellular
compartments and across different cell types. ATF6 is a transcription factor that has two
forms, ATF6α and ATF6β, that are both activated under stress conditions by
translocation to the golgi, followed by proteolytic cleavage, which allows their active
cleaved forms to translocate to the nucleus and induce expression of target genes (2729). Manifestly, only nuclear ATF6 is able to perform its transcriptional function. While
we found that nuclear AFT6β did increase in HAND cases, the majority of the staining
was clearly non-nuclear. This suggests that although ATF6β is increased in HAND, it
may not actually be activating its target genes. ATF6 is cleaved to its active form by
regulated intramembrane proteolysis (RIP) by site-1 protease (S1P) and site-2 protease
(S2P) working together consecutively (28, 29). Several studies have shown that ATF6
translocates to the golgi, but then fails to move to the nucleus in disease states or in
models. One study found that pharmaceutical inhibition of the serine proteases
prevented cleavage of AFT6 and thus prevented its nuclear localization. This inhibition
did not, however, inhibit ATF6 translocation to the golgi (30). Another study indentified
nucleobindin 1 as an endogenous inhibitor of S1P, and found that overexpression of this
inhibitor did not inhibit ATF6 localization to the golgi, but prevented cleavage to its
active, nuclear form (31). Finally, mutant Chinese hamster ovary cells, M19 cells, are
defective in induction of BiP and are deficient in S2P activity (32, 33). Nadanaka et al.
(34) found that some of the ATF6 in these cells is constitutively localized to the golgi.
Considering these findings, it is possible that ATF6β in HAND tissue is translocating to
the golgi but is then unable to move to the nucleus. It would be interesting to conduct
IFA in HAND cortical autopsy tissue co-labeling for ATF6β and a golgi matrix marker,
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such as GM130, to determine if ATF6β is perhaps getting stuck in the golgi in this
disease.
The implications of a lack of nuclear localization of ATF6β are not clear. As
mentioned previously, ATF6 has two forms, both of which are activated by stressors and
are proteolytically cleaved to their active forms in the golgi. The active form of ATF6α is
a stronger, yet much shorter-lived transcriptional activator than is that of ATF6β. The
roles of these two isoforms of ATF6 are not clear. Some studies have suggested that
ATF6β, when localized to the nucleus, is an inhibitor of ATF6α transcriptional function
(35), suggesting that ATF6β may function to regulate the strength and duration of
ATF6α activity (36). Interestingly, ATF6β undergoes N-glycosylation, which is necessary
for its proteolytic cleavage, but not necessarily for its translocation to the golgi (37). This
may allow for control in the timing of ATF6β transcriptional repression of ATF6α
activity. Since we see increased ATF6β protein levels, but not high levels of nuclear
ATF6β, it is possible that its N-glycosylation is being prevented, to allow continued
transcriptional activation of ATF6α target genes. It would be interesting to determine the
glycosylation state of ATF6β in HAND cortical tissue.
In contrast to studies suggesting a transcriptional repressor function for ATF6β,
other studies have found that, although ATF6β is a much less potent inducer of
transcription, it is still able to provide some protection against stress by its induction of
target ER stress genes (38). Taken together with the fact that the transcriptionally active
fragment of ATF6α is rapidly degraded, while that of ATF6β is longer lived, these
findings that ATF6β may not be a transcriptional repressor of ATF6α, but rather an
activator of ER stress genes, suggest the possibility that ATF6α may act as a strong
immediate, but temporally limited, response to stress, while ATF6β would be responsible

118

for a lower level, longer-lived response to chronic stress, such as that observed in HAND
(36, 39). There are antibodies available to ATF6α and it would be interesting to examine
whether that isoform is also increased in HAND and whether or not it shows strong
nuclear localization.
In this study, we found that although pPERK does not increase in HAND or in
HIV(+) tissue, peIF2α, a target for pPERK-mediated phosphorylation, does increase in
both

HAND

and

HIV(+)

tissue,

compared

with

respective

control

tissue.

Phosphorylation of eIF2α inhibits its function in the initiation of translation causing a
general attenuation of the translation of new proteins (40). However, the
phosphorylation of eIF2α actually increases the translation of particular proteins that
include an IRES in their 5’ untranslated region (41), such as the ISR protein, ATF4.
Importantly, eIF2α is the target of several other kinases, including double-stranded
RNA-activated protein kinase (PKR) and general control non-depressible-2 (GCN2). As
mentioned previously, the ISR possesses both pro-survival and pro-apoptotic roles, and
peIF2α is capable of both. In particular, one study suggested that the timing of
phosphorylation of eIF2α may determine whether it is pro-survival or pro-apoptotic in
its function, and further, this study suggested that the nature of the role of peIF2α in a
given stress response may be influenced by the kinase that phosphorylates it under any
given stress (42). While all kinases known to target peIF2α do phosphorylate it on its
serine 51 (S51), these kinases themselves are differentially regulated and perhaps the
timing of their activation or the identities of their other target proteins affect whether
peIF2α will play a pro-survival or a pro-apoptotic role. Interestingly, since we found that
pPERK does not increase with HAND or with HIV-infection, this suggests that another
kinase potentially phosphorylates eIF2α in the cortex of these patients. Of particular
interest is PKR, given that it responds to double-stranded RNA, as well as to interferon
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(43) and also considering that the increase of peIF2α was more striking in HIV(+) tissue
over HIV(-) tissue, than in HAND tissue over neurocognitively normal controls. Muaddi
et al. (42) show data suggesting a pro-survival role for PERK and PKR, and a proapoptotic role for GCN2, although other studies have suggested that PKR often has prodeath function. It would be interesting to examine the role of peIF2α in HAND by
utilizing an in vitro model of HIV-induced neuronal damage along with PKR inhibitors,
as well as inhibitors of PERK and GCN2. Additionally, over-expression of
phosphomimetic or unphosphorylatable eIF2α in this model might prove revealing as to
the role of eIF2α phosphorylation in HAND.
The final ISR protein we examined in this study was ATF4, which is a
downstream target of the PERK/eIF2α pathway of the ISR. Interestingly, given our
finding that peIF2α increases in HAND tissue and in HIV(+) tissue, we found that total
and nuclear ATF4 decreases in HAND tissue, although it shows no change in HIV(+)
tissue, compared with controls. In contrast, we found that ATF4 levels do not change in
the cytoplasm of neurons and actually increase in the cytoplasm of astrocytes. These
apparently contradictory findings are actually reconcilable when one takes into account
that ATF4 in the cytoplasm of astrocytes makes up a very small amount of the total ATF4
and also that certain cells show very strong ATF4 nuclear staining, which is not
surprising given that ATF4 is a transcription factor. One possible explanation for the
overall decrease in ATF4 levels despite an increase in peIF2α levels relates back to the
multiple functionality of peIF2α. Conceivably, in HIV(+) tissue and in HAND, eIF2α
functions mostly to inhibit global protein translation and does not promote the
expression of ATF4 protein. Additionally, the increases of peIF2α staining were far more
apparent in HIV(+) tissue than they were in HAND tissue compared with respective
controls, while total and nuclear ATF4 decreases are seen in HAND tissue, but not in
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HIV(+) tissue, suggesting an alternate method of regulation of ATF4 expression in this
case. Interestingly, although ATF4 is usually discussed as a translationally regulated
protein, there is evidence that it is transcriptionally regulated as well. In particular,
another study found that phosphorylation of peIF2α failed to increase expression of
ATF4 in their model, and that, rather, ATF4 was regulated at the transcriptional level by
TRIF-mediated signaling through toll-like receptors 3 and 4 (44). Using mRNA
extraction from fresh-frozen HAND tissue, it would be interesting to see whether ATF4
mRNA is reduced in HAND tissue. Whether this reduction in ATF4 expression
represents a failure of the ISR to protect in HAND or whether it is actually a regulatory
mechanism functioning to protect cells from the pro-apoptotic side of the ISR is unclear,
but could be examined in an in vitro model of HIV-induced neuronal degeneration.
Here we present the initial studies designed to characterize the nature of the ISR
response in HAND. Our findings clearly show that the ISR does not respond in an all or
none fashion in HAND, but rather demonstrates a nuanced activation pattern in this
disease. However, the studies presented here are not yet complete. All the IFA data we
present must be confirmed using immunoblotting for the examined ISR proteins.
Specifically, ATF4, pPERK, total PERK, peIF2α, and total eIF2α should be examined,
and although we had previously examined ATF6β levels via immunoblotting (26) and
found that they support our IFA data presented here, it would be interesting to examine
the ATF6α response via immunoblotting, as well. These experiments must be performed
before these IFA results can be published. Additionally, but not necessarily for the
publication of the data presented here, it would be interesting to examine levels of the
spliced form of XBP1, since this is arguably the only effective way to examine activation
of the third pathway of the ISR, for which IRE1α is the initiator protein, acting to splice
XBP1 mRNA to its active form. The data presented in this paper are an important first
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step towards characterizing the ISR response in HAND, which will be necessary if we are
to understand whether this catch-all stress pathway is merely unsuccessful in its
attempts to protect neurons from death in the toxic environment of the HIV-infected
CNS and should thus be supported in its function via therapeutic intervention or
whether the ISR is actively destroying neurons in this disease and should therefore be
inhibited by any potential therapeutic interventions. Alternatively, it is not unlikely that
some aspects of the ISR are protective in this disease, while others are apoptotic, and an
understanding into the nuances of ISR activation following HIV-infection is vital to the
development of therapies to prevent progression to HAND and to treat patients already
suffering from this devastating disease.
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Figure 1
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Figure 1 ATF6β increases in mid-frontal cortical gray matter of patients with HAND and of
patients infected with HIV.
Formalin-fixed, paraffin embedded mid-frontal cortical autopsy tissue was quadruple labeled for ATF6β and
for the cell-type markers for astrocytes (GFAP) and neurons (MAP2), in addition to using the DNA-binding
compound, DAPI to label nuclei. A) Gray matter in labeled slides was imaged using laser confocal
microscopy: ATF6β is shown in green, GFAP and MAP2 are shown in red and are not both present in the
same images, and DAPI is shown in blue. Overlap of ATF6β with a cell-type marker appears yellow. ATF6β
overlap with DAPI appears blue-green. An example is shown for a neurocognitively normal case and for a
HAND case for each cell-type marker. B and C) ATF6β protein levels from confocal images (5 per case)
were quantified by determining integrated pixel intensity using Metamorph 6.0 software. Total ATF6β
increases in HAND cases (n=12) over neurocognitively normal cases (n=5) (B) and in HIV(+) cases (n=14)
over HIV(-) (n=3) controls (C). Values are shown as mean±SEM. Student t test and Mann-Whitney U posthoc analysis was used for statistical analysis to determine significance. * p<0.05, compared with control.
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Figure 2
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Figure 2 Neuronal and astrocytic ATF6β increases in HAND and in HIV(+) compared with
neurocognitively normal and HIV(-) tissue, respectively, while nuclear ATF6β increases only
in HAND tissue.
Using Metamorph 6.0 software, total integrated pixel intensity of ATF6β was quantified and colocalization
with cell-type markers was determined and normalized to area of cell type marker to account for losses of
marker protein due to disease. A and B) ATF6β increases in the cytoplasm of neurons both in HAND cases
and in HIV(+) cases when compared to neurocognitively normal and HIV(-) cases, respectively. C and D)
ATF6β increases in the cytoplasm of astrocytes both in HAND cases and in HIV(+) cases when compared
with neurocognitively normal and HIV(-) cases, respectively. E and F) Total nuclear ATF6β protein levels
increase in HAND cases over neurocognitively normal cases, but do not increase in HIV(+) cases over that
seen in HIV(-). Values are shown as mean±SEM. Student t test and Mann-Whitney U post-hoc analysis was
used for statistical analysis to determine significance. * p<0.05, compared with control.
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Figure 3
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Figure 3 pPERK shows no significant difference with either neurocognitive status or HIV
status.
Cortical autopsy tissue was quadruple labeled for pPERK, GFAP, MAP2, and DAPI. A) Gray matter in
labeled slides was imaged using laser confocal microscopy: pPERK is shown in green, GFAP and MAP2 are
shown in red, and DAPI is shown in blue. Overlap of pPERK with a cell-type marker appears yellow and with
DAPI appears blue-green. An example is shown for a neurocognitively normal case and for a HAND case for
each cell-type marker. B and C) pPERK protein levels from confocal images (5 per case) were quantified by
determining integrated pixel intensity using Metamorph 6.0 software. pPERK does not change with either
neurocognitive status (B) or with HIV status (C) (HAND cases, n=12; neurocognitively normal cases, n=5;
HIV(+) cases, n=14; HIV(-) cases, n=3). Values are shown as mean±SEM. Student t test and Mann-Whitney
U post-hoc analysis was used for statistical analysis to determine significance. Values of less than 0.05 were
considered significant.
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Figure 4
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Figure 4 Total and neuronal peIF2α increase in HIV(+) tissue compared with HIV(-) tissue.

Cortical autopsy tissue was quadruple labeled for peIF2α, GFAP, MAP2, and DAPI. A) Gray matter in
labeled slides was imaged using laser confocal microscopy: peIF2α is shown in green, GFAP and MAP2 are
shown in red, and DAPI is shown in blue. Overlap of peIF2α with a cell-type marker appears yellow and with
DAPI appears blue-green. An example is shown for a neurocognitively normal case and for a HAND case for
each cell-type marker. B-E) peIF2α protein levels from confocal images (5 per case) were quantified by
determining integrated pixel intensity using Metamorph 6.0 software. Total and cytoplasmic neuronal
peIF2α increases in HIV(+) cases over HIV(-) cases (C and E) and in HAND tissue over neurocognitively
normal tissue, however the increase is quite small, despite reaching significance (B and D). HAND cases,
n=7; neurocognitively normal cases, n=10; HIV(+) cases, n=13; HIV(-) cases, n=4. Values are shown as
mean±SEM. Student t test and Mann-Whitney U post-hoc analysis was used for statistical analysis to
determine significance. * p<0.05, compared with control.
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Figure 5

131

Figure 5 Total ATF4 decreases in HAND tissue compared with neurocognitively normal
tissue.
Cortical autopsy tissue was quadruple labeled for ATF4 GFAP, MAP2, and DAPI. A) Gray matter in labeled
slides was imaged using laser confocal microscopy: ATF4 is shown in green, GFAP and MAP2 are shown in
red, and DAPI is shown in blue. Overlap of ATF4 with a cell-type marker appears yellow. ATF4 overlap with
DAPI appears blue-green. An example is shown for a neurocognitively normal case and for a HAND case for
each cell-type marker. B and C) ATF4 protein levels from confocal images (5 per case) were quantified by
determining integrated pixel intensity using Metamorph 6.0 software. Total ATF4 decreases in HAND cases
(n=12) over neurocognitively normal cases (n=5) , but shows no change in HIV(+) cases (n=14) compared
with HIV(-) (n=3) controls (C). Values are shown as mean±SEM. Student t test and Mann-Whitney U posthoc analysis was used for statistical analysis to determine significance. * p<0.05, compared with control.
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Figure 6
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Figure 6 While nuclear ATF4 protein levels parallel total ATF4 protein levels, neuronal ATF4
does not change with disease state and astrocytic ATF4 actually increases in both HAND and
HIV(+) tissue compared with neurocognitively normal and HIV(-) tissue, respectively.
Using Metamorph 6.0 software, total integrated pixel intensity of ATF4 was quantified and colocalization
with cell-type markers was determined and normalized to area of cell type marker to account for losses of
marker protein due to disease. A and B) ATF4 in the cytoplasm of neurons does not change with disease
state. C and D) ATF4 in the cytoplasm of astrocytes increases in both HAND cases and HIV(+) cases when
compared with neurocognitively normal and HIV(-) cases, respectively. E and F) Total nuclear ATF4
protein levels decrease in HAND cases over neurocognitively normal cases, but do not change in HIV(+)
cases over those seen in HIV(-) tissue. Values are shown as mean±SEM. Student t test and Mann-Whitney U
post-hoc analysis was used for statistical analysis to determine significance. * p<0.05, compared with
control.
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Table 1

	
  
Neurocog

HIV Status

Sex

Age

PMI

NNTC ID

HAND 1

+

M

35

9.25 hrs

6866

HAND 2

+

F

34

5 hrs

7680

HAND 3

+

M

57

5.5 hrs

7480

HAND 4

+

M

32

14.5 hrs

7569

HAND 5

+

M

38

5.5 hrs

7766

HAND 6

+

M

32

14 hrs

6568

HAND 7

+

M

36

2.5 hrs

6883

HAND 8

+

M

37

11.5 hrs

8382

HAND 9

+

M

31

8.83 hrs

6683

HAND 10

+

M

49

67.33 hrs

8270

HAND 11

+

M

42

27.33 hrs

6768

HAND 12

+

M

50

21 hrs

7467

HAND 13

+

M

43

unknown

8483

NORMAL 1

+

M

50

18 hrs

8087

NORMAL 2

+

M

46

2.75 hrs

6771

CONTROL 1

-

M

46

27.65

8083

CONTROL 2

-

F

47

19.18

7665

CONTROL 3

-

M

40

14.66 hrs

7686

CONTROL 4

-

F

51

21.75

7166

Neurocog: neurocognitive status, PMI: postmortem interval, N/A: not available

Table 1 For ATF6b, ATF4 and pPERK, the cases in table 1 were used for immunofluorescent
staining.
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Table 2
Neurocog

HIV Status

Sex

Age

PMI

NNTC ID

HAND 1

+

M

44

8.5 hrs

10011

HAND 2

+

M

31

20 hrs

10015

HAND 3

+

M

51

5 hrs

10063

HAND 4

+

M

33

6 hrs

10119

HAND 5

+

N/A

34

5 hrs

7680

HAND 6

+

N/A

32

14 hrs

16568

HAND 7

+

N/A

57

5.5 hrs

7480

NORMAL 1

+

N/A

52

15 hrs

36568

NORMAL 2

+

N/A

41

N/A

7479

NORMAL 3

+

N/A

44

21.25 hrs

6580

NORMAL 4

+

N/A

46

2.75 hrs

6771

NORMAL 5

+

N/A

45

13 hrs

8466

NORMAL 6

+

N/A

44

16.4 hrs

7172

CONTROL 1

-

N/A

58

7.42 hrs

8371

CONTROL 2

-

N/A

34

24.25 hrs

8377

CONTROL 3

-

N/A

51

21.75 hrs

7166

CONTROL 4

-

N/A

58

12.16 hrs

7068

	
  
Neurocog: neurocognitive status, PMI: postmortem interval, N/A: not available

Table 2 For peIF2a immunofluorescent staining, the cases listed in table 2 were used.
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Examining the Endogenous Antioxidant Response through
Immunofluorescent Analysis of Nrf2 in Tissue
Kathryn A. Lindl, A.B. and Kelly L. Jordan-Sciutto, Ph.D

Abstract
As organisms designed to depend upon oxygen to sustain life, humans are
necessarily and continually exposed to damaging oxidizing agents. As a vital
protective measure, oxygen-dependent organisms have developed a highly
evolutionarily conserved mechanism for preventing oxidative stress. NF-E2
(nuclear factor (erythroid-derived 2))-related factor-2 (Nrf2) is the primary
regulator of this endogenous antioxidant response. Many diseases that plague
human society, ranging from various cancers to neurodegenerative diseases,
have oxidative stress as a component of their etiology, and thus, much disease
research has focused on Nrf2, both as a potential point of biological failure
and as a promising therapeutic target. As a transcription factor, Nrf2 is active
only when it is nuclear, and is regulated largely by its subcellular distribution.
Thus, Nrf2 protein levels and subcellular localization are both key pieces of
information

when

studying

the

endogenous

antioxidant

response.

Immunofluorescent analysis (IFA) of Nrf2 in human tissue is a particularly
powerful tool in the study of Nrf2 in disease, because it allows examination of
both of these regulatory mechanisms that modulate Nrf2 activity.
Key Words: Nrf2, immunofluorescence, confocal microscopy, endogenous
antioxidant response
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1. Introduction
Oxidative stress is a constant presence in the cells that make up animal life forms
and, thus, inevitably plays a significant role in the pathogenesis of many diseases. To
combat this omnipresent oxidative stress, animal cells have evolved an endogenous
antioxidant response. Nuclear factor (erythroid-derived 2) (NE-F2)-related factor 2
(Nrf2), is the key regulator of antioxidant response genes, making it an essential player
in this endogenous cellular antioxidant response (Itoh et al., 1997; Chan and Kan, 1999;
McMahon et al., 2001; Leung et al., 2003; Kraft et al., 2004; Lee and Johnson, 2004;
Motohashi and Yamamoto, 2004). Nrf2 is a member of the Cap ’n’ Collar family of
transcription factors, which includes Nrf1, Nrf3, p45, Bach1, and Bach2 (Motohashi and
Yamamoto, 2004). Nrf2 binds the antioxidant responsive element (ARE), also known as
the electrophile response element (EpRE)), a cis-acting regulatory element found in the
5’-flanking region of genes encoding enzymes for antioxidant production and of other
Nrf2 target genes (Itoh et al., 2004; Lee and Johnson, 2004; Motohashi and Yamamoto,
2004). Genes regulated by Nrf2 include heme oxygenase-1 (HO-1), ubiquitin/PKC-ζinteracting protein A170, glutathione S-transferases (GST), NAD(P)H quinone
oxidoreductase (NQO1), peroxiredoxin 1, catalase, glutathione peroxidase, superoxide
dismutase (SOD), and thioredoxin (Itoh et al., 1997; Ishii et al., 2000; Kwak et al., 2001;
McMahon et al., 2001; Lee et al., 2003; Kobayashi and Yamamoto, 2005). Additionally,
Nrf2 regulates the expression of scavenger receptors, chaperone proteins, proteosome
proteins, and transcriptional regulators (Lee et al., 2003; Kobayashi and Yamamoto,
2005).
Nrf2 is largely regulated through the control of its subcellular distribution, rather
than through its induction, evidenced by the fact that Nrf2 mRNA levels remain
relatively constant throughout treatment with oxidative stressors (Itoh et al., 1999;

146

Numazawa and Yoshida, 2004). Subcellular localization of Nrf2 is controlled by the
actin-binding, cytoplasmic Kelch-like erythroid cell-derived protein with CNC homology
(ECH)-associated protein 1 (Keap1), which binds the N-terminal Neh2 [Nrf2-ECH
homology 2] domain of Nrf2, tethering it to the cytoplasm (Itoh et al., 1999; Motohashi
and Yamamoto, 2004) (Figure 1). In addition to regulating Nrf2 subcellular localization,
Keap1 also regulates Nrf2 protein levels, by mediating proteasomal degradation of Nrf2.
Keap1 binds the ubiquitin ligase, Cullin 3 (Cul3) (Kobayashi et al., 2004). In effect,
Keap1 acts as a bridge between Cul3 and Nrf2, resulting in rapid Nrf2 degradation
(Cullinan et al., 2004; Furukawa and Xiong, 2005). As shown in figure 1, in the presence
of mediators of oxidative stress, such as reactive oxygen species (ROS), modification of
Keap1 cysteines and phosphorylation of Nrf2 act cooperatively as regulatory mechanisms
allowing Keap1 release of Nrf2, and consequently, nuclear translocation of Nrf2 (Huang
et al., 2000; Dinkova-Kostova et al., 2002; Huang et al., 2002; Kang et al., 2002; Bloom
and Jaiswal, 2003; Cullinan et al., 2003; Numazawa et al., 2003; Motohashi and
Yamamoto, 2004; Kobayashi et al., 2006). This system of regulatory mechanisms
provides precise control of Nrf2 activation.
While Nrf2 subcellular localization is a crucial determining factor of Nrf2 activity,
several additional mechanisms modulate Nrf2 activity. Nrf2 DNA binding and
transactivation both depend upon Nrf2 heterodimerazation with small Maf proteins
(Itoh et al., 1997; Motohashi et al., 2004). In addition to small Mafs, studies have
suggested that c-Jun and activating transcription factor 4 (ATF4) also form heterodimers
with Nrf2 and augment its transactivation activity (Venugopal and Jaiswal, 1998; He et
al., 2001). Further, Nrf2 has two transcriptional activation domains. These domains bind
CBP (cyclic adenosine monophosphate (cAMP) response element binding protein
(CREB) binding protein) or p300, which then mediate transcriptional activation of Nrf2
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target genes (Katoh et al., 2001; Zhu and Fahl, 2001). Synergistic activity of
simultaneous CBP/p300 binding at both Nrf2 transactivation domains may explain the
large potency of Nrf2 transactivation activity as compared with that of other CNC
transcription factors (Katoh et al., 2001; Kobayashi and Yamamoto, 2005).
The exquisite control over Nrf2 function (figure 1) implies an extreme importance
of precise Nrf2 activity, and also provides a large number of potential points of
malfunction and targets for therapeutic strategies in disease states affected by oxidative
stress. Because Nrf2 is regulated by control of both its subcellular localization and its
protein level, immunofluorescent analysis (IFA) is a particularly powerful tool for
examining the endogenous antioxidant response as controlled by this transcription
factor. In particular, IFA in human tissue allows study of the role Nrf2 plays in human
disease. However, because Nrf2 is expressed at relatively low levels, particularly in
certain tissues, such as brain, IFA of this protein is not straightforward. Further, IFA is
only scientifically useful for semiquantitative analysis of protein levels and subcellular
localization when it is performed with certain considerations to allow for distinction
between slight variations in protein level and when it is analyzed with confocal laser
microscopy.
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2. Materials
2.1 Equipment
1. Microtome
2. Biorad Radiance 2100 laser confocal microscope equipped with Argon, Green He/Ne,
Red Diode, and Blue Diode lasers (Biorad, Hercules, CA, USA), as described
previously (Strachan et al., 2005).
2.2 Reagents
1. Histoclear (National Diagnostics, Atlanta, GA, USA).
2. Ethanol (200 proof, Absolute, Anhydrous, ACS/USP Grade) in deionized H2O (dI
H2O) at 70%, 90%, and 95% and 100% ethanol.
3. A stable solution of 30% H2O2 (Sigma-Aldrich, St. Louis, MO, USA) is mixed with
methanol (Thermo Fisher Scientific, Waltham, MA, USA) to a final concentration of
3% H2O2.
4. 10X Target Retrieval Solution (Dako, Carpinteria, CA, USA) in dI H2O to its 1X
concentration.
5. Phosphate buffered saline (PBS) (ScyTek Laboratories, Inc., Logan, UT, USA)
purchased at 25X and diluted in dI H2O to its final 1X concentration.
6. Normal goat serum (Chemicon (Millipore), Billerica, MA, USA) diluted in PBS to a
final concentration of 5%.
7. Super Pap Pen (Ted Pella, Inc., Redding, CA, USA)
8. Normal Antibody Diluent (NAD) (ScyTek Laboratories, Inc., Logan, UT, USA).
9. Tyramide Signal Amplification (TSA Biotin System) (TSA Kit) (Perkin Elmer,
Waltham, MA, USA).
10. Streptavidin FITC (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA,
USA)
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11. Nucleic acid stains: DAPI (Molecular Probes), propidium iodide (Sigma-Aldrich), or
Hoechst (Thermo Fisher Scientific) diluted in NAD according to manufacturers’
recommendations.
12. RNase A (Roche Pharmaceuticals, Nutley, NJ, USA) diluted in NAD according to
manufacturer’s recommendation.
13. Citifluor AF1 mounting media (Citifluor, Ltd., London, UK).
14. Nail polish (any commercially available variety).
15. Primary antibodies: Nrf2 C-20, Nrf2 H-300 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), Nrf2 MO1, Nrf2 MO3 (Abnova Corporation, Taipei City, Taiwan).
16. Secondary Antibodies (Jackson ImmunoResearch Laboratories Inc.): biotinconjugated goat anti-rabbit antibody, biotin-conjugated goat anti-mouse antibody,
fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit antibody, FITCconjugated goat anti-mouse antibody.
2.3 Supplies
1. MetaMorph 6.0 image analysis software (Universal Imaging, Inc, Downingtown, PA).
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3. Methods
When the endogenous antioxidant response is active, the overall protein levels of
Nrf2 increase and its subcellular localization is altered. Given the importance of these
two regulatory mechanisms in Nrf2 activation, immunofluorescent analysis (IFA) is an
especially powerful tool for the examination of Nrf2-mediated endogenous antioxidant
activity in human tissues. However, Nrf2 is a relatively scarce protein, particularly in
certain types of tissue, such as brain. Thus, to successfully visualize this protein using
immunofluorescence, the signal must be amplified using tyramide signal amplification
(TSA). This amplification method utilizes the enzymatic activity of horseradish
peroxidase (HRP), which induces activation of short-lived, but highly reactive tyramide,
which then covalently attaches to nucleophilic residues near the site to which the HRP is
tethered. To start, Nrf2 is recognized by a primary antibody directed against it, which is
then recognized by a secondary antibody that is conjugated to biotin. The biotin then
binds HRP-conjugated streptavidin with high affinity, affixing the HRP in close vicinity
to Nrf2 proteins. Then, biotinylated tyramide is added, and subsequently activated by the
HRP causing it to covalently bind to nearby electrophilic residues. Finally, fluorescein
isothiocyanate (FITC)-conjugated streptavidin binds to the biotinylated tyramide,
allowing amplified visualization of Nrf2.
In addition to allowing visualization of scarce proteins, TSA also allows more
flexibility in the choice of primary antibodies that can be used to triple- and quadruplelabel tissue. Specifically, when TSA is not used, only one polyclonal antibody made in
each type of animal may be used (e.g. only one rabbit antibody, not two, may be used in
any given sample), or in the case of monoclonal antibodies, only one of each type of
antibody isotype may be used. However, when using TSA, primary antibodies can be
used at such a low dilution that they are not visible without the use of TSA. Thus, after
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TSA is used to amplify one antibody, even though a second secondary will recognize both
primary antibodies made in the same animal, the TSA-amplified antibody will be such a
small amount that it will not contribute to the signal visualized with the second
secondary.
While TSA is a powerful tool for the visualization of Nrf2, it must be used
appropriately if it is to allow for discrimination between protein levels in different
experimental conditions (e.g. disease versus normal). Specifically, the appropriate
dilution factor for the primary antibody must be empirically determined prior to data
generation. Further, confocal laser microscopy must be used to visualize fluorescent
staining of Nrf2, when attempting to accurately discern subcelluar localization of this
protein.
3.1 Immunofluorescent Labeling in Paraffin-Embedded Tissue
1. Slice paraffin-embedded tissue into 7 µm sections using a microtome. Mount
individual sections on (+) charged slides and allow them to dry, and, thus, become
fixed to the slide.
2. Heat paraffin-embedded sections to 55°C overnight. If necessary, this step can be
shortened, but slides must be heated for at least 30 minutes. Then, deparaffinize
slides by 3 incubations in Histoclear for 10 minutes each (see Note 1).
3. Rehydrate sections as follows: 2 incubations for 10 minutes each in 100% alcohol
followed by 5 minute incubations in each of 95% alcohol, 90% alcohol, 70% alcohol,
and deionized H2O.
4. Incubate slides for 30 minutes in a solution of 3% H2O2 in methanol to quench
endogenous peroxidase activity in the tissue, followed by a 5-minute wash in
deionized H2O.
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5. Perform antigen unmasking by immersing slides for 1 hour in Target Retrieval
Solution (DAKO) preheated to 95°C (see Note 1). After a 1 hour incubation in the
Target Retrieval Solution at 95°C, remove the Coplan jar containing the slides from
the water bath to the benchtop, and allow it to cool gradually to room temperature.
After cooling, wash slides 3 times in PBS for 5 minutes each.
6. To minimize non-specific binding of secondary antibodies, block slides by incubating
them for 1 hour in a phosphate-buffered saline (PBS)-based solution of 10% normal
serum of the animal in which the secondary antibody was produced. This incubation
is done at room temperature. Unless otherwise indicated, all incubations and washes
should be conducted at room temperature. After 1 hour of blocking, wash slides 3
times in PBS for 5 minutes each.
7. Remove slides from the PBS wash one at a time, dry the portions of the slide that
have no tissue with a paper towel and encircle the tissue with the hydrophobic
marking of a Pap Pen (see Note 2). Apply Nrf2 primary antibody to the area enclosed
by the Pap Pen mark and incubate slides overnight at 4°C. Antibody should be
diluted in Normal Antibody Diluent (NAD). To allow for discrimination between the
levels of protein in different experimental conditions (e.g. diseased versus normal
tissue), determination of the correct primary antibody dilution is critical, and must
be empirically determined prior to use of the antibody for data generation. (See
section 3.1.1 for a detailed procedure for empirically optimizing primary antibody
dilution.) After overnight incubation, wash slides 3 times in PBS for 5 minutes each.
8. This step begins the TSA amplification process. Incubate slides for 30 minutes (see
Note 3) in biotin-conjugated secondary antibody directed against immune fragments
of the animal in which the primary antibody was made (e.g. use an antibody directed
against rabbit IgG for a primary antibody made in a rabbit). For all secondary
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antibodies used throughout the course of the protocol, use antibodies made in the
animal against which the tissue was blocked in step 6. Secondary antibodies should
be diluted in NAD, following the manufacturer’s recommendation (see Note 4).
Following the 30-minute incubation, wash slides 3 times in PBS for 5 minutes each.
9. Incubate slides first in TNB (Tris NaCl Blocking)(TSA kit) Buffer for 30 minutes,
then in horseradish peroxidase (HRP)-conjugated Streptavidin (TSA kit) diluted in
TNB at a dilution factor of 1:400 for 30-minutes. Following these incubations, wash
slides 3 times in PBS for 5 minutes each.
10. Incubate slides for 30 minutes in biotinylated tyramide, diluted 1:100 in
amplification diluent (TSA kit). Following this incubation, wash slides 3 times in PBS
for 5 minutes each (see Note 5).
11. Incubate slides for 30 minutes in Streptavidin conjugated to fluorescein
isothiocyanate (FITC) or another fluorescent molecule whose excitation and emission
frequencies are different from those of the nucleic acid markers to be used (e.g. DAPI
or propidium iodide). Following this incubation, wash slides 3 times in PBS for 5
minutes each (see Note 6).
12. Incubate slides in second primary antibody for 1 hour at 37°C, 2 hours at room
temperature, or overnight at 4°C (see Note 7). The second primary antibody may be a
cell-type specific marker, used to allow determination of cell-type specific Nrf2
staining, or it may be another experimental protein of interest. However, the
recognized protein must be sufficiently abundant that its visualization does not
require TSA amplification, as only one course of TSA amplification may be used in
any staining protocol. Following this incubation, wash slides 3 times in PBS for 5
minutes each.
13. Incubate slides for 30 minutes in the second secondary antibody, which should be
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conjugated to cyanine 3 or another fluorescent molecule whose excitation and
emission frequencies are different from the fluorescent molecule already used during
TSA amplification and from the nucleic acid markers to be used. This antibody
should be directed against immune fragments of the animal in which the second
primary antibody was made and should be diluted in NAD, following the
manufacturer’s recommendation. Following the 30-minute incubation, wash slides 3
times in PBS for 5 minutes each.
14. Steps 12 and 13 can be repeated for a third or fourth primary antibody. Please note,
no two primary antibodies can have been made in the same type of animal, except for
the host animal of the antibody amplified using TSA, which may be used twice (see
3.1.2 for necessary controls if this is to be the case). Additionally, each primary
antibody must be visualized using a fluorescent molecule with distinct excitation and
emission frequencies from others used in the same staining protocol.
15. If desired, incubate slides in a nucleic acid stain to label cell nuclei (see Notes 8 and
9). Dilute stain according to manufacturer’s recommendation. If propidium iodide or
Hoechst stains are to be used, slides must first be incubated in RNase A, diluted
according to manufacturer’s recommendation, for at least 30 minutes at room
temperature.
16. Coverslip slide using 3 drops of Citifluor mounting medium (see Note 10). Seal the
edges of the coverslip with nail polish, to prevent leakage of the mounting medium
and the resultant drying of the tissue.
3.2 Empirically Optimizing Primary Antibody Dilution
1. To allow for discrimination between the levels of protein in different experimental
conditions (e.g. diseased versus normal tissue), use of the correct primary antibody
dilution is critical, and must be empirically determined prior to use of the antibody
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for data generation. If too much antibody is used, the signal becomes saturated and
any differences between experimental conditions are masked and cannot be seen,
thereby resulting in a type II error (false positive) (see Note 11).
2. To empirically determine the appropriate primary antibody dilution, test different
dilutions in one case from each experimental condition (e.g. disease versus normal),
which will allow discernment of differences in levels of the target protein. For this
process, it may be possible to avoid use of tissue that is highly experimentally
valuable, in favor of tissue that is relevant but not as valuable. For example, when
studying Alzheimer’s disease, a disease that greatly affects hippocampal brain tissue,
determination of appropriate primary antibody dilutions can often be conducted in a
brain region that is more abundant, but still has pathology such as the anterior
cingulate cortex, using both normal and diseased tissue.
3. Determination of the ideal dilution may require several rounds of empirical testing.
To start, use dilutions that span the range provided by the manufacturer, in a nonlinear distribution. For example, if the manufacturer recommends using a dilution
between 1:100 and 1:1000, the testing dilutions should be 1:100, 1:300, and 1:1000.
If the manufacturer does not provide recommendations and there are no previous
publications using the antibody for IFA, start testing dilutions between 1:100 and
1:1000. Ideally, protein level differences will be visible with one of the dilutions used.
However, if this is not the case, and if your lowest dilution factor does not show
staining, then try lower dilution factors using a similar distribution scheme.
Alternatively, if even the most dilute antibody results in very robust staining, then
repeat the process using higher dilutions with a similar distribution (i.e. 1:1000,
1:3000, 1:10000). When one dilution shows potential as the optimal dilution, one
more test should be conducted using dilutions closer to the chosen dilution. See
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Figure 2 for an example protocol scheme.

3.3 Controls
1. During empirical determination of the appropriate dilution factor for the primary
antibody, two controls must be performed. Both of these controls need only be
performed once for a given type of tissue (species and tissue type) and a given
antibody. However, when a new lot of any antibody (primary or secondary) is
purchased, these controls should be rerun, to ensure that the antibody has not
changed from lot to lot.
2. The first control is conducted to ensure that the secondary antibody does not cause
non-specific background staining and must be conducted each time a new secondary
antibody is used, regardless of the primary antibody being used. Prepare one slide
that is not incubated in primary antibody. Instead, this slide should be incubated
overnight in NAD as the other slides are incubating in primary antibody (3.1.7).
Following this step, treat this control slide exactly as the other slides are treated,
following each step of the protocol. This control slide should show no staining.
3. The second control acts to ensure that there is no visible Nrf2 signal if the primary
antibody signal is not amplified using TSA. This control must be performed every
time a new primary antibody is used with TSA, regardless of the secondary antibody
being used, and is particularly important if a second primary antibody made in the
same animal will be used (e.g. if using both a rabbit Nrf2 antibody and a rabbit celltype marker antibody in the same slides). This control slide is prepared by skipping
the TSA process. Thus, to prepare this slide, at step 8 (3.1.8), which starts the TSA
amplification, rather than using the biotin-conjugated secondary antibody, incubate
your control slide with a secondary antibody conjugated to the same fluorescent
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molecule as that conjugated to the streptavidin in the final TSA step (3.1.11). Do NOT
treat this slide with the remaining TSA steps, but rather, continue with the protocol
starting from incubation with the second primary (3.1.12). This control slide should
show no staining.
3.4 Confocal Laser Microscopy Image Capture
1.

Images should be captured using confocal laser microscopy to allow determination of
Nrf2 subcellular localization, specifically whether it is in the nucleus or the
cytoplasm. When choosing which fluorescent molecules to use for visualization of
antibody staining, consider the lasers included in available confocal microscopes.
Collect 5-10 images from each tissue section. Images should be collected randomly
from within the regions of interest in each section (e.g. in cortical brain tissue
consider gray versus white matter when collecting images) and in a researcherblinded manner. Collect all images at uniform settings to allow comparisons across
samples.

3.5 Post-acquisitional Analysis
1.

Perform post-acquisition analysis for immunofluorescent staining using MetaMorph
6.0 image analysis software (2.3.1). To determine total Nrf2 protein levels, measure
integrated pixel intensity for Nrf2 per image, where the integrated pixel intensity is
defined as total pixel intensity per image times the area of pixels positive for the
signal. For colocalization of Nrf2 with specific cell types in each image, examine
integrated pixel intensity for Nrf2 that is overlapping with the pixels positive for your
specific cell-type marker. Often when determining Nrf2 colocalization with specific
cell types, it is necessary to normalize the values to the area of pixels positive for the
specific phenotypic marker to account for variations in phenotypic marker
expression in different experimental conditions. Additionally, Nrf2 subcellular
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localization can be examined in a similar manner by determining Nrf2 colocalization
with nuclear markers, such as propidium iodide.
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4. Results
1. AD is a region-specific neurodegenerative disease, affecting in particular the
hippocampus and various parts of the cortex. Examination of Nrf2 in hippocampal
autopsy tissue from AD patients reveals that Nrf2 subcelluar localization is altered as
compared with control autopsy hippocampal tissue (Ramsey et al., 2007). In this
study by Ramsey et al., phenotypic cell-type specific markers and nucleic acid stains
demonstrate that Nrf2 is present in both neurons and astrocytes, and allow
discrimination of different Nrf2 subcellular staining patterns in these two cell types
(Figure 2 from (Ramsey et al., 2007)). Specifically, the findings presented by Ramsey
et al., show that in normal hippocampal CA1 neurons, Nrf2 is predominantly nuclear,
while in AD hippocampal CA1 neurons, it is predominantly cytoplasmic, and
therefore not transcriptionally active. These findings suggest that Nrf2 is unable to
initiate the endogenous antioxidant response in neurons in the hippocampi of AD
patients, and may thereby contribute to pathogenesis of this disease that tragically
affects so many lives.
2. The protocol outlined in this chapter can be extended to examination of proteins
other than Nrf2. As can be seen in Lindl et al (Lindl et al., 2007), the endoplasmic
reticulum (ER) stress response protein, Binding Protein (BiP), can be visualized
using IFA with TSA in human midfrontal cortical autopsy tissue from HAD patients.
In this tissue, BiP total protein levels were quantified using Metamorph software and
were seen to increase in gray matter. Additionally, astrocytic BiP increased as
determined using Metamorph software to analyze BiP staining that colocalized with
astrocytic marker, GFAP staining. These findings demonstrate that the ER stress
response in activated in the midfrontal cortical gray matter in HAD autopsy tissue.
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5. Notes
1. The antigen-unmasking step (3.1.5) is usually done in a Coplan jar, which will crack if
heated quickly. Thus, it is prudent to prepare the Target Retrieval Solution in a
Coplan jar while the slides are in the first step of Histoclear, and place the jar in a
water bath set to 37°C and allow the Target Retrieval Solution to heat as the water
bath heats up to 95°C.
2. When applying Pap Pen, be careful not to mark over the tissue and do not to allow
the tissue to dry out.
3. As a general rule, all 30-minute incubations should be limited to 30 minutes.
Specifically: do not allow slides to incubate in secondary antibodies for much longer
than 30 minutes, as this may increase non-specific binding of the secondary
antibody; do not allow slides to incubate in Streptavidin-HRP or -FITC for much
longer than 30 minutes (3.1.9), as this may increase background staining; finally, it
is critical that slides are not allowed to incubate in biotinyl-tyramide for longer
than 30 minutes (3.1.10), as this is step utilizes an enzymatic activity and, thus,
additional incubation time may significantly increase staining, resulting in an overamplification of both specific and non-specific antibody signal. Two exceptions to
this general rule: 1) endogenous peroxidase quenching (3.1.4), which can be extended
to several hours and 2) the TNB incubation (3.1.9), which can be greatly extended,
but care should be taken that TNB does not remain on slides for a length of time that
would allow contamination of the buffer.
4. Occasionally, the manufacturers recommended dilutions for secondary antibodies
are not optimal and result in high non-specific or background staining. If this is the
case, apply the steps outlined in section 3.1.1 for optimization of the primary
antibody dilution to optimization of the secondary antibody dilution.
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5. After step 10 (3.1.10), slides should be kept in the dark as much as possible. Changing
of solutions can be done in a light room, but during washes and incubations, slides
should be kept in a dark place.
6. If the Nrf2 antibody is the only primary antibody that will be used, proceed directly
from step 11 to step 16 (3.1.11-3.1.16).
7. Incubations in primary antibody should be carried out for 1 hour at 37°C, 2 hours at
room temperature, or overnight at 4°C. Ideally, slides should be incubated in the
Nrf2 antibody overnight at 4°C. Further, any additional experimental proteins of
interest should be incubated overnight at 4°C, ideally. However, antibodies to celltype specific markers often work well in any of the three incubation conditions, and
do not result in non-specific background staining or weak specific staining. In
particular, antibodies to microtubule-associated protein 2 (MAP2) and glial
fibrillary-associated protein (GFAP) are known to work at any of the incubation
conditions.
8. While all nucleic acid stains thoroughly mark astrocytic and oligodendrocyte nuclei,
propidium iodide most clearly marks neuronal nuclei.
9. To save time, RNase A and nucleic acid stains can be included in other incubations;
in particular, secondary antibody incubations, since they utilize the same conditions,
are particularly convenient. However, please note the RNase A step must be
completed prior to adding propidium iodide or Hoechst stain.
10. When coverslipping, avoid trapping air bubbles on top of the tissue in the Citifluor,
as this will distort the visualization of the tissue. To prevent air bubbles, roll the
coverslip onto the tissue from one end of the slide, rather than dropping it directly
onto the slide.
11. The ideal antibody dilution will result in a signal just stronger than that required to
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visualize the protein of interest, thus avoiding saturation of the signal.
12. This protocol can be used for immunohistochemistry with some slight modification.
Specifically, rather than using fluorescent-tagged streptavidin in the final TSA step
(3.1.11), use Strep-HRP as used in step 9 (3.1.9). To visualize Nrf2 staining in this
case, use a kit such as Vector Red (Vector Laboratories, Burlingame, CA, USA)
according to manufacturer’s recommendation. Then, dehydrate slides by immersion
for 5 min each in dI H2O, 70% ethanol, 90% ethanol, 95% ethanol, and the 2 times in
100% ethanol. Finally, coverslip the slides using Permount. Keep in mind that
immunohistochemistry does not have the quantitative power of IFA and that it does
not allow for the use of cell-type markers to distinguish Nrf2 expression in different
cell types.
13. This protocol can be used for IFA in tissue culture with some slight modification.
First, wash cell 3 times in PBS for 5 minutes each and then 2 times for 10 minutes
each in PBS with 0.1% Tween-20. Then, fix cells using a 30-minute incubation in 4%
paraformadlehyde/2% sucrose in PBS. Skip the steps required for deparaffinization,
and proceed directly to blocking. However, include 0.1% Triton-X 100 in the blocking
solution, to ensure the cells are fully permeablized.
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Figure 1:

Figure 1: Schematic for Nrf2 Regulation and Function.
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Figure 2:

Figure 2: Optimization of Primary Antibody Dilution
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Abstract
In response to oxidative stress, the Nrf2 transcription factor translocates from
the cytoplasm into the nucleus and transactivates expression of genes with antioxidant
activity. Despite this cellular mechanism, oxidative damage is abundant in Alzheimer
and Parkinson disease (AD and PD). To investigate mechanisms by which Nrf2 activity
may be aberrant or insufficient in neurodegenerative conditions, we assessed Nrf2
localization in affected brain regions of AD, Lewy body variant of AD (LBVAD), and PD.
By immunohistochemistry, Nrf2 is expressed in both the nucleus and the cytoplasm of
neurons in normal hippocampi, with predominant expression in the nucleus. In AD and
LBVAD, Nrf2 was predominantly cytoplasmic in hippocampal neurons and was not a
major component of beta amyloid plaques or neurofibrillary tangles. By immunoblotting
we observed a significant decrease in nuclear Nrf2 levels in AD cases. In contrast, Nrf2
was strongly nuclear in PD nigral neurons, but cytoplasmic in substantia nigra of
normal, AD, and LBVAD cases.

These findings suggest that Nrf2 -mediated

transcription is not induced in neurons in AD, despite the presence of oxidative stress.
In PD, nuclear localization of Nrf2 is strongly induced, but this response may be
insufficient to protect neurons from degeneration.
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Introduction
Although Alzheimer disease (AD) and Parkinson disease (PD) have distinct
pathologic features, there is considerable evidence to support oxidative stress as a
common pathogenetic mechanism in both disorders. Evidence of lipid peroxidation,
protein nitration, and nucleic acid oxidation is abundant in affected brain regions of both
AD and PD (reviewed in (1-6)).

Oxidative damage occurs early in disease (5, 7)

suggesting that oxidative stress plays a role in disease progression.

Increased

antioxidant activity confers protection in mouse and culture models (8, 9) and has been
reported to lower the risk of AD (10, 11). However, how disease mechanisms affect
endogenous antioxidant defenses are still incompletely understood.
Reducing cellular oxidative stress occurs via an endogenous mechanism
regulated at the transcriptional level. Genes whose products participate in reducing
oxidative stress, inflammation, and accumulation of toxic metabolites contain a common
promoter element called the antioxidant response element (ARE) or electrophile
response element. ARE containing gene promoters include glutathione-S-transferase
(GST), coenzyme Q10 (Q10), NAD(P)H:quinone oxidoreductase (QR) and superoxide
dismutase 1 (SOD1). The ARE promoter element is bound by several transcription
factors, however the Nuclear factor E2-related factor 2 (Nrf2) is responsible for
activating transcription in response to oxidative stress (12). Nrf2 transcriptional activity
is known to be regulated by several mechanisms including protein interaction, protein
stability, nuclear cytoplasmic shuttling, and phosphorylation (13-28). Several reports
suggest that interaction with the kelch-like ECH associated protein (Keap1) sequesters
Nrf2 in the cytoplasm leading to ubiquitination and subsequent degradation by the
proteasome (13-15).

Either oxidation of sulfhydryl groups on specific cysteines in

Keap1(29) or phosphorylation of Keap1 and/or Nrf2 induces Keap1 to release Nrf2 (19-
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28). Free of Keap1, Nrf2 is stabilized and translocates from the cytoplasm to the nucleus
via a bipartite nuclear localization signal where it transactivates expression of
detoxification enzymes, antioxidant enzymes, reducing molecules, and Nrf2 itself (13, 14,
16, 30-33). These gene products go on to protect the cell from oxidative damage. Nrf2
also contains a nuclear export sequence near its nuclear localization signal, presumably
to remove Nrf2 from the nucleus when the antioxidant response is no longer needed (1618).
In primary murine cortical cultures, neurons lacking Nrf2 are more susceptible to
oxidative stress via H2O2 and non-excitotoxic glutamate (34) and are rescued by
overexpression of Nrf2 (30). Overexpression of Nrf2 can rescue neurons from
mitochondrial complex II inhibition and ischemic insult in animal models of
Huntington's disease and stroke respectively (35, 36). Thus, neurons and astrocytes
depend on Nrf2 activation of ARE containing genes for protection from oxidative death.
In AD, expression of two Nrf2 target genes, GST and QR, exhibit altered activity
and expression, respectively, in AD brain (37, 38). While the increase in QR protein
levels suggests activation of the antioxidant response, the reduction in GST activity
suggests that the response is incomplete, aberrant, and/or insufficient. In PD, two other
Nrf2 targets, GSH and Q10 display reduced levels suggesting a loss of Nrf2 response (39,
40). Providing GSH and Q10 exogenously lessens neuronal loss in animal and culture
models of PD (41-43).
Given the extensive oxidative damage in AD and PD, we would expect an
upregulation of Nrf2 activity in the nuclei of neurons and astrocytes during disease
progression; however, in AD and PD, levels of some ARE containing gene products are
reduced suggesting disruption of the pathway. As subcellular trafficking is critical to
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activity of this pathway, we examined expression and localization of Nrf2 in susceptible
neuron populations in AD and PD brain tissues. Nrf2 expression patterns and protein
levels in AD and PD suggest aberrant regulation of Nrf2 in AD, while disrupted or
insufficient ARE responses likely occur downstream of Nrf2 nuclear localization in PD.
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Materials and Methods
Human Subjects
Autopsy brain tissues were obtained from patients with PD, AD, and age-matched
controls from the Alzheimer Disease Core Center tissue bank at the University of
Pennsylvania and the Alzheimer Disease Research Center at the University of Pittsburgh
Medical Center.

Both AD and PD were defined by clinical history, neurological

examination, and neuropathologic assessment of Braak neurofibrillary tangle stage (44)
for all cases, and the Braak PD stage for PD cases only (45), as this staging criteria was
developed for non-demented cases (See Table 1 for case staging data). Using these
criteria, 12 cases were diagnosed as AD, 5 as normal age-matched controls, 5 as PD and 3
as Lewy body variant of AD (LBVAD). All cases have post-mortem intervals of less than
12 hours before autopsy with a single exception. Age characteristics are shown in Table
1.

From these cases, paraffin embedded, formalin fixed tissue sections from the

hippocampus and substantia nigra were used. In the hippocampus, special attention was
paid to the CA1 region, as these neurons are particularly vulnerable to injury. Frozen
tissue was obtained from the Alzheimer's Disease Core Center (ADCC) at the University
of Pennsylvania. Mid Frontal cortex was dissected from fresh frozen tissue of 9 AD cases
and 9 control cases with similar characteristics as our fixed tissue cohort. Average ages
between AD and control cases were not significantly different (79.1 ± 10.6 and 79.9 ± 9.6
respectively). Post-mortem interval for AD cases ranged from 5 to 12 hours while control
cases ranged from 4 to 24 hours. As for the paraffin embedded, formalin-fixed tissue, AD
cases were Braak stages 4, 5, or 6 and control cases were Braak stage 1.

Immunohistochemistry and Immunofluorescent Confocal Microscopy
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Paraffin-embedded sections were heated to 50 degrees Celsius overnight and
deparaffinized in Histoclear (3 x 15 min; National Diagnostics, Atlanta, GA, USA).
Sections were rehydrated as follows: 100% alcohol twice for 10 min; 95% alcohol for 10
min; 90% alcohol for 10 min; 70% alcohol for 10 min; and water for 5 min. Endogenous
peroxidase activity was inactivated by immersing in 3% hydrogen peroxide for 30 min.
Antigen unmasking was performed by placing slides in target retrieval solution (DAKO,
Carpinteria, CA, USA) at 95 degrees Celsius for 1 h. After gradual cooling to room
temperature, tissue sections were blocked with 10% normal goat serum (Chemicon
International, Temecula, CA, USA) in phosphate buffered saline (PBS). Antibodies for
Nrf2 (Table 2) were characterized for immunohistochemistry and used at empirically
determined concentrations using a dilution series with tyramide amplification (NENPerkin Elmer, Wellesley, MA, USA). Similar results were seen with both Nrf2 antibodies
indicated. Immunostaining was visualized by Vector Red (Vector Laboratories, Inc.
Burlingame, CA, USA).

Slides were counterstained with Gill's hematoxylin (Vector

Laboratories, Inc., Burlingame, CA, USA) for 30 seconds, dehydrated and mounted in
Permount (Fisher, Fair Lawn, NJ, USA).
For immunofluorescent staining, the Nrf2 was detected as above except the
tyramide was directly conjugated to FITC. At the concentration of Nrf2 antibody used,
no Nrf2 staining can be detected with a secondary directly conjugated to a fluor,
therefore, a second label with a polyclonal antibody will not cross react with Nrf2
antibody complexes. This is similar to methods we have described previously (46).
Nucleic acids were labeled with DAPI (10 µM for 30 minutes; Invitrogen, Molecular
Probes, Carlsbad, CA, USA) or propidium iodide (PI, 10 µg/ml for 30 minutes; Sigma, St
Louis, MO, USA) following RNase A treatment (10 µg/ml for 30 minutes) to remove
RNA. The following antibodies were each used in combination with Nrf2 in double label
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immunofluorescent microscopy (See Table 2 for experimental details and commercial
source): MAP2 antibody to detect neurons; GFAP antibody to detect astrocytes; beta
amyloid antibody to determine amyloid plaques (4G8; Gift from Dr. Virginia M.Y. Lee,
University of Pennsylvania); AT8 to detect tau, and hydroxylnonenal (HNE) as a marker
of oxidative damage.

These antibodies were detected using appropriate secondary

antibodies (Table 1, goat anti-mouse or goat anti rabbit; Jackson Immunologicals, West
Grove, PA, USA) conjugated to Cy5 at 1:200. Slides were mounted in gelvetol and
analyzed by immunofluorescent confocal microscopy.
Confocal microscopy was performed on a Bio-Rad Radiance 2100 (BioRad,
Hercules, CA, USA) with the 488 nm line of an Argon laser to excite FITC, a Red Diode
laser (637 nm) to excite Cy5, and a blue Diode Laser (405 nm) to excite DAPI. The
following filters were used for capture respective fluor emissions (FITC – 515 df30; Cy5 –
650 LP; DAPI 476 df 48). Each fluor was excited and captured sequentially to eliminate
bleed through. Further, FITC and Cy5 fluors were chosen because there is minimal
overlap from the emission spectra.

Protein Extraction and Immunoblotting
Protein extracts were prepared from mid-frontal cortex of 9 frozen normal
human brains and 9 brains from patients with a diagnosis of definite Alzheimer Disease.
Tissues were homogenized on ice with 4 strokes in a manual dounce homogenizer in 2
tissue volumes of Buffer A [10 mM Hepes pH 7.9, 1.5mM MgCl2, 10 mM KCl, 0.5mM
DTT, and 1:1000 protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO)] and spun at
3000 rpm for 5 minutes at 4° C. The supernatant was removed and the pellet was
resuspended in 4 pellet volumes of NP40 lysis buffer [0.1%NP-40, 10 mM Tris (pH 8.0),
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10 mM MgCl2, 15 mM NaCl)] with 1:1000 protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO) and incubated on ice for 15 minutes. The tissue pellet was then homogenized
on ice with 30 manual strokes in the dounce homogenizer and centrifuged for 30
minutes at 10,000 rpm at 4° C. The supernatant was collected and labeled as the
"cytoplasmic" fraction for immunoblotting. The pellet was resuspended in 2 pellet
volumes of Buffer B [20 mM Hepes pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM DTT, 25% glycerol, and 1:1000 protease inhibitor cocktail (SigmaAldrich, St. Louis, MO)],

incubated on ice for 15 minutes, and centrifuged for 30

minutes at 10,000 rpm at 4° C. The supernatant (the "nuclear" fraction) was collected
and used in immunoblots. Cytoplasmic extraction was verified by the presence of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Nuclear fractions lacked

appreciable GAPDH by immunoblot.
Prior to immunoblotting, protein concentrations were determined in the nuclear
and cytoplasmic fraction using the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA).
Equal amounts of nuclear extracts or cytoplasmic extracts from 9 AD and 9 Normal midfrontal cortices were electrophoresed through a discontinuous SDS-polyacrylamide gel
(8% resolving gel) with prestained protein standards (Bio-Rad, Hercules, CA, USA) and
10 µg of protein extracts from NIH3T3 cells transfected to overexpress Nrf2 as a control.
The proteins were transferred from the 8% SDS-polyacrylamide gel to ImmunBlot PVDF membrane (Bio-Rad, Hercules, CA, USA) and blocked in 2% bovine serum
albumin in PBST (PBS + 0.1% Tween 20). Details of the antibodies used are contained
in Table 2. All antibodies were used at 1:1000 in PBST overnight at 4º C. Blots were
washed four times in PBST for 10 minutes. Goat anti-Rabbit HRP (for Nrf2) (1:10,000;
Southern Biotechnologies Inc, Birmingham, AL) was used to detect the appropriate
primary antibodies. The secondary antibody was washed in PBST, four times for 10
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minutes. The antibody was then visualized using enhanced chemiluminescence (ECL)
(Amersham Biosciences, Buckinghamshire, England.) ECL was captured on the Kodak
Image Station 440 CF and by autoradiography. Blots were stained with Colloidal Gold
Total Protein Stain (BioRad, Hercules, CA) to verify equal loading and protein integrity.
Quantification of appropriate bands on western images was done using the Kodak 1D 3.5
software on scanned autoradiographs. All defined regions of interest were the same size.
Nrf2 intensity for each case was divided by the Nrf2 intensity of AD1 for each blot to view
relative Nrf2 levels.

To normalize Nrf2 levels, Nrf2 intensity was divided by GAPDH

intensity (which also serves as a cytoplasmic marker) for cytoplasmic blots and the
intensity of a band near Nrf2 in size stained by colloidal gold for cytoplasmic and nuclear
blots. Average values of Nrf2 intensity normalized to colloidal gold loading control and
standard deviation for AD cases or normal cases were determined.

Quantification of Nuclear and Cytoplasmic Nrf2 Staining.
Quantification of nuclear and cytoplasmic Nrf2 staining was determined from three
contiguous 87.5 µm x 87.5 µm fields of CA1 hippocampus for each case in AD, PD,
LBVAD, and control. Presence of Nrf2 in nuclear and cytoplasmic compartments was
scored by an individual blinded to the disease state.

A total number of neurons

inspected, ranging from 20 to 100 per case, was used to calculate the percentage of
neurons exhibiting staining in either compartment. An average and standard deviation
was determined for each category (AD, PD, LBVAD, and control).

Statistical Analysis
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Significant differences between disease states and controls for quantification of the
percentage of nuclear and cytoplasmic Nrf2 were determined using a one way ANOVA
with Student-Newman-Keuls using Graphpad Prism 3.02 for Windows (San Diego, CA,
USA).

To determine if our observed changes in Nrf2 compartment staining were

significant for disease sets, we used a Fisher's Exact text using SPSS Version 11.5.
Quantification of western images was performed using digital images captured on the
Kodak Image Station 440 CF using the Kodak 1D 3.5 software. Two independent western
blots were quantified. The average and standard deviations for each data set is shown. A
two-tailed student T-test (Microsoft Office Excel 2003) was used to determine significant
differences between Nrf2 levels in nuclear and cytoplasmic fractions from AD and
Normal tissue extracts.
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Results
Nrf2 expression patterns are altered in hippocampi of AD and LBVAD.

The

Nrf2 transcription factor controls expression of the genes necessary to reduce oxidative
stress (30). Because evidence of increased oxidative damage is observed in AD, PD, and
Lewy body variant of AD (LBVAD)(2, 5-7), we sought to determine if Nrf2 was localized
appropriately for activation of the endogenous antioxidant response in affected brain
regions of these diseases. Further, as LBVAD has pathologic features of both AD and PD,
we were interested in determining whether it more closely resembled AD or PD with
regard to Nrf2 localization.

In AD, damage initiates in the entorhinal cortex and

hippocampus but progresses to the temporal and frontal cortex resulting in memory
deficits and cognitive decline (47). In PD, a preponderance of damage occurs in the
substantia nigra resulting in loss of neuromelanin-positive dopaminergic neurons.
Therefore, we compared Nrf2 localization by immunohistochemistry in hippocampi and
substantia nigra neurons from 12 AD, 3 LBVAD, 5 PD and 5 age-matched control cases
(Table 1,3). In normal age-matched control hippocampi, we observed Nrf2 staining in
both the nucleus and cytoplasm of cells with the morphology of neurons and astrocytes
(Figure 1A, column 1, Normal). In contrast, Nrf2 immunostaining was predominantly
cytoplasmic in hippocampal neurons from individuals with AD and LBVAD (Figure 1A,
columns 2 and 3). Consistent with minimal pathologic findings in hippocampi of PD
patients, Nrf2 staining in PD patients more closely resembled age-matched controls,
although occasional neurons exhibited exclusively cytoplasmic Nrf2 staining similar to
AD (Figure 1A, column 4). In the 5 normal cases, 99% of neurons in the CA1 region of
the hippocampus had nuclear staining for Nrf2 (Figure 1C). However, only 12.5 % or 1.0
% of neurons in CA1 region of the hippocampus exhibited nuclear Nrf2 staining in pure
AD cases or LBVAD cases respectively (Figure 1C). Interestingly, there is statistically less
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nuclear Nrf2 in hippocampal neurons of PD cases as compared to normal age-matched
controls (86.7%, p < .001, Figure 1C *). In normal, AD, LBVAD, and PD, a similar
percentage of neurons contained Nrf2 staining in the cytoplasm (Figure 1C). Therefore,
in AD and LBVAD, we see a dramatic and significant reduction in nuclear Nrf2 in
hippocampal neurons, which is different from the expected localization in neurons
responding to oxidative stress.
Nrf2 exhibits increased nuclear staining in substantia nigra neurons from
patients with PD. In PD, the neuronal population of the substantia nigra is selectively
lost during disease progression. Loss of dopaminergic neurons manifests as movement
abnormalities such as slow voluntary movements, shuffling gait, rigidity, and stooped
posture (48). It is also the substantia nigra that prominently accumulates oxidative
damage

(49).

Therefore,

we

assessed

Nrf2

expression

patterns

by

immunohistochemistry in the substantia nigra from 5 PD cases, 8 AD, 3 LBVAD and 5
normal age matched control cases to determine if Nrf2 is translocating to the nucleus in
PD.

In substantia nigra of all 5 control cases, 8 AD cases, and 3 LBVAD cases, weak

Nrf2 immunostaining was observed primarily in the cytoplasm (Table 2; Figure 1B,
control, AD, LBVAD, columns 1-3).

Neuromelanin containing neurons (brown),

however, exhibited strong nuclear Nrf2 staining and cytoplasmic staining in substantia
nigra of all 5 PD cases (Figure 1C, PD, column 4). Thus, changes in Nrf2 localization in
affected brain regions of PD are consistent with activation of the endogenous antioxidant
response in neurons, while nigral neurons in AD and LBVAD resemble control neurons.
These findings suggest that deficits in Nrf2 target gene expression observed in the PD
literature (39, 40) either occur downstream of Nrf2 nuclear translocation, or may simply
reflect nigral neuron loss.
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Altered expression patterns of Nrf2 are observed in neurons and astrocytes of
AD hippocampus. Using triple label laser confocal microscopy, we assessed localization
of Nrf2 staining in specific cell types within the hippocampus from normal and AD cases.
In normal cases, the most intense Nrf2 staining (green) was observed in the nucleus
(blue) of hippocampal neurons (MAP2 – red; Figure 2A, row 1). This confirms our
immunohistochemical observations that Nrf2 is seen in neurons. In AD cases, we
observed cytoplasmic Nrf2 staining (green) in neurons (red) of the CA1 region of the
hippocampus (Figure 2B, row 2). Nrf2 staining (green) overlapped considerably with
immunostaining for the neuronal marker MAP2 (red) as shown in Figure 2B, while Nrf2
staining did not overlap with a nuclear stain (propidium iodide (PI), blue; Figure 2B).
Astrocytes labeled with glial fibrillary acidic protein (GFAP, red) exhibited minimal Nrf2
staining, but when observable it was predominantly nuclear (green) in the CA1 region of
AD hippocampus (Figure 2C, row 3). These findings demonstrate that a majority of
hippocampal neurons lack nuclear Nrf2 staining in AD while nuclear Nrf2 staining is
predominant in normal hippocampal neuronal nuclei.
Altered Nrf2 localization occurs in proximity to pathologic features of AD
hippocampus, but is not a major component of beta amyloid plaques or neurofibrillary
tangles. To determine if Nrf2 staining occurred in association with pathologic features
of AD, we used triple label confocal microscopy for Nrf2 (green), nuclei (blue), and either
beta amyloid plaques (AΒ, red) or neurofibrillary tangles (NFT; AT8, red) in AD
hippocampal tissue. Nrf2 immunostaining was observed in proximity to beta amyloid
plaques (Figure 3A); however, the majority of Nrf2 was seen in the cytoplasm of neurons
in the absence of plaque structures.

Similarly, we did not observe co-localization

between Nrf2 staining (green) and tau containing neurofibrillary tangles using the AT8
antibody (red; Figure 3 B, C).

When present in AT8-positive neurons of the
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hippocampus (red), Nrf2 was still cytoplasmic, but did not co-localize with tau (Figure 3
B, C, arrows). A subset of AT-8 positive neurons contained little or no observable Nrf2
(arrowheads).

However, neurons without neurofibrillary tangles (AT8-negative)

exhibited predominantly cytoplasmic Nrf2 (green; asterisks). These findings indicate
that Nrf2 does not co-localize with beta amyloid or tau, the major components of the
hallmark pathologic features of AD.

However, the altered localization of Nrf2 is

observed in neurons in the vicinity of beta amyloid plaques and neurofibrillary tangles.
As Nrf2 changes localization in response to oxidative stress, we wanted to
determine if there was evidence of oxidative stress in neurons positive for Nrf2. Using
an antibody to hydroxynonenal (HNE), a marker of lipid peroxidation, we determined if
neurons positive for Nrf2 (Figure 3D, green) exhibited evidence of oxidative damage
(Figure 3D, red) in AD hippocampi. We observed cytoplasmic Nrf2 in neurons with
abundant evidence of oxidative damage (Figure 3D) in the CA1 region of the
hippocampus. These findings suggest that Nrf2 is not localizing to the nucleus despite
the presence of oxidative stimuli in neurons.
Reduced Nrf2 protein levels were observed in nuclear fractions from AD frontal
cortex as compared to normal control frontal cortex.

It has been reported that

cytoplasmic Nrf2 interacts with the Keap1:Cul3 complex, an ubiquitin E3 Ligase complex
that leads to Nrf2 degradation by the proteasome (15). However, dissociation of Nrf2
from the complex in response to oxidative stress stabilizes Nrf2 and allows its
translocation to the nucleus. To determine if the alterations in Nrf2 localization in AD
reflects Nrf2 protein stability, we assessed Nrf2 protein levels by immunoblotting protein
extracts from mid frontal cortex of 9 AD and 9 normal cases. Subcellular fractionation
resulted in cytoplasmic and nuclear fractions, which were immunoblotted for Nrf2 and
appropriate subcellular compartment markers. In cytoplasmic extracts, we observed
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Nrf2 in both normal and AD cases (Figure 4 A). Quantification of cytoplasmic Nrf2 did
not reveal a trend for more or less Nrf2 in AD cases as compared to control cases
whether using the raw values (which were controlled for by protein quantity),
normalized to the cytoplasmic marker glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), or normalized to a band stained for colloidal gold (Figure 4 C and E). Average
Nrf2 levels in AD cases were not significantly different from Nrf2 levels in normal cases
using either raw or normalized values (Figure 4 G). However, in the GAPDH-negative
nuclear fractions less Nrf2 was observed in AD cases as compared to normal cases by
immunoblotting (Figure 4 B; data not shown).

Quantification of Nrf2 in the nuclear

fractions demonstrated less Nrf2 in AD cases using both raw Nrf2 levels (controlled for
protein quantity at loading) and Nrf2 levels normalized to a band stained by colloidal
gold (Figure 4 D and F). Average nuclear Nrf2 levels in AD cases were significantly less
than Nrf2 levels in normal cases using either raw or normalized values (p < .001, Figure
4 H). These findings indicate that there is less Nrf2 in nuclear fractions from cortex in
AD cases consistent with our immunohistochemical observations in the hippocampus.
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Discussion
Oxidative stress is a common pathogenic mechanism implicated in AD, PD and
other diseases associated with aging(1-6).

The cellular mechanism for eradicating

oxidative stress involves release, stabilization and nuclear translocation of the Nrf2
transcription factor (13, 14). By activating expression of genes whose products reduce
oxidative stress and inactivate toxic chemicals, Nrf2 acts as the "on" switch for the
endogenous antioxidant response. It would be expected that Nrf2 would be activated in
AD and PD based on the presence of oxidative damage in these diseases.

Our

observations indicate that Nrf2 is not translocating to the nucleus in hippocampal
neurons in AD cases, despite evidence of oxidative stress in these cells, preserved total
levels of Nrf2 protein, and abundant nuclear Nrf2 in normal age-matched controls. In
contrast, in PD, nuclear Nrf2 is more abundant in the remaining dopaminergic neurons
within the substantia nigra. These observations demonstrate a difference in neuronal
response to oxidative stress associated with AD as compared to PD.
Our observation that Nrf2 is predominantly cytoplasmic in hippocampal neurons
in AD indicates that Nrf2 is not being translocated to the nucleus or is less antigenically
available in AD neuronal nuclei. However, the biochemical extracts from frontal cortex
confirm decreased levels of nuclear Nrf2 in AD cases. One explanation for these findings
is that Nrf2 is not responding properly to oxidative stress in AD neurons. Neither
neurons nor astrocytes exhibited abundant Nrf2 staining in their nuclei in AD cases.
These findings suggest several scenarios with regard to Nrf2 regulation in the CNS.
Based on known functions of Nrf2 in non-neuronal cells, the abundant nuclear Nrf2
observed in age-matched controls suggest that there is enough oxidative stress or some
other inducer (i.e. toxins, misfolded proteins, inflammation) in neurons of control
patients to activate the endogenous antioxidant response. Alternatively, Nrf2 may have
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an additional role that requires nuclear localization in age-matched control hippocampal
neurons. The lack of Nrf2 in the nuclei of AD hippocampal neurons suggests that Nrf2 is
not performing the activities seen in age-matched control individuals. Whether Nrf2 is
responding to oxidative stress in control cases or has a novel role in neuronal nuclei, AD
hippocampal neurons are deficient in this activity. This suggests that in AD, some
process is blocking Nrf2 nuclear activity, potentially contributing to neuronal
dysfunction and/or loss. Our immunoblots indicate that there is a loss of nuclear Nrf2 in
AD, but that the level of cytoplasmic Nrf2 is not different between age matched control
cases and AD. Thus, the nuclear deficit is not due to generalized loss of total Nrf2
protein, but may reflect impaired nuclear trafficking, as has been observed with other
transcription factors (50). In either case, our observations suggest that the Nrf2 pathway
is likely dysfunctional in hippocampal neurons of AD.
In PD, our observations are different. The localization of Nrf2 immunostaining in
the hippocampal neurons in PD is somewhere between the predominantly cytoplasmic
Nrf2 seen in AD and LBVAD, and the strong nuclear staining in observed in age-matched
control cases. However, in the most severely affected brain region, the substantia nigra,
dopaminergic neurons exhibit a Nrf2 expression pattern consistent with a neuronal
response to increased oxidative stress: weakly cytoplasmic in control cases, but more
abundant with increased nuclear staining in PD neurons.

The different Nrf2

localizations observed in hippocampal neurons as compared to nigral neurons in agematched controls suggest distinct regulation of Nrf2 in these neuronal subpopulations
and potentially divergent functions.

It is interesting to speculate that altered Nrf2

regulation may be one of the functional differences between these two neuronal types. It
may also indicate a difference in susceptibility to oxidative stress between these neuronal
populations. Nrf2 localization in PD nigral neurons is consistent with the expected Nrf2
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response to oxidative stress. The neurons we observe in PD are the surviving neurons
which may indicate that these neurons were able to delay death, but protection by Nrf2
was insufficient in neurons that have been lost. Alternatively, additional downstream
mechanisms may interfere with ARE transactivation despite nuclear stabilization of
Nrf2.

Further investigation is needed to understand why Nrf2 translocation is not

sufficient

to

protect

oxidatively

stressed

nigral

neurons

in

PD.

In addition to interaction with keap1, Nrf2 activity is also regulated by
phosphorylation via several kinases including phosphoinositol-3 kinase (PI3K),
extracellular signal-regulated protein kinase

(ERK), protein kinase C (PKC), and

pancreas enriched kinase (PERK) (19-25, 27). Interestingly, several of these kinases
localize to mitochondria, a major source of intracellular oxidative stress (51), and the
subcellular distribution of ERK is also altered in degenerating AD and PD neurons (5254). Though PI3K and ERK activity are required for Nrf2 activation in certain cell types
or in response to specific stimuli, direct phosphorylation of Nrf2 has been demonstrated
for PKC and PERK (19, 28). Phosphorylation by PKC can disrupt interaction with Keap1,
but is not required for stabilization and translocation of Nrf2 to the nucleus. Disruption
of Nrf2:Keap1 interaction by PKC further suggests this complex can be regulated by
extracellular signaling cascades as well as oxidative insult. Since there is a pronounced
inflammatory component to amyloid plaques (55), one possibility is that Nrf2
translocation is inhibited by inflammatory signaling molecules such as cytokines,
chemokines and neurotrophic factors. Phosphorylation of Nrf2 by PERK also disrupts
the interaction between Nrf2 and Keap1 and leads to nuclear translocation (15, 19).
PERK is one of several kinases activated in response to endoplasmic reticulum (ER)
stress. It has been shown that cell survival after ER stress is mediated by the increase in
Nrf2-induced glutathione (19). A major cause of ER stress is accumulation of unfolded
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proteins (reviewed in (56)).

As two of the major pathologic features of AD (amyloid

plaques and neurofibrillary tangles) are composed of misfolded proteins, it is likely that
ER stress is activated in neurons and astrocytes at some point during AD progression.
Together these findings suggest that several pathways act to regulate Nrf2 function.
Understanding how these pathways intersect to regulate Nrf2 will be important for
uncovering why Nrf2 is not responding to oxidative stress, misfolded proteins, or
signaling proteins present in the neuronal environment in AD brain tissue.
Previous studies have shown that astrocytic Nrf2 is sufficient to rescue neurons
from oxidative stress (33, 34). Our observations suggest that astrocytes have also lost
nuclear Nrf2 in AD. By triple label immunofluorescent confocal microscopy, we only
identified a few astrocytes with weak nuclear staining in the hippocampus. Similarly,
our immunoblotting studies indicate minimal nuclear Nrf2 from all cell populations in
the mid frontal cortex.

Kraft et al (34) have shown that Nrf2 induction activates

expression of different gene products in cultured astrocytes as compared to cultured
cortical neurons.

While some genes, including glutathione-S-transferase m1, were

upregulated in both neurons and astrocytes treated with an inducer of Nrf2 activity (tert
butylhydroquinone - tBHQ), the genes upregulated in astrocytes included detoxification
enzymes, glutathione synthesis, and other protective molecules. In contrast, the genes
upregulated in neurons treated with tBHQ included those that regulated synaptosome
formation and function and neurotransmitter homeostasis.

The ability of Nrf2 to

regulate distinct subsets of genes in neurons and astrocytes supports a distinct role for
Nrf2 in neurons in addition to protection from oxidative stress. Our data suggest that
Nrf2 is not nuclear in AD hippocampal neurons and therefore is not transactivating
expression of proteins that regulate synapse function or antioxidant activity.
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The

absence of this activity is likely detrimental to neuronal function and implicates Nrf2
dysfunction in AD.
Our findings indicate that Nrf2 is not localizing to the nucleus in neurons or
astrocytes in AD despite the presence of oxidative stress and misfolded proteins, two
stimuli that can induce nuclear Nrf2. However, Nrf2 does translocate to the nucleus of
substantia nigra neurons in PD. In light of the findings by Kraft et al (34) showing Nrf2
regulates unique subsets of genes in neurons vs. astrocytes, it is also possible that Nrf2
may regulate different gene products in hippocampal neurons vs. nigral neurons. Future
studies are needed to determine how Nrf2 localization is regulated, why it is aberrant in
AD, and how it differs in various neuronal subpopulations.

By understanding this

pathway and how it has been altered by AD progression, we will gain insight into how
neurons lose their endogenous protection, leading to potential strategies to restore this
function prior to neuronal loss.
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Figure 1:
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Figure 1. Nrf2 expression patterns are altered in hippocampal neurons of AD and LBVAD
and neurons of the substantia nigra in PD. A) Immunohistochemistry for Nrf2 (red) is shown from
the CA1 region of hippocampus from Control (column 1), AD (column 2), LBVAD (column 3), and PD
(column 4). Similar Nrf2 localization was observed in CA2, CA3, and CA4 of the hippocampus (data not
shown). These slides stained with the C20-Nrf2 antibody are representative of our findings with the H300
antibody and KAP-125 antibody (Table 2). Nuclei are counterstained with hematoxylin (purple). Row 1
shows images captured with a 20X objective and Row 2 shows an image captured with a 40X objective. Bar
is equivalent to 20 µm. Images in Row 1 and Row 2 are from 2 different cases for each disease group. B) In
control substantia nigra (column 1), AD (column 2), and LBVAD (column 3), Nrf2 (red) was weakly
cytoplasmic in dopaminergic neurons. In PD, Nrf2 immunostaining (red) was stronger and exhibited more
nuclear staining in remaining dopaminergic neurons.

All images also show counter staining with

hematoxylin (purple). Bar = 20 µm. 40X objective was used. C) The percentage of cells with nuclear Nrf2
(left) and cytoplasmic Nrf2 (right) were counted in the CA1 region of the hippocampus of 12 AD cases, 3
LBVAD cases, 5 PD cases and 5 control cases. Shown are the average percentages of Nrf2 positive nuclei
(left) and Nrf2-positive cytoplasm (right). Error bars indicate standard deviation. * indicates significantly
different from control (p< 0.001) and # indicates significantly different from AD (p< 0.001) as determined
by one way ANOVA, Student-Newman-Keuls.
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Figure 2:

Figure 2. Altered expression patterns of Nrf2 are observed in neurons and astrocytes of AD
hippocampus. Row A. Triple label immunofluorescent confocal microscopy revealed Nrf2 (green) is
predominantly expressed in the nucleus (blue) of neurons (MAP2, red) present in the CA1 region of control
hippocampus. Row B. In contrast, Nrf2 (green) is predominantly cytoplasmic in neurons (MAP2, red) in the
CA1 region of the AD hippocampus. Row C. In the CA1 region of the AD hippocampus, Nrf2 (green) does not
stain astrocyte cytoplasm intensely (GFAP, red), but is occasionally observed in the nuclei (blue, arrows).
Merged images are shown in the first column. Bar = 20 µm.
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Figure 3:
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Figure 3. Altered Nrf2 localization occurs in proximity to pathologic features of AD, but
does not co-localize with beta amyloid plaques or tau. Row A. In CA1 of the hippocampus of AD
cases, Nrf2 (green) was observed within a beta amyloid plaque (AB-red), however, did not significantly colocalize with beta amyloid (co-localization appears yellow in the merged field). Instead, the majority of Nrf2
was cytoplasmic in neurons adjacent and distal to the beta amyloid plaque. Row B and C. Tau as labeled by
AT8 (red) was present in a subset of cells staining for Nrf2 (green) in CA1 of AD hippocampi, but tau and
Nrf2 did not co-localize in these neurons (arrows). When observed in AT8-positive neurons, Nrf2 (green)
staining was predominantly cytoplasmic (arrow). A subset of AT-8 positive neurons contained little or no
observable Nrf2 (arrowhead).

Neurons without neurofibrillary tangles (AT8-negative) also exhibited

predominantly cytoplasmic Nrf2 staining (green; asterisk). Row D. In CA1 of AD hippocampi, oxidative
damage of lipids was determined by labeling with an antibody to 7-hydroxynonenal (HNE-red). In neurons
with evidence of oxidative processes as indicated by HNE staining (red), Nrf2 is cytoplasmic (green). For all
rows, merged images are shown in the first column, co-localization appears yellow when present, and the
Bar = 20 µm.
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Figure 4:
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Figure 4. Reduced Nrf2 proteins levels were observed in nuclear fractions from AD frontal
cortex as compared to age-matched control frontal cortex. Cytoplasmic and nuclear protein
extracts were obtained from mid frontal cortex from 9 AD and 9 control cases. Equal quantities (21 µg of
protein for cytoplasmic and nuclear) were fractionated by size on an 8% discontinuous SDS polyacrylamide
gel and immunoblotted for Nrf2. A) By immunoblot, Nrf2 levels in cytoplasmic extracts (21 µg) from 9 AD
cases (AD1-9) and 9 normal control cases (N1-9) do not exhibit a difference. 10 µg of protein extract from
NIH3T3 cells transfected with pcDNA3.1-Nrf2 was included as a control. In addition to Nrf2 (top row), we
immunoblotted for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; bottom row) to demonstrate
cytoplasmic extraction. To control for protein degradation, we stained the membrane with colloidal gold and
quantified the intensity of a band near Nrf2 in size (bottom row; control). B) By immunoblot, Nrf2 levels in
nuclear extracts from 9 AD (AD1-9) cases are lower than Nrf2 levels in 9 normal age-matched control cases
(N1-9). As a control, 10 µg of protein extract from NIH3T3 cells transfected with pcDNA3.1-Nrf2 was
included as a control. To control for protein degradation, we stained the membrane with colloidal gold and
quantified the intensity of a band near Nrf2 in size (bottom row). Quantification of the Nrf2 band from the
cytoplasmic immunoblot (C) did not show any statistical differences for control or AD cases; however,
quantification of Nrf2 levels from the nuclear immunoblot (D) demonstrated lower Nrf2 levels in AD.
Cytoplasmic sample AD3 was dropped from further consideration as the protein from this sample was
degraded. E) Comparison of Nrf2 levels normalized to GAPDH from cytoplasmic extracts showed no evident
trend or statistical difference (E). F) Normalizing nuclear Nrf2 to the selected colloidal gold band by
dividing Nrf2 band intensity by the colloidal gold band intensity demonstrated decreased levels in AD as
compared to age-matched control.

G)

Average Nrf2 levels in normal cytoplasmic extracts were not

statistically different from average Nrf2 levels in AD cytoplasmic extracts. Error bars indicate standard
deviation. H) Average Nrf2 levels in normal nuclear extracts were significantly higher (* p <0 .001) than
average Nrf2 levels in AD nuclear extracts. Error bars indicate standard deviation. * indicates statistically
significant difference from normal (p < 0.001), Students T-test.

201

Table 1:

Age

Age

PMI

Braak

Diagnosis Average

Range

average

PMI range

Stage

Normal

78.6 ± 8.5

70 - 92

12.45

6-24

1

AD

77.9 ± 9.7

56 - 89

8.5

5.5-12

4-6

LBVAD

82 ± 5.6

76 - 87

5.2

2.5-10

4

PD

79 ± 7.6

67 - 87

7.3

4-8

1-2

Table 1. Neuropathological and Clinical Case Information. Clinical data for patient groups used for
this study. Average Age in years with standard deviation and range are shown. Post Mortem Interval (PMI)
is represented in hours. Braak stage diagnostics are given for each group.
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Table 2:
clone
Antigen

or

Dilution

TSA

Species

Application

Manufacturer

catalog
Santa
Nrf2

H300

1:200

Yes

Rb

IHC, IF

Cruz

Biotechnology,
Santa Cruz, CA,
USA
Santa

Nrf2

C20

1:2,000

Yes

Rb

IHC, IF

Cruz

Biotechnology,
Santa Cruz, CA,
USA
Stressgen,

Nrf2

KAP-

1:200

Yes

Rb

IHC

TF125

Victoria,

BC,

Canada
Santa
Nrf2

H300

1:1000

No

Rb

IB

Cruz

Biotechnology,
Santa

Cruz

CA,

USA
DAKO,
GFAP

Z0334

1:80

No

Rb

IF

Carpinteria,
USA
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CA,

MAP2

SMI-52

1:500

No

Ms

IF

Covance, Berkeley,
CA, USA
Alpha Diagnostics

HNE

HNE11-

1:50

No

Rb

IF

S

International, San
Antonio, TX, USA
Chemicon

GAPDH

MAB374

1:100

No

Ms

IB

International,
Temecula,

CA,

USA
Gift from Drs. Lee
APP,
amyloid

4G8

1:20,000

No

Ms

IF

and Trojanowski,
University

fragment

of

Pennsylvania
NFT

AT8

1:300

No

Ms

IF

Pierce,

Rockford,

IL, USA

Table 2. Summary of antibodies used in this study are shown. If antibody staining was amplified
with tyramide amplification system (TSA) for immunofluorescent or immunostaining, it is indicated (yes).
The species of animal in which the primary antibody was raised is indicated (species; Mouse – Ms, Rabbit –
Rb). Applications using antibodies include immunohistochemsitry (IHC), immunofluorescence (IF), and
Immunoblotting (IB).
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Table 3:

Hippocampus

Substantia Nigra

Diagnosis

Nuclear

Cytoplasmic

Nuclear

Cytoplasmic

Control

5/5

5/5

0/5

5/5

AD

1/12*

12/12

0/8

8/8

LBVAD

0/3#

3/3

0/3

3/3

PD

5/5

5/5

5/5*

5/5

Table 3: The number of cases exhibiting nuclear or cytoplasmic Nrf2 staining in neurons of
PD, two diagnostic categories of AD, or Age-matched controls.The fraction of cases exhibiting
nuclear or cytoplasmic Nrf2 staining in hippocampus and substantia nigra among 3 diagnostic groups: Agematched control (Control), Alzheimer's disease (AD), Lewy Body variant of Alzheimer's disease (LBVAD)
and Parkinson's disease (PD). * indicates significantly different from Control (p < 0.01) using Fisher's Exact
test.

#

indicates significantly different from Control (p < 0.05)
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Examining of the Endogenous Antioxidant
Response in HAND
Introduction
HIV-associated neurocognitive disorder (HAND) is a disease in which HIV-infected
patients develop motor, cognitive, and behavioral impairments. The cause of neuronal
death in this disease has not been determined, however evidence points to a role for the
virus-induced inflammatory response that occurs in the CNS following HIV infection.
We have shown that there is induction of the cellular integrated stress response (ISR) in
individuals with this disease (1) and have begun characterization of the nature of ISR
activation in the CNS of HAND patients. To further characterize the nature of ISR
activation, we began study of the antioxidant component of the ISR. The transcription
factor, nuclear factor (erythroid-derived 2) (NF-E2)-related factor 2 (Nrf2), is the master
regulator of the endogenous antioxidant response, initiating this response via
transactivation of Nrf2 target genes, all of which contain an antioxidant responsive
element (ARE) in their promoter region (2). Genes regulated by Nrf2 include heme
oxygenase-1, glutathione S-transferases, glutathione peroxidase, superoxide dismutase,
NAD(P)H quinone oxidoreductase, and thioredoxin (2-7). We have found that Nrf2 subcellular localization is altered in the brains of Alzheimer disease and Parkinson disease
patients when compared with normal patients (8). To begin study of antioxidant
response activation in HAND, we first used immunoblotting and immunofluorescent
analysis (IFA) to examine Nrf2 levels in mid-frontal cortical autopsy tissue from HAND
patients. We then began characterizing the Nrf2 response in neurons in vitro to allow
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future studies of the antioxidant response in our in vitro model of HIV-induced neuronal
death and damage.
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Materials and Methods
Protein Extraction and Immunoblotting for Human Cortical Autopsy Tissue: We
obtained fresh frozen mid-frontal cortical tissue samples from HAND (n=13) and
neurocognitively normal (n=5) human autopsy cases from the National NeuroAIDS
Tissue Consortium (NNTC). The age, sex, neurocognitive status, and postmortem
interval of each specimen was provided by NNTC (Table 1). Using a Dounce tissue
grinder (Kimble/Kontes, Vineland, NJ), tissue was homogenized in lysis buffer (50 mM
Tris-HCl (pH 7.5), 0.5 M NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1% SDS, 2 mM
EGTA, 2 mM EDTA, 5 mM NaF, 0.1 mM PMSF, 1 mg/ml leupeptin, 1 mM DTT, and
protease inhibitor cocktail (Sigma)). After homogenization, tissue was sonicated 3 times
in 6 second cycles, followed by centrifugation for 30 min at 25,000 rpm. Protein
concentrations were determined using the Bradford method following collection of the
supernatants. Protein (40ug) from each sample was loaded to 10% Bis-Tris gels for
separation. A broad range molecular weight ladder (BioRad, Hercules, CA) was run
along-side the samples to allow for determination of protein size. Following separation,
protein was transferred onto PVDF membranes and blocked in 5% nonfat milk (in TBS
containing 1% Tween-20 (TBS-T)) for 1h at room temperature. Membranes were
incubated overnight at 40C in primary antibody (Nrf2 C-20, Santa Cruz Biotechnology,
Santa Cruz, CA) in TBS-T with 5 % bovine serum albumin (BSA). After incubation in
primary antibody, the membranes were washed 3 times for 10 min each with TBS-T and
were then incubated with HRP-conjugated secondary antibody (goat-anti-rabbit-HRP,
Pierce Biotechnology, Rockford, IL) in TBS-T + 5% BSA for 1h at room temperature.
Following incubation with secondary, membranes were washed 3 times for 10 min each
with TBS-T. Membranes were developed using SuperSignal West Dura Extended
Duration Substrate (Pierce Biotechnology, Rockford, IL) and were exposed to Amersham
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Hyperfilm (GE Healthcare, Piscataway, NJ) for visualization of signal. Autographs were
scanned into Adobe Photoshop (Adobe Systems, San Jose, CA), and bands were assessed
for pixel intensity by NIH ImageJ program (V 1.36b). For quantitative band analysis,
pixel intensity of autograph bands were normalized to the pixel intensity of loading
controls, which were obtained by staining the PVDF membranes with a Coomassie
Brilliant-Blue R-250 (BioRad, Hercules, CA) solution (0.1% Coomassie (w/v) in 50%
Methanol) for 5 min, followed by destaining with 25% acetic acid in 50% methanol for 30
min. The coomassie-stained membranes were photographed by a Nikon Coolpix 995
camera and pixel intensity was determined using NIH ImageJ, as described above.
Immunofluorescent Histochemistry: We obtained sectioned (7 mm) and pre-mounted
paraffin-embedded tissue sections from HAND (n=13) and neurocognitively normal
(n=5) human autopsy cases from the National NeuroAIDS Tissue Consortium (NNTC).
Immunofluorescent staining was conducted as described in chapter 3 of this thesis
(REF). Briefly, paraffin-embedded sections were deparaffinized and rehydrated and
endogenous peroxidase activity was inactivated. Following antigen unmasking,
performed at 95°C for 1 h using Target Retrieval Solution (Dako, Carpinteria, CA, USA),
tissue sections were blocked with 10% normal goat serum in PBS. Rabbit polyclonal
antibodies to Nrf2 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA) and to GFAP
(Z0334, 1:80, Dako, Carpinteria, CA) and a mouse monoclonal antibody to were the
primary antibodies used. The tyramide amplification system (New England Biolabs,
Beverly, MA) along with a biotin-conjugated, goat-anti-rabbit secondary antibody
(Jackson Immunoresearch), was used to detect Nrf2. DNA was visualized using the
DNA-specific nucleic acid stain, DAPI (5 mM, Molecular Probes, Carlsbad, CA). After
being mounted using Citifluor AF1 (Citifluor, Ltd., London, UK), slides were imaged by
laser confocal microscopy, using uniform threshold and intensity settings for each iamge,
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with a Biorad Radiance 2100 equipped with Argon, Green He/Ne, Red Diode, and Blue
Diode lasers (Biorad, Hercules, CA, USA). Ten 212 µm x 212 µm images were captured
randomly from the areas of positive staining in the mid-frontal cortical gray matter for
each case. Post-acquisition analysis was performed using MetaMorph 6.0 software
(Universal Imaging, Inc, Downingtown, PA). Total Nrf2 was ascertained by the
measurement of integrated pixel intensity for Nrf2 per image. Integrated pixel intensity
is a term defined as total pixel intensity per image times the area of pixels positive for a
given signal, Nrf2 in this case. For analysis of cell-type specific Nrf2, integrated pixel
intensity for Nrf2 overlapping the pixels positive for MAP2 or GFAP, to examine
neuronal or astrocytic Nrf2, respectively, was determined for each image and was then
normalized to the area of pixels positive for the specific phenotypic marker, to account
for differences in expression of the phenotypic marker expression as a result of disease.
All data was analyzed using GraphPad Prism 3.02 software (GraphPad Software, San
Diego, CA, USA). Averages are expressed as mean±SEM and a student t-test was used for
statistical analysis of immunoblotting and immunofluorescence quantification. Values of
p<0.05 were considered significant.
Preparation of primary mixed neuroglial and pure neuronal rat cortical
cultures: Primary mixed neuroglial rat cortical cultures were prepared from embryonic
day 17 Sprague Dawley fetal rat pups, as described previously (9). Cells were plated at a
density of 5 x 106 cells per 10mL of neurobasal media (Invitrogen) with B27 supplement
(Invitrogen) in a 100mm dish, pre-coated with poly-L-lysine (Peptides International,
Louisville, KY, USA) and were maintained in at 37°C, 5% CO2. Half of the media was
replenished every seven days, starting from day 10, and cultures were utilized at 21 days
in vitro (DIV), unless otherwise indicated. Pure neuronal rat cortical cultures were
prepared similarly to mixed cutures, except that cells were plated at 8 x 106 cells per
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10mL of neurobasal meida + B27 supplement. Also, 36h following plating, cells were
treated with 10uM arabinosylcytosine. There was no full media replacement following
arabinosylcytosine treatment, but arabinosylcytosine was not replenished following
replacement of ½ of the media that occurred every 7 days starting on day 10 for cell
culture maintenance.
rtPCR from mRNA from primary rat cortical cultures Cells were lysed and total
RNA was extracted with RNeasy Plus Mini kit (Qiagen). Reverse transcription was
performed using the Superscript II

TM

RT kit (Invitrogen). PCR was performed using

HotStarTaq Plus Master Mix Kit (Qiagen). Primers used were: Nrf2 forward, TCT GGA
GAC GGC CAT GAC TGA TTT; Nrf2 reverse, TCC ATT TCC GAG TCA CTG AAC CCA;
GFAP forward, ATC TGT GTC AGA AGG CCA CCT CAA; GFAP reverse, TGT TAG TTG
GAG ATG CAG GGT GGT.
Immunoblotting of primary rat cortical cultures: To prepare the whole cell
extracts use for Western blotting, cells from mixed or pure neuronal cultures were lysed
with ice-cold cell lysis buffer consisting of 50 mM Tris–HCl, 150 mM NaCl, 0.1% sodium
dodecyl sulfate (SDS), 0.1% NP-40, 0.5% sodium deoxycholate, and a protease inhibitor
cocktail (Sigma) and then underwent 2 freeze-thaw cycles. Supernatants from the lysates
were collected following centrifugation at 4oC for 10 min and then the Bradford method
(BioRad, Hercules, CA, USA) was used to determine protein concentration of the
extracts. For each sample, 10 µg of protein was loaded to each lane of a 4-12% tris-bis
gradient gel for separation (Invitrogen), and was run alongside a broad range molecular
weight ladder (BioRad) to allow size-determination of proteins. The rest of the
immunoblotting was conducted as described in the section for immunoblotting of
extracts from human cortical autopsy tissue. Primary antibodies used was HO-1 (HSP32, Stressgen).
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Statistical analysis: Quantified results are expressed as mean±SEM and a student ttest was used for statistical analysis. Values of p<0.05 were considered significant.
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Results
Nrf2 is increased in mid-frontal cortex of HAND patients
To begin our examination of the antioxidant response in HAND, we used
immunoblotting to examine Nrf2 protein levels in whole cell extracts prepared from
fresh-frozen mid-frontal cortical autopsy tissue from patients with HAND (n=12), as well
as that from neurocognitively normal patients (n=5). Nrf2 protein levels were increased
significantly in tissue from HAND cases over levels seen in neurocognitively normal
cases (Figure 1a,b). Additionally, when cases were divided into HIV(-) (n=3) and HIV(+)
(n=14) cases, we found that Nrf2 levels increased significantly in mid-frontal cortical
autopsy tissue from HIV(+) patients (Figure 1a,c). However, these data are difficult to
interpret given the small sample sizes of neurocognitively normal HIV(+) and
neurocognitively normal HIV(-) cases, for which n=2 and n=3, respectively.
To confirm the immunoblotting results and to assess Nrf2 protein levels in
different cell types, we conducted IFA of Nrf2 in mid-frontal cortical autopsy tissue from
HAND patients. We quadruple labeled tissue for Nrf2, MAP2 (neuronal cell marker),
GFAP (astrocytic cell marker), and DAPI (nucleic acid marker). We found that total
levels of Nrf2 increase in gray matter of HAND cases when compared with
neurocognitively normal cases, when assessed by IFA (Figure 2a,b). Additionally, Nrf2
levels increase in HIV(+) cases over those seen in HIV(-) cases (Figure 2a,c). Nrf2 levels
were assessed in mid-frontal cortical white matter, as well, but no difference was
observed. To determine the cell-type specific Nrf2 levels in different disease conditions,
we determined Nrf2 levels in areas that co-localized with either MAP2 or GFAP. To
account for disease-induced changes in cell-type marker, values were normalized to area
of the respective cell-type marker in each image. These cell-type markers are both
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cytoplasmic proteins, thus only cytoplasmic Nrf2 was quantified for specific cell types.
Unfortunately, the DAPI staining was not captured well on the confocal microscope,
making nuclear quantification of Nrf2 difficult to interpret. We found that cytoplasmic
Nrf2 increased in both neurons and astrocytes in mid-frontal cortical gray matter from
autopsy tissue of HAND cases when compared with neurocognitively normal controls
(Figure 3a,c) and also increased in HIV(+) cases compared with HIV(-) controls (Figure
3b,d). Finally, we found that nuclear Nrf2 increased in HIV(+) cases compared with
HIV(-) cases (Figure 3f). In HAND cases, while nuclear Nrf2 trended towards an increase
over that seen in neurocognitively normal cases, this difference did not reach
significance (Figure 3e).
Nrf2 mRNA is transcribed in rat cortical neurons in vitro
Given our findings in cortical autopsy tissue from HAND patients, we would like to
examine the Nrf2 response in our in vitro model of HIV-induced neurotoxicity, in which
supernatants from monocyte-derived macrophages infected with a neurovirulant strain
of HIV are use to treat rat cortical neuroglial cultures (day E17, grown for 14-21 days in
vitro) (10). However, before examining the Nrf2 response in this complicated model of
HIV-associated neurotoxicty, we first needed to further characterize the Nrf2 response in
neuroglial cells, particularly in neurons.
First, we sough to determine whether Nrf2 is transcribed in neurons. We
harvested mRNA for use in reverse transcriptase PCR (rt-PCR) from pure neuronal rat
cortical cultures, which we made by treating E17 mixed cortical cells with
arabinosylcytosine. We designed Nrf2 primers that span an exon in the genomic
sequence, to allow us to distinguish between potential contaminating genomic DNA and
Nrf2 mRNA. We also used the same strategy to design rt-PCR primers for GFAP so that
we could determine whether our neuronal cultures were contaminated with astrocytes.
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Finally, we also prepared mixed cortical cultures, containing both neurons and
astrocytes, from which we harvested mRNA. Since astrocytes are known to express Nrf2
(11), these extracts acted as a positive control. As can be seen in Figure 4a, we detected
Nrf2 mRNA in both mixed and pure neuronal cortical cultures. Further, only the mixed
cultures contained GFAP mRNA, demonstrating that the neuronal cultures did not
contain contaminating astrocytes.
Expression of classic Nrf2 targets differs between pure neuronal cultures and mixed
neuroglial cutures
Given the vastly wide range of regulatory mechanisms controlling Nrf2 function,
examining Nrf2 function in vitro directly using antibodies directed against Nrf2 or
quantitative real-time PCR (qPCR) to detect Nrf2 mRNA levels proves quite difficult and
relatively uninformative. Thus, to begin the characterize the Nrf2 response in neurons,
we chose to examine classic Nrf2 targets using western blot, as examination of Nrf2
targets is a commonly used means of examining Nrf2 activity (7, 12-14). Specifically, we

examined the response of the classic Nrf2 target, heme oxygenase-1 (HO-1), in pure
neuronal cultures and in mixed cortical cultures following treatment with tertbutylhydoquinone (tBHQ), an activator of Nrf2. While a lack of consistency of the degree
of the response prevented meaningful quantification of the data, one observation
persisted quite consistently. Specifically, although HO-1 is present in the mixed cortical
cutlures, it is absent when detected by Western blot in cultures containing only neurons
(Figure 4b).

224

Discussion
ISR activation is a common feature of several neurodegenerative diseases. We had
previously shown that the ISR is activated in HAND patients. In this chapter, we
continue to characterize the nature of ISR activation in this neurocognitive disorder.
Specifically, we present data to suggest that the antioxidant component of the ISR, as
mediated by the transcription factor, Nrf2, may be an active facet of the ISR in this
disease. Using immunoblotting and IFA, we demonstrated that Nrf2 protein levels are
increased in mid-frontal cortex of patients with HAND and in that of patients positive for
HIV, when compared with neurocognitively normal and HIV negative control patients,
respectively. Additioanlly, to prepare for further investigation of the Nrf2-mediated
response in HAND using our in vitro model of HIV-induced neuronal degeneration, we
began to characterize the Nrf2 response in neurons. Using reverse transcriptase PCR, we
demonstrated that Nrf2 mRNA is expressed in neurons grown in pure neuronal cultures.
Additionally, we examined the response of the classic Nrf2 target gene, HO-1, in neurons,
following treatment with tBHQ, and we found that it is not detectable via
immunoblotting, although it is easily detectable in mixed cortical cultures, containing
both neurons and astrocytes. These findings represent the start of investigation into
what may prove to be an important therapeutic target for treatment of HAND patients.
That Nrf2 increases according to both HIV status and neurocognitive status is
interesting, as it might suggest that the presence of HIV alone may trigger this response,
which would imply that neurocognitive decline happens in spite of an active endogenous
antioxidant response and that the natural response is simply overwhelmed. However, it
is also possible that, although Nrf2 levels are increased, the antioxidant response is
thwarted further downstream of the initial increase in Nrf2. In consideration of this
possibility, it is especially interesting that nuclear Nrf2 only appears to increase in with
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HIV positive status, and not with neurocognitive status. As a transcription factor, Nrf2
must move into the nucleus to transactivate its targets, thereby initiating the protective
capabilities of the antioxidant response. It is an intriguing possibility that, in patients
who actually progress to HAND, the Nrf2-mediated antioxidant response may not be
functioning properly. With its many points of regulation, it is possible an intermediate
mechanism fails to activate or allow activation of the Nrf2 response. One such possibility
is that following HIV infection, Kelch-like ECH-associated protein 1 (Keap1), a major
inhibitor of Nrf2 and mediator of Nrf2 degradation (14), may release Nrf2, resulting in
our observed increase in total and cytoplasmic Nrf2. However, Nrf2 transcriptional
activity requires numerous other events, including post-translational modification (12,
15). Specifically, several kinases, including PERK, MAPKs, PKC, and PI3Ks (12, 13, 1618), have been implicated in Nrf2 activity. It is likely that some of these kinases mediate
Nrf2 translocation to the nucleus, either by increasing its nuclear import or decreasing
its nuclear export, as Nrf2 contains both a nuclear localization signal and a nuclear
export signal, and some studies have suggested that, even under physiological
conditions, Nrf2 shuttles between the cytoplasm and the nucleus (19, 20). Thus, it is
possible that in some HIV(+) patients, a necessary phosphorylation event does not occur,
thereby preventing Nrf2 accumulation in the nucleus and the initiation of a full-scale
endogenous antioxidant response.
While these possibilities are certainly intriguing and suggest that further
investigation into the role of Nrf2 in HAND is likely to prove fruitful, these studies in
human autopsy tissue are not yet complete. Specifically, of the neurocognitively normal
cases, only 2 were HIV(+). This makes it impossible to differentiate between the Nrf2
response corresponding to HIV status versus the Nrf2 response corresponding to
neurocognitive status. Since these studies were conducted, we have obtained more tissue
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samples, including many more neurocognitively normal cases, both HIV(-) and HIV(+).
Continuing our studies of the Nrf2 response in human autopsy tissue using these newly
obtained cases, will be invaluable to characterizing the Nrf2 response in HAND, as
compared with that in HIV(+) patients not suffering from cognitive decline. Additionally,
the IFA findings need to be replicated with an additional Nrf2 antibody. The currently
available lots of Nrf2 antibody either do not work for IFA or are notoriously promiscuous
in the number of bands they reveal when used for immunoblotting, which makes IFA
data collected using these antibodies suspect. That the IFA data presented here
corroborate the immunoblotting data, suggests that they may be meaningful, however to
be certain of the IFA findings, these experiments must be repeated with another, reliable
antibody. Of note, in the past, there have been certain lots of Nrf2 antibodies that were
both highly specific for Nrf2, showing only one band via immunoblot, and useable for
IFA. We used these antibodies in past studies involving Nrf2 (8), but unfortunately have
been unable to find comparable antibodies for the current studies, despite examination
of many candidates, including testing of the available antibodies in Nrf2 knockout mouse
brain, which unfortunately is actually a knock-through rather than a knockout and thus
is not a useful control for testing these antibodies. Another important furtherance in this
line of investigation is to find a means of differentiating between astocytic and neuronal
nuclear Nrf2. We have attempted to utilize the neuronal-specific nuclear marker, NeuN,
but were unable to find an antibody against NeuN that worked in IFA in concert with
Nrf2. If such an antibody or an alternative cell-type specific marker were to become
available, it could prove interesting to see if there is a difference in changes in nuclear
Nrf2 levels across cell-types. Finally, classic Nrf2 targets, such as HO-1, NQO1, and GSTµ1, need to be examined in cortical autopsy tissue from HAND patients.
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Although the above-mentioned experiments are still needed to fully explore the
Nrf2 response in HAND, the autopsy tissue data presented here suggest that
examination of the Nrf2 response in vitro would provide understanding into a relevant
component of the CNS response to HIV infection and how this response contributes to
and/or is unable to prevent the cognitive decline observed in HAND. Here we also
present data from the initial phases of a study of Nrf2 in our in vitro model of HIVinduced neurodegeneration. Specifically, we are beginning this study with an
investigation into the Nrf2 response in neurons, since this endogenous antioxidant
response has not been well characterized in this cell type. Presented here are data
showing that Nrf2 mRNA is expressed in neurons, but also data suggesting that the Nrf2
response in these cells is different from that seen in other cell types. Moving forward, we
will continue to characterize the neuronal antioxidant response downstream of Nrf2 by
continuing our examination of Nrf2 target genes in pure neuronal cultures, both in
response to compounds known to induce Nrf2 in other cell-types, such as tBHQ, and in
response to our in vitro model of HIV-induced neurotoxicity. Additionally, that a chronic
or acute Nrf2-triggered antioxidant response would be beneficial and not toxic to
neurons is not immediately apparent. For instance, expression of the xCT subunit of the
cystine/glutamate exchange transporter (xC) is under control of Nrf2 (21, 22). The xC
plays a vital role in the synthesis of glutathione (GSH), which is an important part of the
endogenous cellular defense against ROS (23). Specifically, xC imports the GSH
precursor, cystine, into the cell, while, in exchange, exporting glutamate out of the cell
(24, 25). In the CNS, overabundance of extracellular glutamate causes excitotoxicity, a
phenomenon observed in multiple disease states, including HAND (10). Thus, to
continue to characterize the Nrf2 response in vitro, we would overexpress WT Nrf2, as
well as a dominant negative Nrf2 in neuronal a mixed cortical cultures. Phosphorylation
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of Nrf2 on its serine 40 residue induces Keap1 release of Nrf2, enabling Nrf2 to move
into the nucleus and be transcriptionally active. Thus, it may prove informative to
overexpress Nrf2 with a mutation at this serine to examine the function of this residue in
the protection of neural cells against HIV-induced neurotoxicity.
The findings presented in this chapter represent the start of an investigation into
the Nrf2 response in the CNS of HAND patients. While the study is at this point
incomplete, the data presented here from cortical autopsy tissue from HAND patients,
suggest activation of the Nrf2 response in the CNS of these patients. However, it seems
that this response may be activated in response to HIV infection, and then may
ultimately be failing in patients that progress to HAND, perhaps contributing to the
environment that allows progression to this disease state. Given the findings presented
here, continuation of this line of investigation may prove highly valuable for the
development of new therapeutic targets for patients suffering from HAND or, ideally,
therapies that may prevent HIV-infected patients from progressing to this debilitating
neurocognitive disease state.
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Figure 1

Figure 1 Total Nrf2 protein levels are increased in the mid-frontal cortex of HAND and
HIV(+) autopsy cases.
Whole cell extracts from fresh frozen mid-frontal cortical autopsy tissue were assessed via immunoblotting
for Nrf2 protein levels. A) Nrf2 protein levels increase in HAND cases (n=13) over levels seen in
neurocognitively normal control cases (n=5). Additionally, Nrf2 protein levels increase in patients infected
with HIV (n=14) as compared with HIV(-) control cases (n=4). Coomassie staining of the gel was used as a
control to normalize for protein degradation and loading error. B and C) Nrf2 levels were quantified and
normalized to the quantified coomassie band for each lane. Values are shown as mean±SEM. Student t test
was used for statistical analysis. * p<0.01 compared with control.
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Figure 2

Figure 2 Total Nrf2 protein levels are increased in the mid-frontal cortex of HAND and
HIV(+) autopsy cases as seen by IFA.
Formalin-fixed, paraffin embedded mid-frontal cortical autopsy tissue was quadruple labeled for Nrf2 and
for the cell-type markers, GFAP (astrocytes) and MAP2 (neurons), as well as for the nuclei using DAPI,
which binds DNA. A) Gray matter in labeled slides was imaged using laser confocal microscopy: Nrf2 is
shown in green, GFAP and MAP2 are shown in red and are not both present in the same images, and DAPI is
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shown in blue. Overlap of Nrf2 with a cell-type marker (both markers labeled in red in their corresponding
images) appears yellow. Nrf2 overlap with DAPI appears blue-green. An example is shown for a
neurocognitively normal case and for a HAND case for each cell-type marker. B and C) Nrf2 protein levels
from confocal images (6 per case) were quantified by determining integrated pixel intensity using
Metamorph 6.0 software. Total Nrf2 levels increase in HAND cases (n=12) over those in neurocognitively
normal cases (n=5) (B) and in HIV(+) cases (n=14) over HIV(-) (n=3) controls (C). Values are shown as
mean±SEM. Student t test was used for statistical analysis. * p<0.01, ** p<0.001 compared with control.
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Figure 3
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Figure 3 Cytoplasmic levels of Nrf2 increase in both neurons and astrocytes with
neurocognitive status and HIV status, however nuclear Nrf2 only increase with HIV status.
Using Metamorph 6.0 software, total integrated pixel intensity of Nrf2 was quantified and colocalization
with cell-type markers was determined and normalized to area of cell type marker to account for losses of
marker protein due to disease. A and B) Nrf2 increases in the cytoplasm of neurons in both HAND cases
and HIV(+) cases when compared with neurocognitively normal and HIV(-) cases, respectively. C and D)
Nrf2 increases in the cytoplasm of astrocytes in both HAND cases and HIV(+) cases when compared with
neurocognitively normal and HIV(-) cases, respectively. E and F) Total nuclear Nrf2 protein levels increase
in HIV(+) cases over those seen in HIV(-) cases, but do no increase in HAND cases over neurocognitively
normal cases. Values are shown as mean±SEM. Student t test was used for statistical analysis. * p<0.01, **
p<0.001 compared with control.
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Figure 4

Figure 4 Nrf2 mRNA is expressed in neurons grown in pure neuronal cultures, but there is
differential expression of Nrf2 target genes in neurons from pure neuronal cultures
compared with that of neurogial cells from mixed cortical cultures, containing both neurons
and astrocytes.
Rat cortical cells were grown in purified neuronal cultures or in mixed neuroglial cultures and total mRNA
(A) or total protein (B) was collected. A) Nrf2 mRNA is expressed in both mixed cultures and in pure
neuronal cultures, as determined by reverse-transcriptase PCR. Both types of cultures were treated with the
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Nrf2-inducer, tBHQ, or with vehicle for 1 or 4h or were left untreated. Data shown are the results of 1 of 2
experiments, both of which showed Nrf2 expression in pure neuronal cultures. There was no GFAP
expressed in pure neuronal cultures that were “untreated” or were treated for 1h with tBHQ, indicating that
there is no astrocytic contamination of these cultures and Nrf2 expression is still detectible. B) HO-1 is
expressed in mixed neuroglial cultures, but was not detectible by immunoblotting in extracts prepared from
cultures containing only neurons. Both types of cultures were treated with the Nrf2-inducer, tBHQ, or with
vehicle for 2 or 6h or were left untreated. Data shown are the results of 1 or 2 experiments, both of which
showed undetectable levels of HO-1 protein in extracts from pure neuronal cultures.
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Table 1:
Case

HIV

Gender

Age
(years)

PMI
(hr)

NeuroCog

Neuropath
Dx

HIV 1

+

M

35

9.25

HAD

Not HIVE

HIV 2

+

F

34

5

HAD

Not HIVE

HIV 3

+

M

57

5.5

HAD

Not HIVE

HIV 4

+

M

32

14.5

HAD

HIVE

HIV 5

+

M

38

5.5

HAD

HIVE

HIV 6

+

M

32

14

HAD

HIVE

HIV 7

+

M

36

2.5

MCMD

Not HIVE

HIV 8

+

M

37

11.5

MCMD

Not HIVE

HIV 9

+

M

31

8.83

MCMD

Not HIVE
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HIV 10

+

M

49

67.33

MCMD

Not HIVE

HIV 11

+

M

42

27.33

MCMD

Not HIVE

HIV 12

+

M

50

21

MCMD

HIVE

HIV 13

+

M

43

Unknown

MCMD

HIVE

HIV 14

+

M

46

2.75

Normal

Not HIVE

HIV 15

+

M

50

18

Normal

Not HIVE

CONTROL
1

-

M

46

27.65

ND

Control

CONTROL
2

-

F

47

19.2

ND

Control

CONTROL
3

-

M

40

14.66

ND

Control

CONTROL
4

-

F

51

21.75

ND

Control
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Table 1. Summary of case data for mid-frontal cortical autopsy tissue obtained from the
NNTC. Data on the HIV status (HIV), Gender, Age in years, post-mortem interval (PMI) in hours,
Neurocognitive diagnosis (NeuroCog), and Neuropathological diagnosis (Neuropath Dx) are summarized.
Abbreviations include:

F – female, HAD – HIV associated dementia, M – Male, MCMD – minor

cognitive/motor disorder, ND – not determined
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DISCUSSION

HIV-associated neurocognitive disorders (HAND) afflict numerous HIV patients,
negatively impacting their ability to carry out necessary daily activities, including their
ability to follow their antiretroviral therapeutic drug regiment (HAART). Unfortunately,
the mechanism that induces neuronal degeneration in this disease remains unknown. In
this thesis, we present data that demonstrates activation of the integrated stress
response (ISR), which encompasses the battery of cellular responses to stress.
Specifically, in Chapter 1, we showed general activation of the ISR by demonstrating an
increase in the protein levels of the molecular chaperone protein and master regulator of
the ISR, BiP, in HIV(+) and in HAND prefrontal cortical autopsy tissue, compared with
HIV(-) and neurocognitively normal tissue, respectively. Importantly, BiP is a general
indicator of ISR activation, since it is a downstream target of all three major branches of
the ISR. We then proceeded, in Chapter 2, to examine the nature of the ISR activation
that occurs in HAND. We found that ATF6 protein levels increase in HIV(+) tissue and
in HAND tissue. Interestingly, while we see no increase in pPERK levels with either HIV
status or neurocognitive status, we did see that pEIF2α levels increase in HIV(+) cases
compared with HIV(-) cases. Also, we found that while total ATF4 and nuclear ATF4
levels decreased in HAND tissue, cytoplasmic astrocytic ATF4 levels increased. ATF4
showed no change with HIV status. Finally, we began investigation into the antioxidant
component of the ISR, which is mediated by the transcription factor Nrf2. We had
previously found that Nrf2 expression is altered in other neurodegenerative diseases.
Specifically, as presented in Chapter 4, we had found that in hippocampal autopsy tissue
from patients with Alzheimer Disease (AD), Nrf2 is predominantly cytoplasmic, where as
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it is both nuclear and cytoplasmic in age-matched control tissue. Contrarily, we had
found that Nrf2 is strongly nuclear in nigral tissue of Parkinson Disease patients
compared with a predominantly cytoplasmic localization in the substantia nigra of agematched normal and AD control tissue. In our preliminary studies of Nrf2 in HAND,
presented in Chapter 5, we have found that cytoplasmic Nrf2 increases with HIV status
and neurocognitive status, however, nuclear Nrf2 only increases with HIV status.
Characterization of the ISR response in the CNS of HAND patients is vital to
understanding the survival response that is initiated in the brain during the neuronal
insults that occur with this disease and also to understanding how this survival response
ultimately fails or even turns against the neurons.
Although the ISR has numerous protective capabilities, it also is able to induce
apoptosis in cells under certain conditions and the chronic nature of the cellular stress in
the CNS of HAND patients may be just one such condition. Specifically, BiP has antiapoptotic properties, while another downstream target of all three prongs of the ISR,
CCAAT-enhancer binding protein homologous protein (CHOP), is pro-apoptotic.
Importantly, the anti-apoptotic functions of BiP are through its ability to negatively
regulate CHOP, which promotes apoptosis by inducing the production of ROS and by
downregulating Bcl-2 (1), as well as through its role in caspase-4-induced, ER specific
apoptosis (2-5). It is clear that the balance between BiP and CHOP is critical in
determining the survival versus apoptotic fate of a cell. Interestingly, eIF2α, which when
phosphorylated by PERK on its serine 51 (S51) causes a decrease in global translation
initiation, while also increasing the translation of particular proteins that include an
IRES in their 5’ untranslated region (6, 7), is capable of both pro-apoptotic and antiapoptotic actions, and depending on the duration of the stressful conditions, may switch
between its induction of pro-apoptotic and its induction of anti-apoptotic functions over
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time (8). Importantly, in addition to phosphorylation by PERK, eIF2α can also be
phosphorylated by double-stranded RNA-activated protein kinase (PKR) and general
control non-depressible-2 (GCN2) in numerous cell-types (9). While these kinases all
phosphorylate eIF2α on S51, the kinases themselves are differentially regulated and may
result in different actions of peIF2α, perhaps by the timing of their phosphorylation of
eIF2α or by the other proteins concurrently acted upon by a given kinase. We found that
PERK did not appear to be activated in prefrontal cortical tissue from HAND autopsy
cases nor in that from HIV(+) autopsy cases, even though peIF2α did increase in HIV(+)
cases as compared with neurocognitively normal controls. Thus it seems likely that PKR,
which responds to double-stranded DNA, as well as to certain components of an active
inflammatory response, may be phosphorylating eIF2α in the CNS of HIV(+) patients,
rather than PERK. Interestingly, some studies have suggested that PKR induces a proapoptotic role of peIF2α, while PERK induces a pro-survival role for peIF2α (8, 9). Thus,
phosphorylation of eIF2α may be one point at which cell fate is determined in the CNS of
HIV(+) patients and additional studies investigating the role of PKR in HAND may
provide additional insight into the role for peIF2α in neurodegeneration.
Another possible point of differential ISR responses and consequences is the
ATF6 pathway. Of the three initiator-proteins of the ISR, PERK and IRE1α show faster
activation kinetics, while ATF6 responds to stress with a slower response (10). These
results suggest that ATF6 may play a more important role in responding to the chronic
stress conditions that occur in diseases such as HAND. Of interest, that study
demonstrating the different kinetics of the three prongs of the ISR, utilized stress
induced by ER calcium release. Considering that neuronal death in our model of HIVinduced neurotoxicity is mediated by excitotoxicity (11), which largely causes death by
increased calcium release, our finding that the ATF6 prong of the ISR seems particularly
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highly activated seems consistent with the speculation that the ATF6 pathway of the ISR
may be responsible for attempting mitigation of cellular insults in chronic diseases
mediated by excitotoxicity. To add another level of complexity to the ISR response, ATF6
has two forms, ATF6α and ATF6β. Recent studies have suggested that ATF6α is a
transcriptional activator and that ATF6β is a transcriptional repressor and that both of
them can be activated by cellular stress via cleavage to a fragment that translocates to the
nucleus (12, 13). Further, some studies have suggested that phosphorylation of ATF6 is
important for transactivation of its target genes, perhaps by regulation of nuclear
translocation of the ATF6 cleavage product (14). This phosphorylation step provides one
potential mechanism of controlling the influence ATF6α versus that of ATF6β in
activating or inhibiting the ATF6 ISR pathway response, respectively, as these two forms
may be differentially phosphorylated over the duration of a stress response or in
response to different stressors. It would be instructive to examine the response of ATF6α
in HAND, as well as examining the phosphorylation of ATF6 in our in vitro model of
HIV-induced neuronal degeneration using pharmacological kinase inhibitors of kinases
known to target ATF6.
Another example of the double-edged sword of ISR activation can be seen in the
activation of the antioxidant component of the ISR, as mediated by Nrf2. One gene
target of Nrf2 is the xCT subunit of the cystine/glutamate exchange transporter (xC) (15,
16). This transporter imports cystine into the cell, while exporting glutamate out of the
cell in exchange (17, 18). The purpose of this exchange is to allow the production of
glutathione, which has protective functions. However, given the sensitivity of the
nervous system to extracellular glutamate, a chronic activation of the Nrf2 response
could easily turn toxic itself. Examination of the expression of glutamate transporters in
vivo and in vitro would help to elucidate this particular aspect of the Nrf2 response. The
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complexities of the ISR mentioned here are only a few of many variables to the divergent
nature and consequences of ISR activation under the wide-ranging stressors
encountered by cells under physiologic conditions and disease states.
Another aspect of HIV infection that must be considered in the post-HAART era,
is the potential contribution of antiretroviral drugs to neuronal degeneration. HAART
drugs are known to cause peripheral neuropathy in patients, although the effects of
HAART toxicity in the CNS have not been well studied. In our lab, we have undertaken to
determine the effects of HAART drugs on health of the CNS. Interestingly, we have found
that HAART drugs are able to induce cell death and also activate the ISR in vitro (data
not shown). Given that the vast majority of HIV autopsy tissue available for research
comes from patients undergoing HAART therapy, these findings must be taken into
account when considering the implications of the data presented in this thesis. However,
since so many HIV(+) patients do receive HAART therapy, any findings about ISR
activation due to antiretroviral drugs, whether protective or pro-apoptotic in
consequence, must be considered in the quest to prevent HIV(+) patients from
developing HAND.
While the focus of this thesis has been the role of the ISR in HAND, our
laboratory has also investigated other potential mechanisms of neuronal death in this
disease, which may or my not be independent of the ISR response presented here.
Specifically, we have also found that certain cell-cycle proteins appear to play a role in
neuronal death in HAND. We have found that calpain activation of cyclase-dependent
kinase 5 (cdk5) contributes to the neurotoxicity in our in vitro model of HIV-induced
neurodegeneration (Appendix 1 (19)). Also, we have found that the transcription factor,
E2F1, which regulates progression from G1 to S-phase in cycling cells, is increased in
cortical tissue in HIV-associated neuropathologies and in primate models of this disease
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(20). However, in these diseases and in healthy neurons, E2F1 localizes predominantly
to the cytoplasm, which is inconsistent with its role as a transcription factor.
Interestingly, when we examined levels of E2F1 target genes in our in vitro model of
HIV-induced neurotoxicity to attempt to determine whether E2F1 may be contributing to
neuronal death in HAND, we found that its classic target genes did not appear to be
transactivated (Appendix 2 (21)). We believe that, given its predominantly cytoplasmic
localization in neurons, E2F1 may have an as yet uncharacterized cytoplasmic role in this
cell type.
To begin to develop effective therapeutic treatments for HAND, it is necessary to
determine the mechanisms of neuronal death in this disease and the role of the
protective cellular responses that fail to prevent such neuronal loss. Here we present
data that strongly suggest activation of the ISR in cortical gray matter of HAND patients.
It is vital to determine whether the ISR is failing to prevent neuronal death in HAND or
whether it is actively initiating death of these cells. These studies should be carried out in
the future using our in vitro model of HIV-induced neurodegeneration, as well as our in
vitro model of HAART drug treatment. While we first need to characterize the nature of
the ISR response in our in vitro model to be sure that it parallels our in vivo findings, we
hope to eventually determine whether, in HAND, the role of the ISR is ultimately
protective or apoptotic or, more likely, both, depending on the individual component of
the ISR in question. To achieve this we would utilize genetic knockout animals and
pharmacological inhibitors for the various members of the ISR. Regardless of which
answer we would find, the ISR provides promising targets for therapeutic intervention in
preventing progression to HAND, as well as in treating those already suffering from it.

249

References
1.

McCullough KD, Martindale JL, Klotz L-O, Aw T-Y, & Holbrook NJ (2001)
Gadd153 Sensitizes Cells to Endoplasmic Reticulum Stress by Down-Regulating
Bcl2 and Perturbing the Cellular Redox State. Mol. Cell. Biol. 21(4):1249-1259.

2.

Benavides A, Pastor D, Santos P, Tranque P, & Calvo S (2005) CHOP plays a
pivotal role in the astrocyte death induced by oxygen and glucose deprivation.
GLIA 42(4):261-275.

3.

Nakagawa T, et al. (2000) Caspase-12 mediates endoplasmic-reticulum-specific
apoptosis and cytotoxicity by amyloid-beta. Nature 403(6765):98-103.

4.

Rao RV, et al. (2002) Coupling endoplasmic reticulum stress to the cell death
program: role of the ER chaperone GRP78. J Biol Chem 277(24):21836-21842.

5.

Williams BL & Lipkin WI (2006) Endoplasmic reticulum stress and
neurodegeneration in rats neonatally infected with borna disease virus. J. Virol.
80(17):8613-8626.

6.

Komar AA & Hatzoglou M (2005) Internal ribosome entry sites in cellular
mRNAs: mystery of their existence. (Translated from eng) J Biol Chem
280(25):23425-23428 (in eng).

7.

Sonenberg N & Hinnebusch AG (2009) Regulation of translation initiation in
eukaryotes: mechanisms and biological targets. (Translated from eng) Cell
136(4):731-745 (in eng).

8.

Muaddi H, et al. (2010) Phosphorylation of eIF2{alpha} at Serine 51 Is an
Important Determinant of Cell Survival and Adaptation to Glucose Deficiency.
(Translated from Eng) Mol Biol Cell (in Eng).

250

9.

Wek RC, Jiang HY, & Anthony TG (2006) Coping with stress: eIF2 kinases and
translational control. (Translated from eng) Biochem Soc Trans 34(Pt 1):7-11 (in
eng).

10.

DuRose JB, Tam AB, & Niwa M (2006) Intrinsic capacities of molecular sensors
of the unfolded protein response to sense alternate forms of endoplasmic
reticulum stress. (Translated from eng) Mol Biol Cell 17(7):3095-3107 (in eng).

11.

O'Donnell LA, et al. (2006) Human immunodeficiency virus (HIV)-induced
neurotoxicity: roles for the NMDA receptor subtypes. J Neurosci 26(3):981-990.

12.

Thuerauf DJ, Marcinko M, Belmont PJ, & Glembotski CC (2007) Effects of the
isoform-specific characteristics of ATF6 alpha and ATF6 beta on endoplasmic
reticulum stress response gene expression and cell viability. (Translated from
eng) J Biol Chem 282(31):22865-22878 (in eng).

13.

Thuerauf DJ, Morrison L, & Glembotski CC (2004) Opposing roles for
ATF6alpha and ATF6beta in endoplasmic reticulum stress response gene
induction. (Translated from eng) J Biol Chem 279(20):21078-21084 (in eng).

14.

Luo S & Lee AS (2002) Requirement of the p38 mitogen-activated protein kinase
signalling pathway for the induction of the 78 kDa glucose-regulated
protein/immunoglobulin heavy-chain binding protein by azetidine stress:
activating transcription factor 6 as a target for stress-induced phosphorylation.
(Translated from eng) Biochem J 366(Pt 3):787-795 (in eng).

15.

Sasaki H, et al. (2002) Electrophile response element-mediated induction of the
cystine/glutamate

exchange

transporter

277(47):44765-44771.

251

gene

expression.

J

Biol

Chem

16.

Shih AY, et al. (2003) Coordinate regulation of glutathione biosynthesis and
release by Nrf2-expressing glia potently protects neurons from oxidative stress. J
Neurosci 23(8):3394-3406.

17.

Bannai S & Kitamura E (1980) Transport interaction of L-cystine and Lglutamate in human diploid fibroblasts in culture. J Biol Chem 255(6):23722376.

18.

Watanabe H & Bannai S (1987) Induction of cystine transport activity in mouse
peritoneal macrophages. J Exp Med 165(3):628-640.

19.

Wang Y, et al. (2007) Activation of cyclin-dependent kinase 5 by calpains
contributes

to

human

immunodeficiency

virus-induced

neurotoxicity.

(Translated from eng) J Neurochem 103(2):439-455 (in eng).
20.

Jordan-Sciutto KL, Wang G, Murphey-Corb M, & Wiley CA (2002) Cell cycle
proteins exhibit altered expression patterns in lentiviral-associated encephalitis.
(Translated from eng) J Neurosci 22(6):2185-2195 (in eng).

21.

Wang Y, et al. (2010) E2F1 localizes predominantly to neuronal cytoplasm and
fails

to

induce

expression

of

its

transcriptional

targets

in

human

immunodeficiency virus-induced neuronal damage. (Translated from eng)
Neurosci Lett 479(2):97-101 (in eng).

	
  

252

APPENDIX 1:
Activation of cyclin dependent kinase 5 by
calpains contributes to human
immunodeficiency virus-induced
neurotoxicity

253

Activation of cyclin dependent kinase 5 by calpains contributes
to human immunodeficiency virus-induced neurotoxicity

Ying Wang1, Michael G. White1, Cagla Akay1, Rebecca A. Chodroff1, Jonathan
Robinson1, Kathryn A. Lindl1, Marc A. Dichter2, Yang Qian3, Zixu Mao3,
Dennis L. Kolson2, Kelly L. Jordan-Sciutto1*

1Department

of Pathology, School of Dental Medicine, University of Pennsylvania,

Philadelphia PA

19104, U.S.A,

2

Department of Neurology, School of Medicine,

University of Pennsylvania, Philadelphia PA

19104, U.S.A., and

3Departments

of

Pharmacology and Neurology, Emory University School of Medicine, Atlanta, GA
30322, U.S.A.
*Corresponding Author
Kelly L. Jordan-Sciutto, Ph.D.
Department of Pathology
University of Pennsylvania
240 S. 40th St, Rm 312 Levy Bldg
Philadelphia, PA 19104-6030
e-mail: Jordan@path.dental.upenn.edu
phone: 215-898-4196
fax: 215-573-2050

254

Abbreviations:
CDK5 (cyclin dependent kinase 5); DIV (days in vitro); Egr1 (Early growth response
protein 1); ERK1/2 (extracellular signal-regulated kinase 1 and 2); HAART (highly active
antiretroviral

therapy);

HAD

(HIV-

associated

dementia);

HIVE

(human

immunodeficiency virus encephalitis); HIV MDM (HIV-infected, monocyte-derived
macrophage); JNK3 (c-Jun N-terminal kinase 3); linear range (LR); MAP2
(microtubule-associated protein 2); MAPK (mitogen activated protein kinase); MCMD
(minor cognitive motor disorder); MEF (myocyte enhancer factor 2); MEK1/2
(MAPK/ERK kinase 1 and 2); MDL28170 (carbobenzoxy-valinyl-phenylalaninal);
MK801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate);
NMDAR (NMDA receptor); PMI (post-mortem interval); roscovitine (2-(R)-1-Ethyl-2hydroxyethylamino)-6-benzylamino-9-isopropylpurine); SDS (sodium dodecyl sulfate);
U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene)

255

ABSTRACT (200 words)
Although the specific mechanism of neuronal damage in human immunodeficiency
virus (HIV)-associated dementia is not known, a prominent role for NMDA receptorinduced

excitotoxicity

has

been

demonstrated

in

neurons

exposed

to

HIV-

infected/activated macrophages. We hypothesized NMDA receptor-mediated activation
of the calcium-dependent protease, calpain, would contribute to cell death by induction
of cyclin dependent kinase 5 (CDK5) activity.

Using an in vitro model of HIV

neurotoxicity, in which primary rat cortical cultures are exposed to supernatants from
primary human HIV-infected macrophages, we have observed increased calpaindependent cleavage of the CDK5 regulatory subunit, p35, to the constitutively active
isoform, p25.

Formation of p25 is dependent upon NMDA receptor activation and

calpain activity and is coincident with increased CDK5 activity in this model. Further,
inhibition of CDK5 by roscovitine provided neuroprotection in our in vitro model.
Consistent with our observations in vitro, we have observed a significant increase in
calpain activity and p25 levels in mid-frontal cortex of patients infected with HIV,
particularly those with HIV-associated cognitive impairment. Taken together, our data
suggest calpain activation of CDK5, a pathway activated in HIV-infected individuals, can
mediate neuronal damage and death in a model of HIV-induced neurotoxicity.

Keywords:

encephalitis, dementia, cell cycle, CDK5, neurodegeneration, calpain,

NMDA receptor
Running Title: Role of CDK5 in HIV-associated neurotoxicity
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INTRODUCTION
Before

widespread

use

of

highly

active

antiretroviral

therapy

(HAART),

approximately 20% of patients infected with HIV developed HIV-associated dementia
(HAD) (Kaul et al. 2001; Garden 2002; Gonzalez-Scarano and Martin-Garcia 2005). In
the post-HAART era, the incidence of HAD has declined to approximately 8%; however,
the prevalence has increased. In addition, an increasing number (~40%) of HIV-infected
patients on HAART are developing a constellation of less severe neurologic symptoms
referred to as minor cognitive motor disorder (MCMD) (Janssen et al. 1989; Sacktor et
al. 2002; McArthur et al. 2003). Pathologic studies of the brains of patients with HAD
suggest an inflammatory mechanism in the progression of this disease, as evidenced by
astrogliosis, microgliosis, and perivascular macrophage infiltration (Kaul et al. 2001;
Garden 2002; Ghorpade et al. 2003). Although neuronal, dendritic, and synaptic loss
are features of HAD, there is little evidence of direct HIV infection of neurons (Shi et al.
1996; Corasaniti et al. 2001). Instead, neuronal dysfunction and death is mediated by
the release of neurotoxic factors from activated macrophages and microglia including,
but not limited to, reactive oxygen species, and excitatory amino acids (Yoshioka et al.
1995; Pulliam et al. 1997; Conant et al. 1998; Vallat et al. 1998; Bagetta et al. 1999; Nath
et al. 1999; Gartner 2000; Yeh et al. 2000; Wasmuth et al. 2004). Moreover, these
factors stimulate astrocytes and neurons to release additional pro-inflammatory factors,
perpetuating the inflammatory state in the CNS, and potentially exacerbating neuronal
damage (Gonzalez-Scarano and Martin-Garcia 2005).

Correlative evidence suggests

neuronal death in HAD may result from several mechanisms, including calcium influx
(Galicia et al. 2002), NMDA receptor (NMDAR) activation (O'Donnell et al. 2006), p38
mitogen activated protein kinase (MAPK) cascade, caspase activation (Ullrich et al.
2000), inhibition of the NF-kB survival pathway via GSK-3b activation (Sui et al. 2006),
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and/or aberrant cell cycle regulation (Jordan-Sciutto et al. 2002).

Several of these

mechanisms, including calcium influx and NMDAR activation, have been shown to
activate cyclin dependent kinase 5 (CDK5) (Kusakawa et al. 2000; Lee et al. 2000).
CDK5 is a member of the proline-directed serine/threonine kinases of the cyclin
dependent kinase family which regulate progression through the cell cycle. Although
CDK5 shares 60% sequence identity with other CDK members, a role in cell cycle
regulation has not been well established for CDK5 (Cicero and Herrup 2005). Instead,
CDK5 has been implicated in neuronal migration, neurite outgrowth, laminar
configuration of the cerebral cortex during development (Dhavan and Tsai 2001),
modulation of dopaminergic and glutamatergic transmission (Chergui et al. 2004),
regulation of pain signaling (Pareek et al. 2006; Pareek and Kulkarni 2006), and
endocytosis of synaptic vesicles (Tomizawa et al. 2003). Recently, CDK5 has emerged as
a crucial regulator of neuronal survival, neuroprotection, and neuronal death pathways
(Vartiainen et al. 2002; Wang et al. 2006). This is supported by observed somatic
swelling and nuclear margination of brainstem and spinal cord neurons in CDK5
knockout mice (Ohshima et al. 1996). The multifaceted nature of CDK5 demonstrates the
importance of this protein for neuronal function and viability.
Several distinct pathways are regulated by CDK5 which may account for its
paradoxical role in both neuroprotection and neurotoxicity. One mechanism through
which CDK5 mediates neuroprotective function is by attenuating activation of the proapoptotic kinase, c-Jun N-terminal kinase 3 (JNK3) through direct phosphorylation of
JNK3 on threonine 131 (Li et al. 2002). CDK5 can also promote neuronal viability by
increasing pro-survival activity of Akt, an activity lost in CDK5 knock out mice (Li et al.
2003).
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CDK5 activity in neurons is regulated through association with its neuronal-specific
activators, p35 (Tsai et al. 1994) or p39 (Ko et al. 2001). The protective functions of
CDK5 result from its association with the relatively short-lived p35 which has a half-life
of approximately 20-30 min (Patrick et al. 1998), thus limiting p35:CDK5 kinase activity.
In contrast, under pathological conditions, activation of calpain, a calcium-dependent,
cysteine-protease, causes cleavage of p35 to its more stable isoform, p25. Cleavage of
p35 to p25 increases the level and activity of the p25:CDK5 complex, and alters its
subcellular distribution (Musa et al. 1998; O'Hare et al. 2005). This complex has been
associated with CDK5 neurotoxic function (Patrick et al. 1999). One mechanism by
which increased p25:CDK5 has been reported to alter neuronal viability is translocation
of p25:CDK5 to the nucleus and its subsequent inactivation of the pro-survival
transcription factor, myocyte enhancer factor 2 (MEF2), via phosphorylation on serine
444 (Gong et al. 2003). Neurotoxic function of this kinase is further supported by the
observed increase in p25:CDK5 activity in several neurodegenerative diseases, including
Alzheimer’s disease (Pei et al. 1998; Patrick et al. 1999; Tseng et al. 2002; Zheng et al.
2005; Jamsa et al. 2006), amyotrophic lateral sclerosis (Nakamura et al. 1997; Nguyen et
al. 2001; Patzke and Tsai 2002), Parkinson’s disease (Henchcliffe and Burke 1997;
Neystat et al. 2001; Zhu et al. 2002; Chergui et al. 2004; Alvira et al. 2006; Smith et al.
2006), and Huntington’s disease (Luo et al. 2005).
Our previous studies have demonstrated increased calpain activity in an in vitro
model of HIV-mediated neurodegeneration in which hippocampal neurons are treated
with HIV-infected, monocyte-derived macrophage (HIV MDM) supernatants (O'Donnell
et al. 2006). Thus, we hypothesized that neuronal damage and death in HIV-associated
neurocognitive impairment is at least partially induced by activation of CDK5 by calpain
cleavage of p35 to p25. In this study, we demonstrate activation of CDK5 via calpains
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following NMDAR stimulation in an in vitro model of HIV-mediated cortical
neurotoxicity as evidenced by increases in the cleavage products of calpains, p25
formation, and CDK5 kinase activity that are prevented by pharmacologic inhibitors of
NMDAR or calpains. Blocking NMDAR, calpain, or CDK5 activity protects from HIV
MDM supernatant-induced neuronal loss in this in vitro model. Consistent with our in
vitro findings, we observed an increase in cleavage products of calpain and in p25 levels
in autopsy tissue from HIV-infected individuals, including HAD and MCMD patients.
Taken together, these findings suggest that activation of CDK5 via calpain cleavage of
p35 occurs in HIV-infected patients and contributes to neuronal damage and loss.
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Materials and Methods
Chemicals and reagents: MK801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d]
cyclohepten-5,10-imine maleate), MDL28170 (carbobenzoxy-valinyl-phenylalaninal),
roscovitine

(2-(R)-1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine),

and rabbit anti-actin antibody, were from Sigma (St.Louis, MO, USA). U0126 (1,4diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene) was purchased from Tocris
Bioscience (Ellisville, MO, USA). Rabbit antibody against calpain-cleaved spectrin, was
described previously (Roberts-Lewis et al. 1994) and was a generous gift from Dr. Robert
Siman (University of Pennsylvania, Philadelphia, PA, USA). Mouse monoclonal
antibodies to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (6C5), and p-ERK
(E4), and rabbit polyclonal antibodies to p35 (C19) and CDK5 (C8) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal antibody to p-MEF2
(Ser444, site phosphorylated by CDK5) was a generous gift from Dr. Zixu Mao (Emory
University School of Medicine, Atlanta, GA, USA). Rabbit polyclonal antibody to lamin
A/C was from Cell Signaling Technology (Danvers, MA, USA). Mouse monoclonal
antibody to MAP2 was purchased from Covance Research Products (Berkeley, CA, USA).
Goat

anti-mouse-beta-lactamase

TEM-1

conjugated

secondary

antibody

and

FluorocillinTM Green reagent were from Invitrogen (Carlsbad, CA, USA).

Preparation of primary neuronal cultures: Primary rat cortical cultures were
prepared from embryonic day 17 Sprague Dawley rat pups as described previously
(Brewer 1995). Cells were plated at a density of 8 x 105 cells per 35 mm dish pre-coated
with poly-L-lysine (Peptides International, Louisville, KY, USA) and maintained in
neurobasal media (Invitrogen) with B27 supplement (Invitrogen) at 37°C, 5% CO2. Half
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of the media was replenished every seven days, and cultures were utilized at 14 days in
vitro (DIV) unless indicated otherwise.

Monocyte-derived Macrophage (MDM) culture: HIV MDM supernatants were
derived from monocyte-derived macrophages infected with a primary, macrophage
tropic, HIV-1 isolate (Jago) collected from cell-free CSF of a patient with confirmed HAD
as described previously (Chen et al. 2002; O'Donnell et al. 2006). Briefly, primary blood
mononuclear cells were isolated from healthy volunteers as described previously (Chen
et al. 2002) in accordance with protocols approved by the University of Pennsylvania
Committee on Studies Involving Human Beings. Cells were differentiated for 7 days (d)
in macrophage media (DMEM with 10% fetal bovine serum, 10% horse serum, 1%
penicillin/streptomycin, and 1% nonessential amino acids) in six-well plates (2.5 X 106
cells per well). On day 7, cultures were infected with cell free HIV-1 inoculum (100 ng of
p24 per well) and incubated for 24 h. At which point, cells were washed twice with PBS
and incubated in fresh macrophage media. HIV MDM supernatants were monitored for
productive infection by p24 ELISA (NEN, Boston, MA). HIV infection of macrophages
was confirmed by reverse transcriptase activity over time in each case, and only HIV
MDM supernatants exhibiting productive infection, as determined by reverse
transcriptase activity were used to treat neuronal cultures. Reverse transcriptase activity
for each supernatant used and the relevant experiment utilizing that supernatant are
shown in Table 1. Supernatants from HIV MDM and mock-infected MDM (Mock) were
collected at selected time points after infection and stored at -80°C. Cortical cultures
were treated by addition of various dilutions of supernatant (1:10 or 1:40) directly to
their culture media.

Stocks of the HIV isolate, Jago, were prepared in primary T-

lymphocytes derived from the blood of healthy volunteers through the University of
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Pennsylvania Center for AIDS Research Virology Core. As with other macrophage-tropic
HIV strains, Jago productively infects primary T-lymphocytes and macrophages but not
transformed T-cell lines (Chen et al. 2002).

Western blotting of primary cell cultures: Whole cell extracts were prepared
from primary rat cortical cultures. Cells were lysed for 20 min with ice-cold cell lysis
buffer consisting of 50 mM Tris–HCl, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS),
0.1% NP-40, 0.5% sodium deoxycholate, and a protease inhibitor cocktail (Sigma). The
lysates were centrifuged at 4oC for 10 min and supernatants were collected. Protein
concentrations of cell extracts were determined using the Bradford method (BioRad,
Hercules, CA, USA), and 30

g of protein was loaded to each lane of a 4-12% TBE

gradient gel for separation (Invitrogen). A broad range molecular weight ladder (BioRad)
was run on each gel. Following gel separation, proteins were transferred onto PVDF
membranes (Bio-Rad) and blocked in phosphate buffered saline with 1% Tween-20
(PBS-T) and 5% nonfat milk for 1 h at room temperature. Membranes were incubated
overnight at 4 oC with primary antibodies in blocking solution. All primary antibodies
were used at a dilution of 1:1000 except for the calpain-cleaved spectrin antibody and the
actin antibody, which were used at a dilution of 1:15,000. Membranes were then washed
three times with PBS-T and incubated with secondary antibody conjugated to horse
radish peroxidase (HRP; Southern Biotechnology, Birmingham, AL, USA) in blocking
buffer for 1 h at room temperature. After washing with PBS-T three times, membranes
were developed using SuperSignal West Dura Extended Duration Substrate (Pierce
Biotechnology, Rockford, IL, USA) and were exposed to Amersham Hyperfilm (GE
Healthcare, Piscataway, NJ, USA). For densitometric analysis, autographs were scanned
and band size and pixel intensity were quantified by NIH ImageJ program (V 1.36b).
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Target bands were normalized to loading controls to account for protein degradation and
loading discrepancies.

Subcellular Fractionation: Cytoplasmic and nuclear protein extractions were done
using Panomics’ Nuclear Extraction Kit (Panomics Inc., Fremont, CA, USA) following the
manufacturer’s protocol. Briefly, cells were washed twice with ice-cold phosphatebuffered saline and lysed by shaking on ice for 10 min in lysis buffer (10 mM HEPES, pH
7.9, 10 mM KCl, 10 mM EDTA, 4% IGEPAL, 10 mM dithiothreitol, protease inhibitor
mixture). Cells were harvested and centrifuged at 15,000 rpm for 3 min and the
supernatant (cytoplasmic fraction) was collected. The nuclear pellet was resuspended in
a buffer containing 20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 10% glycerol, 10
mM dithiothreitol, and protease inhibitor mixture and was incubated on a rocking
platform at 4 °C for 2 h followed by centrifugation at 15,000 rpm for 5 min at which
point the supernatant (nuclear extract) was collected. Protein (30 µg) was resolved on a
4-12% TBE gradient gel and probed with antibodies against CDK5 and p35-p25.

Western blotting of human brain tissue: Fresh frozen tissue samples from midfrontal cortex of HAD (n=6), MCMD (n=7) and control (n=5) human autopsy cases were
obtained from the tissue banks of National NeuroAIDS Tissue Consortium (NNTC)
(Morgello et al. 2001). Due to limited tissue availability, we were unable to obtain
cortical tissue from more than 1 HIV-infected, cognitively normal case. Donor
demographics are listed in Table 2. For protein extraction, tissue was homogenized on
ice taking 4 strokes using a Dounce tissue grinder (Kimble/Kontes, Vineland, NJ, USA)
in 2 tissue volumes of Lysis Buffer (50 mM Tris-HCl (pH 7.5), 0.5 M NaCl, 1% NP-40,
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0.5% sodium deoxycholate, 1% SDS, 2 mM EGTA, 2 mM EDTA, 5 mM NaF, 0.1 mM
PMSF, 1 mg/ml leupeptin, 1 mM DTT, and protease inhibitor cocktail). Homogenized
tissue was sonicated 3 times in 6 s cycles, and then centrifuged at 25,000 rpm for 30
min. The supernatants from the lysates were collected and protein concentrations were
determined by the Bradford method. 100µg of protein was loaded to each lane of 10 %
Bis-Tris gels for separation, transferred onto PVDF membranes, and processed as
described above for immunoblotting of primary cell cultures.

Coomassie staining: PVDF membranes were stained with the Coomassie BrilliantBlue R-250 (Bio-Rad) solution (0.1% Coomassie (w/v) in 50% methanol) for 5 min,
followed by destaining with 25% acetic acid in 50% methanol for 30 min. The
membranes were then photographed by a Nikon Coolpix 995 camera, and further
analysis was done using NIH ImageJ as described above.

Quantitative real-time polymerase chain reaction (PCR): Cells were treated as
indicated. Total RNA was extracted with TRIzol® reagent (Invitrogen) according to the
manufacturer's instructions. Reverse transcription was performed using the Superscript
II

TM

RT kit (Invitrogen). Expression levels of p35 and the ribosomal rRNA, 18S, were

quantified using the LightCycler Amplification Kit SYBR Green I (Roche Applied
Science, Indianapolis, IN, USA). Results are normalized to 18S rRNA levels and are
reported

using

arbitrary

units.

Primers

used

were:

p35

forward,

GAAATCTCCTACCCGCTCAA; p35 reverse, GTCCCAAAAGGCTTCCTTG; 18S forward,
GAGAAACGGCTACCACATCC; 18S reverse, GGGTCGGGAGTGGGTAAT.CLE IN PRESS
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CDK5 kinase assay: CDK5 kinase assay was performed as previously described
(Wang et al. 2006). Briefly, to prepare protein extracts, cells were scraped in lysis buffer
containing 50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 10 mM EDTA, 0.5% NP-40, 10
mg/ml leupeptin, 1 mM PMSF, 4 mM NaF, and protease inhibitor cocktail. To isolate
CDK5 protein, 200 mg of extracted protein was incubated with 2 mg CDK5 antibody at
4°C for 3 h, followed by incubation with 30 ml 50% protein A/G PLUS-agarose (Santa
Cruz) at 4°C overnight. The beads were pelleted and washed 4 times with lysis buffer and
twice with kinase buffer (20 mM Tris-HCl (pH 7.5), 20 mM MgCl2, 1 mM EDTA, 1 mM
EGTA). The isolated complexes were then incubated at 30°C for 30 min with kinase
buffer containing 2 mg of histone H1 (Sigma), 20 mM ATP, and 10 mCi of (g-32P) ATP in
a final volume of 40 ml. Kinase activity was determined by SDS-PAGE and
autoradiography.

Quantification of HIV-induced neurotoxicity. Neuronal death was quantified
using handcounting of MAP2-positive neurons as previously described (O'Donnell et al.
2006) and using a MAP2 cell-based ELISA assay.
Handcounting of MAP2-positive neurons. Treated cultures were washed once with PBS
and fixed in 4% paraformaldehyde/4% sucrose in PBS for 1 h, followed by permeabilizing
in 0.2% Triton X-100/PBS (10 min). Cultures were then washed twice with PBS, blocked
with 5% goat serum in PBS (30 min at room temperature), and exposed to anti-MAP-2
antibody (1:100 in Normal antibody diluent, ScyTek Labs, Logan, UT, USA) for 1 h at
room temperature. After washing, a fluorescein isothiocyanate-conjugated goat antimouse IgG secondary antibody (1:200 for 30 min at room temperature, Jackson
ImmunoResearch Labs, West Grove, PA, USA) was used for detection of MAP-2 antibody
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binding. The number of surviving MAP-2-labeled neurons was estimated by blinded
counting of all fields (14 at 200X) in two adjacent vertical columns through the center of
each coverslip, proceeding from top to bottom and bottom to top. For each condition, 3
coverslips were counted from two or more independent experiments, and the average ±
SEM number of surviving neurons was determined.
MAP2 cell-based ELISA assay. Primary rat cortical neuroglial cultures were plated in
poly-L-lysine-coated 96-well plates at a concentration of 4x104 cells per well. Following
treatments, cells were fixed for 30 min with 4% paraformaldehyde in 4% sucrose. After
blocking for 1 h with 5% normal goat serum in PBS, the plates were incubated with
mouse anti-MAP2 antibody (1:1000 dilution) overnight at 4°C, followed by washing with
PBS-T. The plates were then incubated for 30 min with goat anti-mouse secondary
antibody conjugated to beta-lactamase TEM-1 (1:500), washed, and incubated at room
temperature for 60 min with 0.5µg FluorocillinTM Green substrate per well. Fluorescence
intensity was measured using a Fluoroskan Ascent fluorometer plate reader (Thermo
Electron, Waltham, MA, USA) with excitation at 485 nm and emission at 527 nm.
Relative changes in the intensity of the fluorescent MAP2 signal were used to estimate
neuronal damage and corresponded closely to changes in the numbers of MAP2 positive
cells as determined by handcounting (see Fig. 1 and 5).

Statistical analysis: Values are expressed as mean ± SEM.
analyzed by student t-test.

Paired results were

Values for protein levels in human tissue in which the

variance is not expected to be equal were analyzed by the Mann-Whitney U test. Data
with multiple categories was analyzed by one-way analysis of variance (ANOVA)
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followed by the Newman-Keuls post hoc test using Prism software (GraphPad Software,
San Diego, CA, USA). Values of p<0.05 were considered significant.
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RESULTS
HIV monocyte-derived macrophage supernatants induce neuronal loss in
primary rat cortical cultures: a model of HIV induced neurotoxicity.
Neuronal damage and death in HIV-infected patients is associated with infiltration and
activation of monocyte-derived macrophages (MDM) and microglia (Ghorpade et al.
2003). To model this disease process in vitro, we treated primary rat cortical, mixed
neuroglial cultures at 14 DIV (days in vitro) with supernatants from HIV-infected MDM
(HIV MDM) similar to our previously reported model (O'Donnell et al. 2006). Our
previous studies have demonstrated that neurotoxicity of HIV MDM supernatant in
primary rat hippocampal neurons is dependent upon: 1) viral replication at the time of
supernatant collection, 2) a heat-stable, protease-resistant, molecule smaller than 3 kD
in size, and 3) NMDAR activation (O'Donnell et al. 2006). To confirm the involvement
of NMDAR in HIV MDM supernatant-induced cortical neuron death, we pretreated 14
DIV cortical cultures with the NMDAR antagonist, MK801, for 30 min prior to the
addition of HIV MDM supernatant. As was the case in hippocampal cultures, HIV MDM
supernatant significantly reduced the number of cortical cells positive for the neuronspecific marker, microtubule associated protein 2 (MAP2), as compared with mockinfected MDM supernatants (Mock) or untreated cultures (Fig. 1A, ### p<0.001) by
hand-counting (O'Donnell et al. 2006). Inhibition of NMDAR by addition of MK801 30
min prior to addition of HIV MDM provided complete neuroprotection (Fig. 1A, ***
p<0.001) from HIV MDM supernatant-induced death, similar to our results in rat
hippocampal neurons (O'Donnell et al. 2006). In conjunction with counting MAP2positive neurons, we have also developed a fluorescent MAP2 cell ELISA to determine
neuronal viability and toxicity based on previously described MAP2 cell ELISAs (Doherty
et al. 1984; Fuhrmann et al. 1997; Brooke et al. 1999). We adapted this assay to a 96-well
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format allowing analysis of more experimental parameters. Using this assay, HIV MDM
treatment resulted in a significant loss of MAP2 fluorescence compared with mockinfected MDM supernatant treatment and untreated cultures (Fig. 1B, ### p<0.001).
Using the fluorescent MAP2 cell ELISA, we also saw complete prevention of MAP2
fluorescence loss in HIV MDM treated cultures when preincubated with the NMDAR
inhibitor, MK801 (Fig. 1B, *** p<0.001). Taken together, these findings suggest that
HIV MDM induces neuronal damage and death in cortical cultures via a similar
mechanism by which it induces death in hippocampal cultures. Further, we have shown
that our fluorescent MAP2 cell ELISA provides comparable results to those obtained by
counting loss of MAP2-positive neurons by hand (Fig. 1A and B).

Calpain cleavage of spectrin is increased in cortical cultures exposed to HIV
MDM supernatant. NMDAR activity leads to an elevation in intracellular calcium
levels and thus, an increased likelihood of calpain activation. Our previous findings
demonstrate that treatment with HIV MDM supernatant leads to activation of the
calcium-dependent protease, calpain, in hippocampal cultures (O'Donnell et al. 2006).
Exposure of rat cortical cultures to HIV MDM induced time- and dose-dependent
appearance of the calpain-specific cleavage product of spectrin by Western blot (Fig. 2A).
In contrast, another cysteine protease, caspase-3, was not activated in response to HIV
MDM treatment at any assessed times or doses as determined by antibodies recognizing
the caspase-3-specific cleavage product of spectrin and the cleaved fragment of activated
caspase-3 (Fig. 2A). These findings suggest that calpain is a major death-associated
protease activated in rat cortical cultures treated with HIV MDM.
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Calpain-mediated generation of p25 is increased in cortical cultures exposed
to HIV MDM supernatant. Activation of calpain can lead to cleavage of the CDK5
regulatory subunit, p35, to p25, an isoform associated with pathologic activity of CDK5
(Kusakawa et al. 2000). To determine if calpain activation due to HIV MDM treatment
also increased levels of p25, we assessed levels of p25 in cortical cultures treated with
HIV MDM. HIV MDM increased the levels of both calpain-cleaved spectrin (Fig. 2B, 3A,
and 3B, ** p<0.01) and p25 (Fig. 2B, 3A, and 3C ** p<0.01) in 14 DIV rat cortical
cultures. Blocking NMDAR activation with MK801 reduced calpain cleavage of both
spectrin and p35 (Fig. 2B). In contrast, treating 7 day old rat cortical cultures with HIV
MDM did not induce calpain cleavage of spectrin or p35 (Fig. 2C). This is consistent
with our previous observation that hippocampal cultures do not become sensitive to HIV
MDM toxicity until 14 DIV which corresponds with the expression of NMDARs
containing NR2B/NR2B or NR2A/NR2B subunit combinations (O'Donnell et al. 2006).
To investigate whether this cleavage of p25 is mediated by calpain activity, we
examined the HIV MDM supernatant-induced production of p25 following a 30 min preincubation with the calpain inhibitor, MDL28170. Treatment of cortical cultures with
MDL28170 prior to and concurrently with HIV MDM supernatant treatment prevented
subsequent increases in levels of both calpain-cleaved spectrin and p25 (Fig. 3A-C, ###
p<0.001).

These findings suggest that HIV MDM supernatant treatment induces

calpain-dependent cleavage of p35 to p25 in cortical cultures.

HIV MDM induces CDK5 kinase activity. Since HIV MDM supernatant exposure
increases cleavage of p35 to p25, a critical activator of CDK5 in neurons, we evaluated
the effect of these supernatants on CDK5 kinase activity in cortical cultures. Following
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HIV MDM supernatant treatments of rat cortical cultures, we immunoprecipitated
endogenous CDK5 protein from cell extracts and assayed its ability to phosphorylate the
common CDK substrate, histone H1. The kinase activity of CDK5 increased significantly
in cortical cultures following HIV MDM supernatant treatment (Fig. 4, ** p < 0.01). This
observation is in agreement with previous results demonstrating potentiation of CDK5
kinase activity in the presence of p25 (Patrick et al. 1999). Further, increased CDK5
activity in our model is dependent on NMDAR activation and calpain activity as
indicated by blockage of HIV MDM supernatant-induced CDK5 activity by MK801 and
MDL28170, respectively (Fig. 4, # p<0.05).

Activation of calpain and CDK5 are required for HIV MDM-induced
neurotoxicity. To determine whether calpain activation of CDK5 contributes to HIV
MDM supernatant-induced neuronal damage, we evaluated the ability of calpain
inhibitor (MDL28170) and CDK5 inhibitor (roscovitine) to block HIV MDM
supernatant-induced reduction in neuronal number and relative protein levels of MAP2
in rat cortical cultures. Exposure to HIV MDM supernatant for 20 h resulted in loss of
MAP2-positive neurons (Fig. 5A and 5C, # p<0.05) and MAP2-fluorescence (Fig. 5B, ##
p<0.01 and 5D # p<0.05) compared with untreated cultures and cultures treated with
supernatants from mock-infected MDM supernatant (Mock).

Preincubation with

MDL28170 blocked the observed HIV MDM supernatant-induced decrease in MAP2positive neurons (Fig. 5A ** p<0.01 and 5C * p<0.05) and MAP2-fluorescence (Fig. 5A,
** p<0.01). Further, pre-treatment of cultures with the CDK5 inhibitor, roscovitine,
significantly attenuated the loss of MAP2-positive neurons (Fig. 5C, * p<0.05) and
roscovitine protection was dose-dependent when evaluated using the MAP2-fluorescence
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assay (Fig. 5D, * p<0.05, *** p<0.001). These results suggest that calpain activation and
CDK5 activation contribute to HIV MDM supernatant-induced neuronal death.

HIV MDM supernatant treatment does not result in CDK5 phosphorylation
of MEF2. Previous reports demonstrate that CDK5 localizes to both cytoplasmic and
nuclear compartments (Musa et al. 1998), and that its function can depend on its
subcellular localization (O'Hare et al. 2005).

Therefore, we assessed p25 levels in

cytoplasmic and nuclear fractions of protein extracts from rat cortical cultures exposed
to HIV MDM supernatant. Increased levels of p25 were detected in both the cytoplasmic
and nuclear fractions of protein extracts from HIV MDM supernatant-treated cultures
(Fig. 6A), consistent with previous reports of p25 distribution (O'Hare et al. 2005).
CDK5 protein levels did not change in either subcellular fraction after HIV MDM
supernatant treatment. Increased nuclear p25:CDK5 has been reported to alter neuronal
viability by inactivating the pro-survival MEF2 transcription factor via phosphorylation
of MEF2 serine 444 (Gong et al. 2003). To determine if HIV MDM supernatant-induced
neuronal loss was due to increased CDK5 phosphorylation of MEF2, we assessed
phosphorylation of MEF2 at serine 444 following HIV MDM supernatant treatment.
MDM supernatant treatment did not result in a significant increase in phospho-MEF2
compared with cultures treated with Mock-infected MDM supernatants or media alone
when assessed by Western blot (Fig. 6B and 6C). These findings suggest that HIV MDM
supernatant treatment of our cultures does not induce p25:CDK5 phosphorylation of
MEF2 on serine 444.
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Increased p25 is not due to extracellular signal-regulated kinase 1 and 2
(ERK1/2) dependent increases in p35 production. Despite its ability to increase
levels of p25, HIV MDM supernatant treatment does not appear to reduce levels of p35
protein, an observation that is similar to previously reported findings (Smith et al.
2006). One possible explanation for this phenomenon is that only a small percentage of
p35 is converted to p25 following HIV MDM supernatant treatment (Smith et al. 2006).
Another possibility is that increased p35 gene expression compensates for the amount of
p35 protein lost to p25 production. Phosphorylation of ERK1/2 (also referred to as
p42/p44 MAPK) at tyrosine 204 (Tyr204) activates ERK1/2 and is necessary and
sufficient for induction of p35 transcription via the transcription factor, Early growth
response protein 1 (Egr1) (Harada et al. 2001). To determine whether increased p35
gene expression is contributing to the increased p25 levels seen in response to HIV MDM
supernatant treatment, we assessed ERK1/2 phosphorylation at Tyr204 following HIV
MDM supernatant treatment. Phosphorylation of ERK1/2 at Tyr204 was increased in
response to HIV MDM supernatant, peaking at 15 min, with detectable increases
sustained for up to 1 h (Fig. 7A).

HIV MDM supernatant induction of ERK1/2

phosphorylation at Tyr204 was blocked by inhibition of the ERK1/2 activator,
MAPK/ERK kinase 1 and 2 (MEK1/2), by the well-characterized inhibitor, U0126 (Fig.
7B) (Duncia et al. 1998; Favata et al. 1998). These findings suggest that the ERK1/2
pathway is activated in cortical cultures treated with HIV MDM supernatant. However,
despite increased ERK1/2 phosphorylation in these cultures, we did not observe a
significant increase in p35 transcript levels in response to HIV MDM supernatant
treatment by real-time PCR (Fig. 7C). Additionally, neither U0126 nor MDL28170
affected levels of the p35 transcript following HIV MDM or mock-infected MDM
supernatant treatment (Fig. 7C). These results suggest that ERK is activated in response
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to HIV MDM supernatant, but does not contribute to activation of CDK5 through
alterations in p35 levels.

Calpain activation and p25 levels are increased in HIV-infected individuals.
To determine if our in vitro model reflects events in human disease, we assessed the
levels of p35 and p25 in cortical autopsy tissue from 14 HIV-positive individuals (6 with
HAD, 7 with MCMD, and 1 cognitively normal) and 4 HIV-negative, cognitively normal
individuals (Table 2). Whole cell lysates were prepared from mid-frontal cortical tissue
and were immunoblotted for p35/p25 (Fig. 8A). We saw no significant changes in p35
levels between non-infected control and HIV-infected samples (Fig. 8A, B) or when
samples were compared by grouping into their reported classifications of neurocognitive
impairment (cognitively normal controls, MCMD and HAD, Fig. 8A, C).

However,

consistent with our in vitro results, p25 levels were statistically increased in HIVinfected cortex when compared with non-infected control cortex (Fig. 8D, **p<0.005).
In addition, both MCMD and HAD cortex had elevated p25 levels compared with
cognitively normal cortex (Fig. 8A, E, * p<0.05). Production of p25 suggests increased
calpain activity. To determine if calpain is active, we assessed the levels of calpaincleaved spectrin in our patient population.

We observed a significant increase in

calpain-cleaved spectrin in cortex of HIV-infected patients as compared with noninfected controls (Fig. 8A, F; ** p<0.005). Calpain-cleaved spectrin levels were also
significantly increased in cortex of HAD patients as compared with cognitively normal
controls (Fig. 8A, G, * p<0.05). Calpain-cleaved spectrin levels in MCMD cortex were
not significantly different from HAD or cognitively normal controls (Fig. 8A, G). As
calpain activation and p35 cleavage to p25 have been reported to increase MEF2
phosphorylation in other models of neuronal loss (Gong et al. 2003; Tang et al. 2005;
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Smith et al. 2006), we assessed the levels of MEF2 phosphorylation in our patient
population.

Consistent with findings in our in vitro model, levels of MEF2

phosphorylation were not significantly different between HIV-infected and non HIVinfected patients (Fig. 8H) or between HAD, MCMD and cognitively normal controls
(Fig. 8A, I). Our results indicate that p25 cleavage and calpain-cleaved spectrin are
increased in HIV infected patients including those with cognitive impairment.

Our

results suggest that increases in p25 cleavage and calpain activation may play a role in
pathogenesis of HIV-associated cognitive disorders.
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DISCUSSION
Although neuronal damage and loss is a prominent feature of HAD, the
mechanisms of neurodegeneration are poorly understood in this disease. Here, we show
evidence of a role for calpain-mediated activation of CDK5 in neuronal death in both an
in vitro model of HIV-associated neurodegeneration and in HIV-infected individuals. In
response to HIV MDM supernatant, we have observed an increase in calpain cleavage of
the CDK5 activating subunit, p35, to the more stable 25 kD isoform, p25. This increase
in p25 levels is coincident with an increase in CDK5 kinase activity.

Importantly,

inhibition of CDK5 kinase activity, calpain activity, or NMDAR activity protects from
HIV MDM supernatant-induced neuronal death. Further, we have observed a significant
increase in p25 levels and calpain-cleaved spectrin levels in mid-frontal cortex of HIVinfected patients, including those with HAD. Taken together, these findings suggest that
activation of CDK5 may contribute to neuronal damage and death in individuals with
HIV-associated cognitive disease.
We have previously reported that neurotoxicity in HIV MDM supernatantexposed hippocampal cultures is mediated by NMDA receptor stimulation and calpain
activation (O'Donnell et al. 2006). Our findings indicate similar effects in cortical
neurons, and further suggest that this toxicity is mediated by calpain-dependent
activation of CDK5 activity and not by caspase activation. Calpain is a calcium-activated,
cysteine protease that is important in the regulation of several physiological processes.
Additionally, several lines of evidence suggest a pivotal role for calpain in various
neurodegenerative injuries and diseases, including excitotoxic injury, Parkinson's
disease, Alzheimer's disease, ischemia, amyotrophic lateral sclerosis, and Huntington's
disease (Crocker et al. 2003; Nixon 2003; Ray and Banik 2003; Wu et al. 2004; Lee et al.
2006; Raynaud and Marcilhac 2006; Shioda et al. 2006; Wootz et al. 2006). Cytosolic
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calcium overload in response to excitotoxins alters key cytoskeletal and membrane
proteins through calpain activation. Here, we demonstrate that induction of calpain
activity by HIV MDM supernatant leads to cleavage of a CNS-specific target, the CDK5
regulatory subunit, p35 (Patrick et al. 1999; Kusakawa et al. 2000; Lee et al. 2000; Nath
et al. 2000). Calpain has been shown to cleave p35 to the more stable p25 isoform,
increasing CDK5 kinase activity (Patrick et al. 1998). Such increases in CDK5 activity
have been implicated in the pathogenesis of several neurodegenerative diseases,
including Alzheimer’s disease (Nguyen et al. 2002; Tseng et al. 2002; Noble et al. 2003),
amyotrophic lateral sclerosis (Nguyen et al. 2001; Patzke and Tsai 2002), and
Parkinson’s disease (Henchcliffe and Burke 1997; Nakamura et al. 1997; Neystat et al.
2001; Oh and Chase 2002; Smith et al. 2006). Here we also report a significant increase
in p25 levels both in mid-frontal cortex of HIV-infected individuals, including those with
cognitive impairment, and in an in vitro model of the human disease, implicating CDK5
activity in the pathogenesis of yet another neurodegenerative disease.
Calpain-induced generation of p25, which causes increased CDK5 activity, has been
associated with the switch of CDK5 from physiological functions to pathological
functions. Two mechanisms have been proposed to account for the pathogenicity of
p25:CDK5 kinase activity. First, the half-life of p25 is 5-10 fold longer than that of p35,
prolonging CDK5 activation and neurotoxic activities (Patrick et al. 1999). Second, p25
has been reported to alter CDK5 localization (Patrick et al. 1999) as generation of p25
results in cleavage of the amino-terminal myristoylation site that tethers the p35:CDK5
complex to the intracellular plasma membrane. Consistent with both of the proposed
mechanisms of p25:CDK5 pathogenicity (Ino and Chiba 1996), nuclear and cytoplasmic
fractions of our HIV MDM supernatant-exposed cultures show increased p25 levels.
Increased nuclear p25:CDK5 kinase activity mediates neuronal death by phosphorylation
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of a nuclear neuronal pro-survival transcription factor, MEF-2 (Gong et al. 2003;
Verdaguer et al. 2005; Smith et al. 2006). Following neurotoxic insult, phosphorylation
of MEF-2 on serine 444 by CDK5 inactivates MEF2, significantly inhibiting its
transcriptional activity and thereby inducing death by a caspase-dependent pathway (Li
et al. 2001; Tang et al. 2005).

However, we did not observe an alteration in MEF-2

serine 444 phosphorylation (Figure 6B,C) or activation of caspases (Fig. 2A) in cortical
cultures exposed to HIV MDM supernatant, suggesting that CDK5 may not be altering
neuronal viability via MEF-2 in this in vitro model. Increased CDK5 kinase activity has
also been shown to lead to apoptotic cell death by the up-regulation of p53
transcriptional activity (Zhang et al. 2002; Wesierska-Gadek et al. 2006). However, a
recent report has demonstrated that CDK5-induced, non-neuronal death can occur
without activation of p53, Apaf-1, caspase-9, or caspase-3 (Lin et al. 2006).

These

studies suggest the existence of alternative mechanisms of CDK5 toxicity that could be
involved in our system since we do not observe activation of caspases (Fig. 2A) or of p53
(data not shown). Future studies are needed to determine the mechanism(s) leading to
CDK5-mediated neuronal degeneration following exposure to HIV MDM supernatants.
Our results demonstrate that induction of calpain is required for generation of p25
in HIV MDM supernatant-exposed cortical cultures. However, our observed increase in
p25 levels in HIV MDM supernatant-treated cultures does not result in a corresponding
decrease in p35 protein level. Two scenarios have been proposed to account for this
apparent discrepancy: 1) Because of the relative stability of p25, an observable increase
of p25 accumulates with cleavage of only a small percentage of the unstable p35 (Smith
et al. 2006) or 2) increased transcription and/or translation of p35 may compensate for
p25 generation. With regard to the latter, recent reports indicate that activation of the
ERK pathway can increase p35 transcription via Egr-1 (Harada et al. 2001). While we
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observed a transient increase in ERK phosphorylation in HIV MDM supernatantexposed cortical cultures, we did not observe a significant change in p35 transcript levels
in our model, which suggests that ERK may have a different role in our model.
Interestingly, activation of ERK has also been shown to activate calpain (Glading et al.
2000; Glading et al. 2001; Glading et al. 2004); however, inhibition of ERK activation by
the MEK1/2 inhibitor, U0126, did not block activation of calpains by HIV MDM
supernatant (data not shown). Although ERK does not appear to be regulating p35
expression or calpain activity in our model, it may have other activities relevant to
neuronal survival.

ERK has been associated with non-apoptotic neuronal death

(Subramaniam and Unsicker 2006), such as that seen in our HIV MDM supernatanttreated cultures (Fig. 2A, data not shown). Moreover, ERK activation has been linked to
increased calcium influx mediated by stimulation of NMDARs containing the NR2B
subunit (Krapivinsky et al. 2003). Further work is needed to uncover the role of ERK in
HIV MDM supernatant-induced neuronal death.
ERK is not the only known regulator of p35 levels. Transcription of p35 in neurons
is regulated by heat-shock factor 2 (HSF-2) (Chang et al. 2006), although the mechanism
of this regulation has not been fully elucidated (Christians and Benjamin 2006). Our
data indicate that alteration in p35 mRNA levels is not the mechanism by which p35
levels are maintained despite p25 generation in our HIV MDM supernatant-treated
cultures (Fig. 7).

As mentioned above, another possibility is that only of a small

percentage of p35 is converted to p25, which then escapes the rapid ubiquitin-mediated
turnover undergone by p35, and that this small percentage of p35 cleavage is all that is
required for observable accumulation of p25 (Patrick et al. 1998). Additional studies are
needed to determine if this is the mechanism at play in our model.
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Several reports have demonstrated a prominent role of NMDARs in HIV MDM
supernatant-induced neurotoxicity (Dawson et al. 1993; Lipton 1993; Power et al. 1998;
Chen et al. 2002; O'Donnell et al. 2006), however, the downstream signaling following
NMDAR activation has not been fully elucidated. Here we demonstrate a significant role
for calpain activation of CDK5 in one instance of NMDAR-regulated neuronal injury.
Blocking NMDAR activity using the synthetic antagonist, MK801, prevents neuronal
loss, calpain activation, and p25 production in cortical cultures exposed to HIV MDM
supernatant. Since inhibition of calpain by MDL28170 or of CDK5 activity by roscovitine
protects neurons from HIV MDM supernatant-induced injury, the calpain/CDK5
pathway is likely one of the downstream mechanisms involved in this NMDAR-mediated
neurodegeneration. Thus, we propose a model for neuronal damage in which exposure
to HIV MDM supernatant activates NMDARs, leading to influx of calcium. The resulting
increase in intracellular calcium activates calpains, which cleave p35 to p25, generating
the more stable p25:CDK5 complex, and a subsequent increase in CDK5 kinase activity.
However, the mechanism by which CDK5 is mediating neuronal death beyond this point
is not known. A recent report suggests that p25:CDK5 phosphorylates the NMDAR
NR2A subunit on serine 1232, further amplifying calcium influx (Li et al. 2001; Wang et
al. 2003). Blocking NR2A phosphorylation by CDK5 protects neurons from death in
models of ischemia (Li et al. 2001; Wang et al. 2003). Future experiments are needed to
determine if this is the mechanism by which CDK5 mediates death in our HIV MDM
supernatant model.
Formation of the p25:CDK5 complex has been linked to several neurodegenerative
diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral
sclerosis (Mandelkow 1999; Patzke and Tsai 2002; Tseng et al. 2002; Giese et al. 2005;
Alvira et al. 2006). However, there is emerging evidence that the previously labeled
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"pathologic" form of CDK5 may have normal functions in learning, memory, and
plasticity (Angelo et al. 2006). In this capacity, targeted, spatio-temporal expression of
p25 increased spatial memory acquisition (Angelo et al. 2003; Ris et al. 2005). In
contrast, prolonged p25 expression resulted in neurodegenerative effects and impaired
spatial learning (Fischer et al. 2005). These findings suggest that prolonged expression
of p25:CDK5 has pathologic activity and that this can induce learning and memory
deficits in mice. These findings correlate well with observed neurological deficits in
patients with HAD, which include cognitive impairment and memory loss (Nath and
Sacktor 2006).

Certainly, our observed increase in cortical p25 in HIV-infected

individuals over non-infected controls could suggest a role for prolonged p25:CDK5
expression in the cognitive changes observed in these patients. Taken together, our data
support a role for the calpain/CDK5 pathway as a downstream effector of NMDARmediated neurotoxicity both following HIV MDM supernatant treatment and in HIVassociated cognitive disorders.

Since CDK5 has been implicated in several

neurodegenerative diseases, it offers an attractive target for protection against neuronal
insults.
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Figure 1:

Figure 1. HIV MDM induces cortical neuron death in a NMDAR-mediated manner. A) Cortical
cultures treated for 20 h with HIV MDM supernatants (black bars, diluted 1:40), resulted in a significant
decrease in the number of MAP2 positive neurons (###) when assessed by hand counting, whereas
Untreated cultures (open bars) or treatment with Mock-infected MDM supernatant (gray bars, 1:40) did not
result in a detectable loss of neurons. Treatment with NMDA antagonist, MK801 (10 µM), beginning 30 min
prior to the addition of supernatants completely protected from neuronal loss caused by HIV MDM
supernatants (***) B) Under the same experimental conditions, a MAP2 cell–based ELISA assay revealed
relative MAP2 fluorescence changes nearly identical the changes detected by the neuron hand counts.
Values are means ± SEM, n=2-3 (A), n=6-12 (B), one-way ANOVA, Newman-Keuls, ### p<0.001 compared
with all other conditions, *** p<0.001 compared with HIV MDM but not statistically different than any other
condition.
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Figure 2:
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Figure 2. HIV MDM induces calpain activation and p25 generation, but not caspase
activation, in an age-dependent manner in cortical neurons. A) 2-week old rat cortical cultures
treated with HIV MDM supernatant (diluted 1:10 and 1:40) showed increased calpain-cleaved spectrin in
both a time- and a dose-dependent manner compared with Untreated or Mock-infected MDM supernatant
(Mock) treated cultures. Caspase-3 activation following HIV MDM supernatant treatment was not observed
by detection of either caspase-cleaved spectrin or cleaved caspase-3. Cytochrome c treated or untreated Hela
cells were used as a positive control (Pos cntrl) or negative control (Neg cntrl) respectively for caspase-3
activation. Full-length spectrin decreased in HIV MDM supernatant treated cultures at later time-points. B)
p25 was detected in 2-week old rat cortical cultures treated for 8 h with HIV MDM supernatant (1:40), but
not in Untreated cultures or cultures treated with Mock-infected MDM supernatant (1:40). Treatment with
MK801 (10 µM), beginning 30 min prior to supernatant treatments, blocked formation of p25 and calpaincleaved spectrin in response to HIV MDM supernatant treatment. C) In 1-week old cortical cultures, neither
p25 nor calpain-cleaved spectrin production was increased under any condition. Because neither calpaincleaved spectrin nor p25 was detected in 1-week old culture lysates using our typical exposure time for
chemiluminescence film to our blots (data not shown), we used extra-long exposure to visualize calpaincleaved spectrin and p25 bands. These extra-long exposures resulted in overexposure of the p35 bands (row
2). A shorter exposure to detect the p35 band in the linear range (LR) of the film is also shown (arrow).
Immunoblots for actin verify equal protein loading.

286

Figure 3:

Figure 3. P25 generation is mediated by calpain activity. A) 2-week old rat cortical cultures were
treated for 8 h with HIV MDM supernatant (diluted 1:40), Mock-infected MDM supernatant (1:40), or left
Untreated. Some cultures were co-treated with the calpain inhibitor, MDL28170 (50 µM), beginning 30 min
prior to the addition of supernatants. Actin was used as a loading control. Quantification of normalized
calpain-cleaved spectrin (B) and p25 (C) levels show a significant increase (**) in HIV MDM supernatantexposed cortical cultures (black bars) compared with Untreated (open bars) or Mock-infected MDM
supernatant-treated cultures (gray bars). The HIV MDM supernatant-induced increase in calpain-cleaved
spectrin (B) and p25 (C) is significantly reduced by MDL28170 (###). Values are means ± SEM, n=2, oneway ANOVA, Newman-Keuls, ### p<0.001 compared with HIV MDM, ** p<0.01 compared with all other
conditions.
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Figure 4:

Figure 4. HIV MDM increases CDK5 kinase activity. CDK5 was immunoprecipitated from cell
lysates from 2-week old rat cortical cultures treated for 8 h with HIV MDM supernatant (diluted 1:40),
Mock-infected MDM supernatant (1:40), or left Untreated. Some cultures were co-treated with 10 mM
MK801 or with 50 mM MDL28170 beginning 30 min prior to the addition of supernatants. CDK5 kinase
activity in the immunoprecipitate was measured by phosphorylation of histone H1 in the presence of

32P-

γATP. Results from a representative histone H1 kinase assay are shown. Coomassie blue staining of the gel
was used to verify equal CDK5 protein pulled down and to control for protein degradation. The graph shows
quantification of CDK5 kinase activity. Values are means ± SEM, n=2-5, one-way ANOVA, Newman-Keuls,
** p<0.01 compared with Mock (gray bars) and Untreated (open bar), # p<0.05 compared with HIV MDM
(black bars).
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Figure 5:

Figure 5. Inhibition of Calpain and CDK5 activity blocks HIV MDM-induced neurotoxicity. A)
Treatment of cortical cultures for 20 h with HIV MDM supernatants (black bars, diluted 1:40), resulted in a
significant decrease in the number of MAP2 positive neurons (#) when assessed by hand counting, whereas
Untreated cultures (open bars) or treatment with Mock-infected MDM supernatant (gray bars, 1:40) did not
result in a detectable loss of neurons. Treatment with MDL28170 (50 µM) beginning 30 min prior to the
addition of supernatants protected from neuronal loss caused by HIV MDM supernatants (**). B) Under
similar experimental conditions, a MAP2 cell–based ELISA assay detected a decrease in MAP2 fluorescence
in 5-week old cortical culture treated with HIV MDM supernatants (##) that was reduced with treatment
with MDL28170 (10 µM, **) beginning 1 hr prior to addition of the supernatants. In these cultures, Mock-
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infected MDM supernatants also resulted in a small reduction in MAP2 fluorescence (@). (C-D) The CDK5
inhibitor, roscovitine (Ros), was added to 2-week old primary rat cortical cultures beginning 30 min before
HIV MDM supernatant or Mock-infected MDM supernatant exposure (20 h), and compared with identical
treatments without roscovitine, or to untreated cultures. Roscovitine protected from HIV MDM supernatantinduced neuronal damage as determined by hand-counting (C) and by a MAP2 cell-based ELISA assay (D).
Values are means ± SEM; n=3 (A and C), n=8-16 (B), n=8 (D), one-way ANOVA, Newman-Keuls, # p<0.05,
## p<0.01, compared with all other conditions; * p<0.05, ** p<0.01, ***p<0.001 compared with HIV MDM.
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Figure 6:
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Figure 6. HIV MDM supernatant treatment does not result in CDK5 phosphorylation of
MEF2. A) 2-week old primary rat cortical cultures were treated for 8 h with a 1:40 dilution of HIV MDM or
Mock-infected MDM supernatants, or were left untreated. Nuclear and cytoplasmic fractions were prepared
and immunoblotted for p25 levels. Increased p25 was observed in both nuclear and cytoplasmic protein
fractions in response to HIV MDM supernatant. GAPDH and Lamin A/C were assayed to demonstrate
cytoplasmic and nuclear fractionation, respectively. Coomassie blue staining of the gel is shown to verify
equal protein loading and to control for protein degradation. B) Whole cell lysates were prepared from
untreated primary rat cortical cultures and from cultures treated for 4, 8, 16, and 20 h with a 1:40 dilution of
HIV MDM or Mock-infected MDM supernatants. Lysates were immunoblotted for phospho-serine 444
MEF2 (p-MEF2(ser444)). Immunoblots for actin are shown to verify equal loading. C) Phospho-serine 444
MEF2 levels were quantified and normalized to actin levels. Values show mean ± SEM, n=3, one-way
ANOVA.
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Figure 7:

Figure 7. Increased p25 is not due to ERK1/2-dependent increases in p35 production. 2-week
old primary rat cortical cultures were treated for 5, 15, 30, and 60 min at a 1:40 dilution of HIV MDM or
Mock-infected MDM supernatants, or were left untreated.

A) ERK activation was determined by

immunoblotting for ERK1/2 phosphorylation at Tyr204 using a phospho-specific antibody. B) Treatment
with the MEK1/2 inhibitor, U0126 (20 µM), beginning 30 min prior to incubation with HIV MDM or Mockinfected MDM supernatants (10 min) blocked ERK1/2 phosphorylation. Immunoblots for actin are shown to
verify equal protein loading. C) 2-week old primary rat cortical cultures were treated with U0126 (20 µM)
alone or in combination with MDL28170 (50 µM) beginning 30 min prior to a 4 h treatment with HIV MDM
or Mock-infected MDM supernatants. RNA was extracted and p35 mRNA levels were analyzed by real-time
PCR and normalized to 18s rRNA levels. No significant differences in p35 transcription level were observed
under any condition (one-way ANOVA). Values show means ± SEM, n= 3.
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Figure 8:
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Figure 8. Calpain activation and p25 levels are increased in HIV-infected individuals. Whole
cell protein extracts were prepared from mid-frontal cortex from 14 HIV-positive patients (6 HAD, 7 MCMD
and 1 cognitively normal case) and 4 HIV-negative control cases (Table 2) and immunoblotted for p35/p25,
calpain cleaved spectrin, and phospho-serine 444 MEF2 (p-MEF2(Ser444)). A) Western blots for p35 and
p25, calpain-cleaved spectrin, and p-MEF2(Ser444) from these 18 cases are shown. A band from coomassie
blue staining of the membrane is shown to verify equal loading of protein and to control for protein
degradation.

Levels of p35, p25, calpain-cleaved spectrin, and p-MEF2(Ser444) were quantified and

normalized to the loading control. Graphs and statistical analysis of each protein are shown in B through I.
B) No statistical differences were observed between p35 levels in HIV-infected individuals versus uninfected
individuals in mid-frontal cortex. C) There were also no differences in p35 levels between HAD, MCMD, and
cognitively normal control cases. (D) In contrast, p25 levels were significantly increased (**) in cortices of
HIV-infected patients as compared with uninfected patients. E) p25 was significantly increased (* p<0.05)
in HAD and MCMD cortices as compared with cognitively normal controls. F) Levels of calpain-cleaved
spectrin were significantly elevated (**) in cortices of HIV-infected individuals as compared with noninfected patients. G) Calpain-cleaved spectrin was significantly increased (*) in HAD cortex as compared
with control, while MCMD is significantly different from neither normal control nor HAD cases. H) No
statistical differences were observed between p-MEF2 (Ser444) levels in HIV-infected individuals verses
uninfected individuals in mid-frontal cortex. I) No differences between p-MEF2 (Ser444) levels between
HAD, MCMD and cognitively normal control cases were observed.

Mean normalized levels ± SEM are

shown in B through I. For all panels * p<0.05, ** p<0.01, Mann-Whitney U test.
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Table 1. HIV MDM supernatants.
Supernatant

reverse

Figure

Dilution

Time(h)

1A-B, 5A-B

1:40

20

as indicated

as indicated

transcriptase
activity(cpm)
Sup 1

41923

Sup 2

60113

Sup 3

49060

2B-C

1:40

8

Sup 4

52801

3A-C

1:40

8

50659

4

1:40

8

2A

Sup 5
5D

20

Sup 6

42341

5C

1:40

20

Sup 7

62341

6A

1:40

8

Sup 8

47135

6B-C

1:40

8

49060

7A

1:40

as indicated

Sup 9

7B

1/6

7C

4

Table 1. HIV infection of macrophages was confirmed by serial quantification of reverse transcriptase
activity in the culture supernatants in each case, and the dilution and incubation times used in each
experiment are shown in the table.
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Table 2. Summary of Case Data
Case

HIV

Gender

Age

PMI

(years)

(h)

NeuroCog

Neuropa
th Dx

HAD1

+

M

35

9.25

HAD

Not HIVE

HAD2

+

F

34

5

HAD

Not HIVE

HAD3

+

M

57

5.5

HAD

Not HIVE

HAD4

+

M

32

14.5

HAD

HIVE

HAD5

+

M

38

5.5

HAD

HIVE

HAD6

+

M

32

14

HAD

HIVE

MCMD1

+

M

36

2.5

MCMD

Not HIVE

MCMD2

+

M

37

11.5

MCMD

Not HIVE

MCMD3

+

M

31

8.83

MCMD

Not HIVE

MCMD4

+

M

49

67.33

MCMD

Not HIVE

MCMD5

+

M

42

27.33

MCMD

Not HIVE

MCMD6

+

M

50

21

MCMD

HIVE

MCMD7

+

M

43

Un-

MCMD

HIVE

Normal

Not HIVE

known
NORMAL1

+

M

46

2.75

297

CONTROL

-

M

46

27.65

ND

Control

-

F

47

19.2

ND

Control

-

M

40

14.66

ND

Control

-

F

51

21.75

ND

Control

1
CONTROL
2
CONTROL
3
CONTROL
4

Table 2. Summary of case data for autopsy tissue obtained from the NNTC. Data on the HIV status (HIV),
Gender, Age in years, post-mortem interval (PMI) in hours, Neurocognitive diagnosis (NeuroCog), and
Neuropathologic diagnosis (Neuropath Dx) are summarized. Abbreviations include: F – female, HAD –
HIV-associated dementia, HIVE – human immunodeficiency virus encephalitis, M – Male, MCMD – minor
cognitive/motor disorder, and ND – not determined.
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Abstract
As human immunodeficiency virus (HIV) does not induce neuronal damage by
direct infection, the mechanisms of neuronal damage or loss in HIV associated dementia
(HAD) remain unclear.

We have shown previously that immunoreactivity of

transcription factor, E2F1, increases in neurons, localizing predominantly to the
cytoplasm, in HIV-associated pathologies. Here we confirm that E2F1 localization is
predominantly cytoplasmic in primary post-mitotic neurons in vitro and cortical neurons
in vivo.

To determine whether E2F1 contributes to neuronal death in HAD via

transactivation of target promoters, we assessed the mRNA and protein levels of several
classical E2F1 transcriptional targets implicated in cell cycle progression and apoptosis
in an in vitro model of HIV-induced neurotoxicity and in cortical autopsy tissue from
patients infected with HIV. By qPCR, we show that mRNA levels of E2F1 transcriptional
targets implicated in cell cycle progression (E2F1, cyclin A, proliferating cell nuclear
antigen (PCNA), and dyhydrofolate reductase (DHFR)) and apoptosis (caspases 3, 8, 9
and p19ARF) remain unchanged in an in vitro model of HIV-induced neurotoxicity.
Further, we show that protein levels of p19ARF, Cyclin A, and PCNA are not altered in
vitro or in the cortex of patients with HAD.

We propose that the predominantly

cytoplasmic localization of E2F1 in neurons may account for the lack of E2F1 target
transactivation in neurons responding to HIV-induced neurotoxicity.
Keywords: E2F1, HIV-associated dementia, transcription factor.
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Human immunodeficiency virus (HIV)-associated dementia (HAD) is a common
neurological disorder associated with HIV infection. Pathologic studies of the brains of
patients with HAD suggest an inflammatory mechanism in the progression of this
disease, as evidenced by astrogliosis, microgliosis, and perivascular macrophage
infiltration (1-3). Although neuronal death, dendritic loss and synaptic loss are features
of HAD, there is little evidence of direct HIV infection of neurons. Instead, neuronal
dysfunction and death likely result from the release of various neurotoxic factors from
activated macrophages and microglia, such as reactive oxygen species and excitatory
amino acids (4-6). Correlative evidence suggests that neuronal damage in HAD may
result from several mechanisms, including decreased neuronal autophagy (7), NMDA
receptor activation (8, 9), abnormal CDK5 kinase activity (10), activation of the p38
mitogen-activated protein kinase (MAPK) cascade (11), caspase activation, inhibition of
the nuclear factor-kB survival pathway via glycogen synthase kinase-3b activation (12),
and/or aberrant cell cycle regulation involving E2F1 (13, 14).
E2F1 is a member of the E2F family of transcription factors, which play a pivotal
role in cell differentiation, proliferation, and apoptosis through transcriptional
regulation. In non-neuronal cells, E2F1 is predominantly nuclear and its transcriptional
activity is regulated by Retinoblastoma protein (Rb). Among the categories of genes
regulated by E2F1 are those necessary for RNA and DNA synthesis, such as dihydrofolate
reductase (DHFR) and proliferating cell nuclear antigen (PCNA) and those necessary for
cell cycle progression, such as Cyclin A (15) and E2F1 itself (16). In addition, E2F1
regulates genes involved in apoptosis, including p19ARF, an initiator of p53-dependent
apoptosis (17), as well as other apoptotic genes that are independent of the p53 pathway,
including APAF1, BID, and caspases 2, 3, 7, 8, and 9 (18). Finally, E2F1 has been shown
to induce cell death independently of gene transactivation through inhibition of the anti-
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apoptotic signaling of the NF-kB pathway (19) or through induction of the calciumactivated, cysteine protease, calpain (20).
Using in vitro models of neurodegeneration, several studies have demonstrated
that E2F1 contributes to neuronal damage and death (21-27). These studies speculate
that E2F1 mediates neuronal death via activation of its transcriptional targets (28).
However, several reports have observed cytoplasmic localization of E2F1 in postmitotic
neurons of patients with neurodegenerative diseases including HIV encephalitis, SIV
encephalitis, Alzheimer

Disease, Parkinson

amyotrophic lateral sclerosis (13, 28-31).

Disease, Huntington

Disease, and

In these diseases, E2F1 immunoreactivity

and/or protein levels were also reported to increase (see review (30)). To assess whether
E2F1 induces cell death in a transcription-dependent manner in neurons in HIV-induced
neurotoxicity despite a predominantly cytoplasmic localization (13, 20, 29), we
determined the localization of E2F1 in primary cortical neurons and in neurons from
human cortex and assayed the expression of several classic E2F1 targets in an in vitro
model of HIV-induced neurotoxicity and in cortical autopsy tissue from 14 HIV-positive
individuals.
As an in vitro model of HIV-induced neurotoxicity, we used a previously welldescribed model in which supernatants from HIV-infected primary monocyte-derived
macrophages (HIVMDM) are used to treat primary rat cortical neurons (8).
Primary rat cortical cultures were prepared from embryonic day 17 Sprague–
Dawley rat pups. Cells were plated at a density of 2 × 106 cells per 60 mm dish precoated with poly-l-lysine (Peptides International, Louisville, KY, USA) and maintained in
neurobasal media (Invitrogen) with B27 supplement (Invitrogen) at 37°C and 5% CO2.
Cultures were utilized at 21 days in vitro (DIV) unless indicated otherwise.
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For western blotting, fresh frozen tissue samples from midfrontal cortex of HIVinfected patients suffering from neurocognitive impairments (n = 13) and control
patients with normal neurocognitive status (n = 5) were obtained from the tissue banks
of National NeuroAIDS Tissue Consortium (33). Tissue was homogenized on ice in Lysis
Buffer [50 mmol/L Tris–HCl (pH 7.5), 0.5 mol/L NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 1% SDS, 2 mmol/L EGTA, 2 mmol/L EDTA, 5 mmol/L NaF, 0.1 mmol/L
phenyl-methane-sulphonylfluoride, 1 mg/mL leupeptin, 1 mmol/L DTT, and protease
inhibitor cocktail]. Membranes were incubated overnight at 4°C with primary antibodies
against p19ARF (Abcam, MA, USA), PCNA, DHFR and Cyclin A (Santa Cruz, CA, USA).
Quantitative real-time polymerase chain reaction (Q-PCR) was performed as
described previously (10). Expression levels of E2F1, p19ARF, PCNA, caspases 3, 8, 9 and
the internal controls of 18S or TATA box binding protein (TBP) were quantified using the
LightCycler Amplification Kit SYBR Green I (Roche Applied Science, Indianapolis, IN,
USA). Results were normalized to either 18S or TBP RNA levels and were reported using
arbitrary units. The primer sequences are available upon request.
Immunofluorescent staining was described previously (34).

The tyramide

amplification system (New England Biolabs, USA) was used to detect E2F1. DNA was
visualized by DAPI staining. Neurons were marked by staining for the neuronal marker,
MAP2. The dilutions used were as follows: E2F1 (1:50, Santa Cruz, CA, USA), DAPI
(5mM, Molecular Probes, CA, USA), MAP2 (1:200, Covance, USA). Slides were mounted
and analyzed by laser confocal microscopy.
The MAP2 cell-based ELISA assay used in the current studies was described
previously (10). Relative changes in the intensity of the fluorescent MAP2 signal were
used to estimate neuronal damage. Values were expressed as mean ± SEM. Data with

321

multiple categories was analyzed by one-way analysis of variance (ANOVA) followed by
the Newman–Keuls post hoc test using Prism software (GraphPad Software, San Diego,
CA, USA). Values of p < 0.05 were considered significant.
E2F1 is well-characterized as a transcription factor that functions to control cell
cycle progression. Its nuclear activity is regulated primarily by its interaction with DP1,
pRB, and Cyclin A:cdk2. However, in 3-week-old rat cortical neurons left untreated (Fig
1, top row), we observed E2F1 (green) predominantly in the neuronal cytoplasm; a
compartment inconsistent with its defined role as a transcription factor. In the midfrontal cortices of uninfected, normal brains, we observed the same pattern of
localization (Fig 1, bottom row). It is worth noting that the predominantly cytoplasmic
localization is not altered by the ages of rat cortical cultures nor by different neurotoxic
treatments, such as mock-infected MDM (mock MDM) and HIVMDM. Moreover, the
cytoplasmic localization of E2F1 in cortical brain tissue of HIV-infected individuals is not
dependent on the neurocognitive status of the patient (data not shown). Taken together,
these data suggest that, in neurons in vitro and in the brains of HIV-infected individuals,
E2F1 is predominantly localized in a subcellular compartment that is inconsistent with
its well-characterized role as a transcriptional activator.
Previous studies (8, 10) have demonstrated that the NMDA receptor, at least
partially, mediates neuronal death in our HIVMDM induced neurotoxicity model. As
NMDAR levels peak in primary neurons at 21 days in culture, we use primary rat cortical
neurons at this age for our studies. Using this model, we observed 50 - 80% neuronal
death depending on the dilutions of HIVMDM (Fig 2A). For our analysis of E2F1 target
transactivation, to capture a point in which neurons were in the process of undergoing
cell death, we used a dilution of HIV MDM that resulted in 50% neuronal loss at 20
hours.
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To determine if HIVMDM-induced neuronal death is mediated by activation of
classical E2F target genes, we assessed mRNA levels of select E2F target genes from each
of the following categores: cell cycle progression, RNA and DNA synthesis, or apoptosis.
E2F1, an indicator of G1 to S progression, and cyclin A, a regulator of S phase exit, were
assessed in our model of HIV-induced toxicity as examples of E2F1 targets that regulate
cell cycle progression. To determine if E2F1 is upregulating genes whose products are
necessary for DNA and RNA synthesis, we assessed PCNA and DHFR, respectively.
Finally, E2F1 has been shown to induce apoptosis by transactivation of several proapoptotic gene products which act in distinct apoptotic cascades. Thus, we assessed the
mRNA levels of targets from each of these pathways (intrinsic apoptosis – caspase 9,
extrinsic apoptosis – caspase 8, effector caspase – caspase 3, and p53-dependent
apoptosis – p19ARF) in neurons responding to HIVMDM.

Three week-old primary

cortical cultures were treated with mock MDM or HIVMDM or were left untreated. As
NMDA activation partially mediates neuronal death in this model, we also included a set
of cultures pretreated with MK801, an NMDA receptor antagonist, to determine if any
observed changes in E2F1 target genes were NMDA-dependent. By Q-PCR, we found
that the mRNA levels of all analyzed target genes were similar in neurons treated with
HIVMDM, mock MDM, MK801-pretreatment, and in cultures left untreated (Fig 2B-I).
When we selectively compared the protein levels of DHFR, PCNA, Cyclin A, and p19ARF
by immunoblot, we were again unable to detect a difference in the expression of these
targets across different treatments (Fig 3A). Our Q-PCR results are consistent with our
previous observation that neither caspase 3 protein levels nor cleaved-caspase 3 are
altered by HIVMDM treatment (10).
Consistent with our findings in vitro, we did not observe differences in expression
of the E2F1 targets, PCNA, Cyclin A, and p19ARF, at the protein level in cortical tissue

323

from patients with HAD compared with cognitively normal, HIV-infected cortex (Fig 3B,
C). We also did not see significant differences in these same target genes in cortex from
HIV-infected patients compared with that from uninfected patients. However, we did
observe an increase in DHFR in cortical tissue of HIV-infected patients (Fig 3B, C).
These data suggest that any role for E2F1 in this model of neurodegeneration would
likely occur via a transcription-independent mechanism.
E2F1 is upregulated in neurons subjected to apoptotic stimuli (19, 35) and is
elevated in neurons of patients with HIVE (13), Alzheimer disease (28), Down syndrome
(36), Parkinson disease (37), Huntington disease(31), amyotrophic lateral sclerosis(38)
and in an animal model of HIV encephalitis, SIV encephalitis (SIVE) (29). In addition,
neurons cltured from mice null for E2F1 are at least partially protected from diverse
insults (25, 37, 39). While transcription-dependent E2F1-induced apoptosis has been
implicated in several in vitro models of neuronal death (37, 40), the role of E2F1
transactivation in neuronal death was not explicitly demonstrated (41-46). Surprisingly,
in our in vitro model of HIV-induced neurotoxicity and in cortical tissues from HIVinfected individuals, we did not observe a change in typical E2F1 target genes (Fig 2B-I
and Fig 3), including those implicated in apoptosis. Interestingly, we have also shown
here that E2F1 is predominantly cytoplasmic in 3-week-old primary rat cortical cultures.
Considering that we have found that E2F1 predominantly resides in the neuronal cytosol
independent of culture treatment (Untreated, Mock MDM or HIVMDM), our results
suggest that the main function of E2F1 in post-mitotic neurons may not be to regulate its
nuclear targets.
E2F1 is able to induce cell death via several distinct pathways. Transcriptiondependent E2F1-induced apoptosis can be both dependent on the p53 tumor suppressor
protein or indpendent of p53. In p53-dependent apoptosis, E2F1 transactivates p19ARF,
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leading to stabiliation of p53 by blocking MDM2-mediated p53 degradation. E2F1 can
also induce apoptosis by transactivation of caspase proteins directly.

Our results

indicate that HIVMDM does not induce increases in p19ARF or caspases at the mRNA or
protein levels (Fig 2B-I, Fig 3). Further, HIVMDM treatment does not induce caspase 3
protein levels or cleavage of caspase 3 in primary rat cortical neurons, as we have
reported previously (10). Among all of the classical targets of E2F1 analyzed here, the
protein level of DHFR is the only one to increase in the cortex of HIV-infected patients
compared with that of unifected patients, although it does not change in the in vitro
model of HIV-induced neurotoxicity.

DHFR has been implicated in the onset and

progression of several neurodegenerative disorders and its turnover can be affected by
oxidative conditions (47). Therefore, it is possible that the observed alteration in DHFR
protein levels in cortical tissue from HIV-infected patients are independent of E2F1
transcritional regulation. Our data from the in vitro model of HIV-induced neurotoxicity
and from cortical tissue from HIV-infected patients suggests that E2F1 is not acting via a
classical, transcription-dependent mechanism in this disease.
The predominant cytoplasmic localization of E2F1 in postmitotic neurons is
highly interesting. Other transcription factors have been reported as being abnormally
localized in the cytoplasmic compartment of neurons under pathological conditions (see
review (30)); however, we also observe cytoplasmic E2F1 in neurons in vitro that are not
exposed to stress, as well as in neurons from autopsy tissue of cognitively normal control
cortex. Interestingly, levels of nuclear E2F1 have been reported to be down-regulated
during the differentiation of keratinocytes (48), and our unpublished data also reveal a
similar finidng during the differentiation of neuronal cell lines (data not shown). These
data suggest that nuclear E2F1 may be decreased as cells permanently exit the cell cycle
and undergo differentiation. In both keratinocyts and primary mouse neurons, E2F1 has
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been shown to shuttle between the nucleus and the cytoplasm in a CrmA-depenendent
manner (48-50). Based on these observations, it would be interesting to investigate the
relationsip between nuclear E2F1 and the differentiation process to determine whether a
change of predominant E2F1 localization to the cytoplasm triggers differentiation or vice
versa.

Furthermore, shuttling and localization of E2F1 are affected by its nuclear

localization signal, its nuclear export signal, and its binding partners, such as Cyclin A
and pRb. While we have previously detected pRb in the nuclear compartment of primary
neurons (13), we have been unable to co-immunoprecipitate pRb and E2F1 in
postmitotic neurons (unpublished data). Further investigation is required to determine
the role that these factors play in the cytoplasmic localization and shuttling of E2F1 in
postmitotic neurons.
To summarize, our data suggest that the two groups of classical targets of E2F1,
genes associated with cell cycle progression, such as Cyclin A, PCNA, DHFR, and genes
associated with apoptosis, such as p19ARF, and caspases 3, 8, and 9, are not affected in
HIV-induced neurotoxicity which may be explained by the predominantly cytoplasmic
localization of E2F1 in postmitotic neurons that we show here. Further studies are
needed to understand the role of cytoplasmic E2F1 in normal neurons and in neurons
responding to neurodegenerative stimuli, such as those seen in HAD. As such roles for
E2F1 are largely unknown, studies to uncover these previously undecribed roles may
lead to novel and unique therapeutic opportunities.
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Figure 1:

Figure 1. E2F1 is predominantly cytoplasmic in neurons. In 3-week-old rat cortical neurons (top
panel) and cortical tissues from individuals (bottom panel), immunofluorescent staining for E2F1 (green) is
predominantly cytoplasmic in neurons (MAP2, cytoplasmic neuronal marker, red); the nuclei are stained
blue (DAPI). Co-localization of E2F1 and MAP2 appears yellow. Bar = 10 µm
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Figure 2:
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Figure 2. E2F1 targets are not induced in HIVMDM-treated primary rat cortical neurons. A)
HIVMDM supernatants induce cortical neuron death in a dose-dependent manner. 3-week-old rat cortical
cultures treated for 20 h with 3 increasing dilutions of HIVMDM resulted in a significant decrease in relative
MAP2 fluorescence when assessed by a MAP2, cell-based ELISA, whereas untreated cultures or treatment
with Mock-infected MDM supernatant (Mock MDM) did not result in a detectable loss of MAP2
fluorescence. Values are mean ± SEM, n = 6, one-way ANOVA, Newman–Keuls, ***p < 0.001 compared
with their respective Mock MDM-treated cultures. B – I ) E2F1 target genes were not altered at the mRNA
level in HIVMDM-treated rat cortical neurons. Using Q-PCR, mRNA levels of E2F1 target genes involved in
cell cycle progression (E2F1 (B) and Cyclin A (C)), in RNA and DNA synthesis (DHFR (D) and PCNA (E)),
and those involved in apoptosis (p19ARF (F), caspase 3 (G), caspase 8 (H) and caspase 9 (I)) were not altered
by HIVMDM, Mock MDM, or MK801 treatment.
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Figure 3:
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Figure 3. E2F1 target genes were not altered at the protein level in the in vitro model of HIVinduced neurotoxicty or in the cortex of patients with HAD. A) As detected by immunoblotting,
protein levels of PCNA, Cyclin A, DHFR and p19ARF were unchanged in HIVMDM, Mock MDM, and MK801
treatments. B) Protein levels of PCNA and Cyclin A were not significantly different in the frontal cortex of
HIV-infected cases compared with HIV negative cases, nor with 13 cases with neurocognitive impairment as
compared with 5 cognitively normal cases, one of which was also infected with HIV. Bands were quantified
and normalized to actin. Protein levels of DHFR were significantly increased in HIV-infected patients and in
neurocognitive impairment cases, as compared with uninfected and with neurocognitively normal cases,
respectively. C) PCNA levels were not significantly different (p>0.05); similar results were observed for
Cyclin A and p19ARF (data not shown). Statistical analysis of DHFR showed significant increases in HIVinfected individuals and in those with neurocognitive impairment, ** p<0.01.
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